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Abstract 
Due to their proposed anti-cancer effects, omega-3 fatty acids (O3FA) may have 
a role to play in both chemoprevention and the adjuvant treatment of colorectal 
cancer (CRC). Novel O3FA drink formulations may provide a more effective 
method of delivering O3FA supplementation, although O3FA bioavailability in 
these preparations compared to traditional capsules has not been ascertained. 
There is also a lack of research exploring the effects of O3FAs on the colonic 
microbiota and whether this may have any protective effect on CRC 
carcinogenesis. 
This thesis reports the findings of a randomised cross-over trial in healthy 
volunteers comparing the bioavailability of equivalent doses of O3FA 
supplementation (2g EPA and 2g DHA daily for 8 weeks) in capsule and drink 
carton formulations. The trial also explores the effects of O3FA on faecal 
microbiome profiles.  In addition I report the analysis of red blood cell membrane 
(RBC) EPA levels from the previously reported EMT trial, a Phase II randomised, 
double-blind, placebo-controlled trial in which patients with colorectal cancer liver 
metastasis (CRCLM) received EPA (2g daily) prior to surgery.   
O3FA supplementation provided in a drinks carton supplementation was non-
inferior to an equivalent dose of EPA and DHA provided in capsule form. Faecal 
microbiome profile analysis revealed subtle changes to the colonic microbiota 
including reversible increases to Lactobacillus and Bifidobacterium. Analysis of 
RBC samples from the EMT study revealed a positive correlation between RBC 
membrane and CRCLM tissue EPA levels. Participants with EPA RBC 
membrane levels of >1.22 also exhibited improved overall survival. 
This work provides evidence that an O3FA containing drink formulation is of 
equivalent bioavailability to traditional capsules. Due to their additional nutritional 
contents they may be of benefit in CRC patients. The effects of O3FAs on faecal 
microbiome profiles is of significant interest particularly their impact on bacteria 
associated with anti-CRC effects. Further work is required to elucidate whether 
O3FAs have a role in CRC chemoprevention or adjuvant treatment via their 
effects on the colonic microbiota.      
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Chapter 1: Introduction 
1.1 Omega-3 fatty acids and colorectal cancer: potential clinical 
applications 
The omega-3 fatty acids (O3FA) eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) are essential long chain polyunsaturated fatty 
acids (PUFA) obtained predominantly via dietary intake. They are of particular 
interest due to their potential anti-inflammatory and anti-colorectal cancer (CRC) 
activities. The ever-increasing burden of CRC and associations with various 
dietary risk factors has led to interest in the role of O3FAs in CRC 
carcinogenesis, particularly their potential applications in chemoprevention and 
adjuvant CRC treatment.  
There is growing understanding of the mechanisms via which O3FAs modulate 
CRC risk and carcinogenesis. Inflammation is considered key in the stepwise 
progression from precursor benign adenomas to invasive adenocarcinomas. 
There is increasing interest in the role of O3FAs as a method of 
chemoprevention, particularly via modulation of inflammatory pathways 
(Schottenfeld & Beebe-Dimmer, 2006; Gu et al., 2015; Park et al., 2013). 
Chemoprevention is defined as the use of natural, synthetic, or biologic chemical 
agents to reverse, suppress, or prevent carcinogenic progression to invasive 
cancer (Tsao et al., 2004; Benetou et al., 2015).  
Although there has been extensive work to elicit the various mechanisms via 
which O3FAs are understood to have anti-cancer effects, there has been limited 
research into the effect of O3FAs on the community of microorganisms 
(microbiota) within the colon and whether this affects CRC risk (Valdes et al., 
2018; Ursell et al., 2012). The colonic microbiome is the collective genome of the 
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microorganisms residing within the colon and is of particular interest as there is 
growing evidence that the gut microbiota plays an important role in colorectal 
carcinogenesis (Valdes et al., 2018; Ursell et al., 2012). Dietary modification and 
exposure to O3FAs are therefore a potential avenue of chemoprevention and 
ameliorating CRC risk through both well recognised anti-inflammatory pathways 
and lesser understood effects on the colonic microbiome.  
The anti-cancer properties associated with O3FAs have also led to 
supplementation being considered as a potential adjunct in the treatment of 
CRC. A recent review highlights that O3FAs may have synergistic effects in 
chemotherapy regimens, ameliorate cancer associated cachexia and potentially 
improve survival outcomes (Lee et al., 2017). O3FA supplements are traditionally 
provided in capsule form. However recently developed novel O3FA liquid 
supplementation drinks are of particular interest as they contain additional 
calorific and nutritional value that would be beneficial in patients recovering from 
CRC treatment. As either a method of chemoprevention or adjuvant treatment in 
CRC, the most effective route of O3FA supplementation is unclear, particularly 
whether the formulations employed in O3FA supplement drinks are an effective 
method of O3FA supplementation.    
1.2 Colorectal cancer 
1.2.1 Epidemiology  
The research into O3FAs as either a form of chemoprevention or adjuvant 
treatment in CRC is in part driven by the prevalence of the disease. CRC is the 
commonest gastrointestinal malignancy worldwide and the second most 
common cause of cancer deaths in the United Kingdom (Bray et al., 2018; 
Cancer Research UK, 2014). There are an estimated 41,000 new cases 
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diagnosed each year, resulting in approximately 16,000 cancer deaths across 
the United Kingdom (UK) (Cancer Research UK, 2014).  Epidemiological data 
suggests that across western society the incidence of CRC diagnoses is steadily 
increasing (Center et al., 2009). Interestingly, this increase has also been 
mirrored in the developing world where the adoption of a western style diet has 
been implicated (Center et al., 2009). In the UK, CRC incidence started to fall in 
the 1990s but has again increased since the advent of CRC screening where 
there is detection of earlier asymptomatic cancers (Jones et al., 2009; Logan et 
al., 2012). Across both genders CRC is predominantly a disease of the over 50s 
with incidence rates rising steeply between the ages of 50 and 54 years and peak 
incidence between the ages of 80 and 84 years (Cancer Research UK, 2014). 
Therefore with an ever-increasing elderly population it is predicted that incidence 
rates will continue to rise.  Both in the UK and across the world the incidence of 
CRC is higher in males with an age-specific incidence rate 1.7 times higher than 
females between the ages of 60 and 64 years (Cancer Research UK, 2014). 
Survival outcomes are related to the stage of disease at diagnosis, with overall 
survival rates at 1 year, 5 years and 10 years reported as 75.7%, 58.7% and 
56.6% respectively (Cancer Research UK, 2014).  
1.2.2 Risk factors 
There are a number of recognised risk factors associated with the development 
of CRC. Hereditary conditions associated with CRC include familial 
adenomatous polyposis (FAP) and the autosomal dominant syndrome hereditary 
non-polyposis colorectal cancer (HNPCC). Inflammatory bowel disease, 
particularly Ulcerative Colitis, is also associated with an increased risk of 
developing CRC (Choi et al., 2017). 
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Lifestyle factors contribute to an individual’s risk of developing CRC. These 
include obesity, physical inactivity, smoking, excess alcohol consumption, diets 
high in red meat and inadequate dietary fruit and fibre intake (Giovannucci, 2002; 
Botteri et al., 2008; Haggar & Boushey, 2009). The risk of developing CRC is 
associated with obesity as examined in a meta-analysis by Xue et al., which 
reported an increased risk of developing CRC of 12% and 18% in obese women 
and men respectively, when compared to persons of normal body mass index 
(BMI) (Xue et al., 2017). Specific dietary factors implicated as risk factors for the 
development of CRC include consumption of red meat and low intake of dietary 
fibre (Parkin, 2011). There are a number of meta-analyses that report CRC risk 
to be 17% to 30% higher per 100-120g/day of red meat consumption (Parkin, 
2011; Aune et al., 2011).  Low intake of dietary fibre is a risk factor in 
approximately 12% of CRC cases (Parkin, 2011). With a range of dietary factors 
implicated in CRC carcinogenesis there is increasing interest in the potential 
protective effects of O3FAs on CRC carcinogenesis, the mechanisms by which 
these might act and whether there are any potential clinical applications. 
1.2.3 Aetiology 
Colorectal adenocarcinoma is the predominant histological type. The location of 
colorectal adenocarcinoma within the colon is variable. The rectum and sigmoid 
colon are the most common sites of primary colorectal tumours (approximately 
50% and 30% respectively) (Cancer Research UK, 2014). The remainder of 
colorectal malignancies are evenly distributed throughout the ascending, 
transverse and descending colon.  CRC is a disease of the colonic mucosa with 
benign colorectal adenomatous polyps the precursor in the ‘adenoma-
carcinoma’ sequence (Fearon & Vogelstein, 1990; Cotton et al., 1996). 
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Development of CRC is multi-factorial with the genetic events that lead to tumour 
development now widely understood. There are a number of genetic mutations 
that inactivate tumour suppressor genes or drive oncogene expression, 
subsequently leading to the transition from benign to malignant invasive disease 
(Goss & Groden, 2000; Morin et. al, 1997; Vazquez et al., 2008; Baker et al., 
1990; Downward, 1998; Bos et al., 1987). 
1.3 Omega-3 fatty acids 
1.3.1 O3FA structure and metabolism 
O3FAs are long chain PUFAs, in which the first carbon to carbon double bond is 
positioned at the third carbon from the methyl (CH3) end of the carbon chain. 
Eicosapentaenoic (c20:5ω-3, EPA, figure 1) and docosahexaenoic acid (c22:6ω-
3, DHA, figure 1) are found naturally in oily fish as a result of the high levels of 
EPA and DHA contained within algae consumed by fish (Monroig et al., 2013). 
Humans primarily acquire EPA and DHA through dietary intake and therefore 
they are referred to as essential fatty acids. EPA consists of a 20-carbon chain 
and five double bonds, whereas DHA is a 22-carbon chain with six double bonds. 
Both are classified as O3FAs due to the location of the first double bond at the 
third carbon from the omega end of the fatty acid structure.  As shown in figure 
2, EPA and DHA are also synthesised from the shorter chain precursor O3FA α-
linolenic acid (ALA), which is found in plant sources such as flax seed (Arterburn 
et al., 2006; Schuchardt & Hahn, 2013). ALA is converted to EPA and eventually 
DHA via a series of enzymatic reactions (Arterburn et al., 2006).  In humans, this 
conversion process is relatively inefficient due to limited Delta-6 desaturase 
activity. Therefore relatively low levels of ALA are converted to the biologically 
active EPA and DHA (Horrobin, 1993; Nakamura & Nara, 2003). The conversion 
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rate of ALA to EPA and DHA is greater in women at approximately 14% 
compared to 10% in men (Yang et al., 2017; Falkiow, 2016). Diets high in linoleic 
acid (LA), for example from sunflower oil, further reduce the conversion of ALA 
to the longer chain O3FAs by substrate competition for the delta-6 desaturase 
enzyme (Emken et al., 1994). Reducing consumption of LA may therefore induce 
modest increases in EPA and DHA levels (Wood et al., 2015).   
PUFA metabolism is affected by single nucleotide polymorphisms (SNP) in the 
FADS1, FADS2 and ELOVL genes which encode for the delta 5 desaturase, 
delta 6 desaturase and elongase enzymes (figure 2) (Marquardt et al., 2000; 
Guillou et al., 2010). SNP in the FADS1 and FADS2 genes may be associated 
with differences in PUFA metabolism exhibited across both sex and ethnicities. 
The rs174547 polymorphism in the FADS1 gene is reported to be associated 
with reduced activity of both delta 5 desaturase and delta 6 desaturase enzymes 
which results in lower DHA and ALA levels, with a higher proportion of LA (Guo 
et al., 2017). A European population based study details a number of FADS1 
and FADS2 haplotypes that exhibit differential serum DPA and EPA phospholipid 
levels (Schaeffer et al., 2006). Specific SNP examined in the FADS2 gene are 
located in CpG islands within promoter regions of the gene which may therefore 
affect transcription of the FADS2 gene and subsequent expression of the delta 
6 desaturase enzyme (Schaeffer et al., 2006; Lattka et al., 2010). The 
metabolism of AA appears to be affected most by a number of SNP in the FADS1 
and FADS2 genes that affect both delta 5 and delta 6 desaturase enzyme activity 
(Bokor et al., 2010; Schaeffer et al., 2006). Much of the scientific literature 
examining various SNP in the FADS1 and FADS2 genes measure PUFA levels 
within serum phospholipids, which may not reflect PUFA metabolism in RBC 
membranes. However there is emerging evidence that the differential activity of 
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both delta 5 desaturase and delta 6 desaturase enzymes associated with various 
SNP is also demonstrated in RBC membranes (zehak et al., 2008).  
SNP may also influence an individual’s response to O3FA supplementation. This 
was apparent in a parallel double-blind placebo controlled trial where carriers of 
minor alleles of the ELOVL2 gene exhibited a greater response to EPA/DHA 
supplementation when measuring plasma O3FA levels (Alsaleh et al., 2014).   
 
 
 
 
 
 
 
 
 
 
Figure 1. Chemical structure of EPA, DHA and AA. 
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1.3.2 Sources of O3FAs 
Although the modern western diet is plentiful in omega-6 fatty acids (O6FA) such 
as linoleic acid (c18:2ω-6, LA), which are primarily found in vegetable oils, the 
major dietary supply of O3FAs is from oily fish such as salmon, mackerel, sardine 
and herring  (Arterburn et al., 2006; Shirai et al., 2006; Bandarra et al., 2018). A 
recent American study highlights that the general population consumes on 
average less than a third of the daily recommended amount of O3FAs (0.5g/day) 
and that in part was due to low levels of fish consumption (Richter et al., 2017). 
O3FAs are widely available as over-the-counter nutritional supplements, due to 
the emerging apparent health benefits. O3FA ‘nutraceuticals’ are most 
commonly found in capsule form, although alternative juice drink cartons are now 
available. O3FAs are considered safe up to daily doses exceeding 4g, although 
doses exceeding 2g daily usually require split dosing (Wang et al. 2006). Side-
effects observed in large cardiology trials with mixed O3FA capsule formulations 
are usually minor and predominantly relate to the gastrointestinal tract, with 
nausea, eructation, abdominal discomfort and diarrhoea in 0-10% of cases 
(Wang et al., 2006; Abdelhamid et al., 2018). A recent meta-analysis of 29 trials 
including over 65000 participants indicated that around three percent of 
individuals reported a gastrointestinal side-effect associated with O3FA 
supplementation (Abdelhamid et al., 2018).   
1.3.3 Chemical forms and absorption of O3FAs 
O3FAs are found in various chemical forms. Marine O3FAs are usually in the 
triglyceride form, whereby long chain O3FAs are bound to a glycerol backbone. 
When consumed in triglyceride form, free fatty acids (FFA) are liberated in the 
small intestine by hydrolysis by pancreatic lipases, after which they are re-
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esterified within enterocytes, subsequently incorporated into chylomicrons and 
then released into circulating lymph for systemic distribution (Schuchardt & 
Hahn, 2013).  Adequate fat intake is required for absorption of triglyceride-bound 
O3FA supplements, in order to stimulate secretion of pancreatic lipases 
(Schuchardt & Hahn, 2013; Elvevoll et al., 2006). It is therefore usually necessary 
to consume triglyceride bound O3FA supplement capsules with a meal, which 
also limits the gastrointestinal side-effects associated with O3FA 
supplementation (Abdelhamid et al., 2018). To a lesser extent FFA O3FAs are 
also found in natural fish oil sources. There are also ethyl-ester O3FA 
preparations found in refined fish oil preparations (Breivik et al., 1997). The 
chemical process of re-esterification enables production of re-esterified 
triglyceride-bound O3FAs that contain much higher concentrations of EPA and 
DHA (Dyerberg et al., 2010).  The importance of the chemical form of O3FA and 
the relationship to bioavailability will be discussed later.  
1.4 Bioavailability of O3FAs 
1.4.1 Measurement of O3FA bioavailability 
The bioavailability of O3FAs is key when considering any potential clinical 
applications. Bioavailability is often cited as the amount of active substance that 
is available within the systemic circulation and is affected by a number of factors 
including absorption from the gastrointestinal tract. However, as discussed later, 
the O3FAs are physiologically active within tissues and may take a number of 
weeks to build up to steady state levels.  It is therefore important to appreciate 
that measures of bioavailability from blood and plasma simply represent the 
amount of O3FAs available rather than the proportion of physiologically active 
O3FAs.    
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There are a number of studies exploring the most appropriate measure of O3FA 
bioavailability. O3FAs compete with O6FAs for incorporation into cellular 
membranes with subsequent activation of multiple cellular mediators (Calder, 
2006). O3FAs are incorporated into the phospholipid membrane of tissues 
throughout the body including the cellular membranes of erythrocytes, which 
provide a convenient measure of O3FA content via collection of red blood cells 
(RBC) (Surette, 2008; Arterburn et al., 2006; Brenna et al., 2018).  
Although plasma O3FA measurement provides a measure of short-term 
systemic O3FA levels, they are subject to significant short-term variability (von 
Schacky & Weber, 1985; Cao et al., 2006; Arterburn et al., 2006). Scaioli et al. 
highlighted a rapid increase in O3FA plasma content compared to RBC 
membrane content in a parallel study comparing 2g daily EPA supplementation 
in both patients diagnosed with inflammatory bowel disease and healthy 
volunteers (Scaioli et al., 2015). Steady state O3FA plasma levels were reached 
at two weeks compared with four to eight weeks in RBC membranes, similar to 
other published results (Katan et al., 1997; Cao et al., 2006; Stonehouse et al., 
2011). There is significant variability of measured O3FA levels in plasma 
compared with RBC membranes, which appear to provide a more consistent 
measure of long-term O3FA incorporation as highlighted by Harris et al. who 
reported O3FA level intra-individual variability of 4.1% +/- 1.9% in RBC 
membranes compared to 15.9% +/- 6.4% in plasma (Harris & Thomas, 2010).  
When used in short-term nutritional studies measuring relatively low daily intakes 
of O3FAs, RBC membrane O3FA levels do not exhibit as strong dose-related 
relationship to other measures of O3FA bioavailability, for example plasma 
(Browning et al., 2012). However for intervention studies that utilise O3FA 
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dosages that far exceed recommended daily intakes, measurement of RBC 
membrane O3FA content is considered an accurate reflection of long-term O3FA 
content within multiple target tissues, in part due to the relatively long half-life of 
RBCs within the systemic circulation (Metcalf et al., 2007; Harris et al., 2004; 
Brenna et al., 2018). This is of importance when assessing compliance and 
determining any correlation between O3FA supplementation and clinical 
outcomes. With specific reference to gastrointestinal tissues, Gurzell et al. report 
that individual EPA and DHA RBC levels, as well as combined EPA and DHA 
levels, the so-called O3FA index (discussed later) are strongly correlated with 
EPA and DHA levels measured within colonic tissue of mice, using a variety of 
O3FA doses up to an equivalent human dosage of 4g per day (Gurzell et al., 
2014).   
There is limited data in the current scientific literature exploring the bioavailability 
of O3FAs in CRC patients. There are two randomised controlled trials (RCT) in 
CRC patients that report rapid incorporation of EPA into colonic mucosal tissue 
following seven to 12 days of O3FA supplementation (Sorensen et al., 2014; Gee 
et al., 1999).  However neither study examined the bioavailability within 
colorectal tumour tissue or assessed whether there was any correlation with 
RBC membrane incorporation. 
The O3FA index is defined as a measure of EPA and DHA content within RBC 
membranes. It is calculated as the sum of EPA and DHA as a percentage of total 
fatty acid content within RBC membranes and was initially widely used as a 
biomarker for determining the risk of cardiac death (Harris & von Schacky, 2004; 
Harris, 2008). An O3FA index greater than or equal to 8% is considered to have 
cardioprotective benefit using a daily EPA/DHA dose of 1g (Harris & von 
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Schacky, 2004). A number of observational studies highlight that higher intake 
of O3FAs, either via supplementation or increased dietary intake is associated 
with increases in the O3FA index (Block et al., 2008; Sands et al., 2005; Itomura 
et al., 2008). A RCT examining the effect of varying O3FA supplementation 
dosages on the O3FA index reported a dose-dependent relationship, and that 
factors including age, gender and baseline O3FA index levels were predictors of 
greater increases in the O3FA index post-supplementation (Flock et al., 2019). 
The O3FA index may be the most suitable measure of O3FA bioavailability in 
long-term intervention studies given the combined nature of many O3FA 
supplements and its dose-dependent properties.   
1.4.2 Factors affecting O3FA absorption and bioavailability 
A number of factors determine absorption and subsequent bioavailability of 
O3FAs, including chemical form. There are multiple studies examining the effect 
of chemical binding type on the bioavailability of O3FAs. However there is 
significant methodological variation, in particular with respect to the blood 
compartment measured, the duration of supplementation and the dosages of 
O3FAs administered, with doses up to 7.3g/day of EPA and DHA combined in 
one study (Krokan et al., 1993). Much of the available literature examines the 
impact of the chemical form of O3FA supplementation on plasma or serum O3FA 
levels, rather than RBC O3FA membrane levels. These studies do not provide 
insight into long-term bioavailability, which is of particular relevance when 
considering the effects of O3FA supplementation and any role in 
chemoprevention or adjuvant cancer treatment (Dyerberg et al., 2010; Reis et 
al., 1990; Hansen et al., 1993; Offman et al., 2017).  
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FFA O3FA formulations exhibit enhanced EPA and DHA bioavailability in plasma 
compared with both triglyceride and ethyl-ester forms of O3FA supplementation, 
which is likely secondary to the bypassing of the pancreatic lipase breakdown 
pathway (El Boustani et al., 1987; Lawson & Hughes, 1988; Davidson et al., 
2012). Re-esterified triglyceride formulations, which have undergone chemical 
modification to produce concentrations of EPA and DHA of up to 90%, provide 
the highest levels of O3FA bioavailability in studies examining both plasma and 
RBC membrane levels (Neubronner et al., 2011; Dyerberg et al., 2010). A RCT 
of 129 participants comparing re-esterified triglyceride-bound O3FA 
supplementation and ethyl-ester forms of O3FA supplementation, over a six 
month period, demonstrated enhanced RBC membrane incorporation in the 
triglyceride-bound group at three and six monthly intervals, compared with 
baseline (Neubronner et al., 2011).  
Other factors that may impact O3FA uptake and bioavailability include dosing 
with food. Consumption of triglyceride-bound O3FA supplements requires the 
concomitant intake of dietary fat to ensure adequate pancreatic lipase secretion 
for hydrolysis and subsequent uptake of O3FAs within the small intestine 
(Schuchardt & Hahn, 2013). It is therefore a requirement to consume many O3FA 
supplements with a meal. The aforementioned long-term studies examining 
bioavailability of O3FAs in various chemical formulations fail to provide any 
measure of dietary fat intake (Neubronner et al., 2011; Dyerberg et al., 2010). 
Short-term supplement studies of O3FA plasma levels report that concomitant 
consumption of higher amounts of dietary fat result in increased O3FA plasma 
levels of both triglyceride and ethyl-ester formulations (Lawson & Hughes, 1988; 
Davidson et al., 2012). This is of significant importance when considering O3FA 
supplementation as either a chemoprevention or adjuvant treatment, as for both 
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purposes the requirement to consume supplements with sufficient dietary fat 
intake may impact acceptability to both healthy individuals and CRC patients. 
Dietary calcium intake may also affect O3FA bioavailability due to the interaction 
between calcium ions and FFAs (Scarsi et al., 2015). 
The chemical stability of various O3FA preparations is also likely to impact the 
bioavailability of O3FAs. Due to the presence of double bonds within the O3FA 
chain they are prone to oxidisation and are replaced by oxidation products 
including aldehydes and ketones (Shahidi & Zhong, 2010; Benzie, 1996). A study 
of 32 individual encapsulated O3FA supplements identified that only three (9%) 
contained equivalent amounts to labelled claims (Albert et al., 2015). The 
addition of antioxidants which reduce the rate of the oxidation process, for 
example α-tocopherol, is now commonplace (Zuta et al., 2007).  
1.4.3 Novel methods of O3FA supplementation 
The requirement to consume many O3FA supplements with dietary fat to 
facilitate absorption has led to the development of new technologies designed to 
limit the requirement to ingest O3FA supplements with high fat meals (Lopez-
Toledano et al., 2017; Maki et al., 2018). These include self-micro-emulsifying-
delivery systems (SMEDS), which enhance the absorption of ethyl-ester 
preparations of EPA and DHA in a fasting state (Maki et al., 2018). An ethyl-ester 
preparation that is modified to form micelles in the absence of bile excretion has 
shown variable absorption of EPA and DHA in the absence of dietary fat (Lopez-
Toledano et al., 2017).  
The development of novel O3FA supplement juice drinks such as Smartfish™ 
Remune has led to a potential role in both chemoprevention and as an adjuvant 
treatment in CRC patients.  O3FA supplement drinks have been used in patients 
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with chronic obstructive pulmonary disease and shown to have clinical benefits 
in cachectic patients (Calder et al., 2017). This is of relevance in CRC patients 
as the cartons may present a more acceptable method of O3FA supplementation 
in individuals whom also require calorific supplementation due to gastrointestinal 
disturbance, either as a result of surgery or chemotherapy. As a 
chemoprevention, supplementation drinks may be used as a method of 
delivering O3FAs in a healthy population, potentially as a substitute to normal 
dietary intake. However there is a lack of evidence exploring bioavailability of 
these preparations, specifically comparing RBC membrane incorporation over a 
prolonged period compared with traditional capsule supplementation. In a 
placebo-controlled trial Kohler et al. showed a mean increase of 2.43% in the 
O3FA index after daily supplementation for eight weeks with a convenience drink 
containing 500 mg EPA/DHA, although the chemical form of O3FA is not clear 
(Köhler et al., 2010). The supplement drink was tolerated well with no severe 
adverse reactions, although the authors acknowledge that the sample size was 
insufficient to detect rare side-effects (Köhler et al., 2010). Alternative O3FA 
preparations are available, including the supplement drink used in the present 
study which provides a combined EPA/DHA dosage of 2000 mg per carton. On 
review of the current literature this is equivalent to the O3FA dosages used in 
human CRC and polyp studies (Courtney et al., 2007; West et al., 2010; 
Sorensen et al., 2014; Cockbain et al., 2014). One of the key questions 
surrounding these drink supplements is whether they contain sufficient fat 
content to stimulate pancreatic lipase release, thus negating the requirement to 
take triglyceride-bound O3FA supplements with food. 
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1.5 Protective role of O3FAs in inflammation and CRC carcinogenesis 
1.5.1 Epidemiological studies 
Interest in the potential health benefits of O3FAs was first identified in population 
studies of the Greenland Inuits which reported low levels of cardiovascular 
disease in the presence of high dietary O3FA intake from fish (Bang et al., 1971). 
A series of epidemiological studies followed, primarily focused on cardiovascular 
disease, which demonstrated an inverse relationship between fish consumption 
and cardiovascular mortality (Daviglus et al., 1997; Hu et al., 2002; Iso et al., 
2001).  The potential cardio-protective benefits of O3FAs prompted research into 
possible interactions with other diseases including CRC. Initial studies suggested 
that as the diets of native Alaskans transitioned from one of relatively high fish 
consumption to one similar to that of non-native Americans there was an 
increase in the incidence of CRC (Byers, 1996).There are a number of 
epidemiological studies that suggest an inverse relationship between O3FA 
supplementation and CRC risk, some of which demonstrate differences across 
sex, ethnicity and tumour location (Kato et al., 1997; Hall et al., 2008; Kim et al., 
2010; Sasazuki et al., 2011). The most tangible epidemiological evidence of a 
protective association between fish consumption, O3FAs and CRC is a 
comprehensive meta-analysis of 41 studies covering a 20 year period (total 
n=1,454,578 patients) which reported that fish consumption was inversely 
related to CRC risk (OR, 0.88; 95% CI, 0.80-0.95) (Wu et al., 2012). The authors 
of the aforementioned study reported heterogeneity across retrospective case-
controlled studies that was not evident in prospective cohort studies and which 
impacted on study outcomes. A meta-analysis of fourteen prospective cohort 
studies reported that the relative-risk of CRC incidence in those consuming the 
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highest amounts of fish compared to the lowest levels was 0.88 (Geelen et al., 
2007). It is apparent that direct comparison of studies is hampered by 
methodological heterogeneity, particularly quantification of dietary O3FA intake. 
This is highlighted by the latest consensus report from the 2017 World Cancer 
Research Fund (WCRF) and the American Institute for Cancer Research (AICR), 
which acknowledges an association between fish consumption and decreased 
CRC risk, but describes the evidence as limited  (WCRF, 2017).  Specific 
epidemiological evidence related to the consumption of O3FAs and reduced 
CRC risk is sparse. In a cohort study of 68109 individuals aged between 50 and 
76 years, Kantor et al. quantified O3FA intake via a dietary questionnaire (Kantor 
et al., 2014). They reported a 49% lower risk in the development of CRC in users 
of fish oil supplements compared to non-users.  
1.5.2 Mechanisms of O3FA anti-neoplastic activity 
In order to implement O3FA supplementation for the purposes of either CRC 
chemoprevention or adjuvant treatment, an understanding of the mechanisms 
via which O3FAs are proposed to have an anti-cancer effect is required. The 
process of inflammation is a driver of colorectal carcinogenesis, with emerging 
evidence to suggest PUFAs influence colorectal carcinogenesis via modulation 
of inflammatory pathways and production of eicosanoids such as prostaglandins, 
thromboxanes and leukotrienes (Gupta & Dubois, 2001; Marnett & DuBois, 
2002). Pro-inflammatory eicosanoids promote carcinogenesis via a number of 
mechanisms including suppression of apoptosis, promotion of angiogenesis and 
stimulation of cell proliferation (Tsutsumi et al., 2002; Leahy et al., 2002; Cianchi 
et al., 2001; Pai et al., 2001). The effect of O3FAs on inflammation over 
prolonged periods is key to their potential application as a method of 
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chemoprevention in CRC. Both O3FAs and O6FAs are substrates for cyclo-
oxygenase (COX) enzymes (Eisinger et al., 2007). This is of significant interest 
in the context of CRC as eicosanoid generating COX enzymes, specifically COX-
2 are overexpressed in 50-80% of tumours (Eberhart et al., 1994; Sano et al., 
1995; Kargman et al., 1995). O3FAs including EPA compete with AA for COX 
binding, thereby effecting eicosanoid production (Smith, 2005; Wang & Dubois, 
2010). AA-derived eicosanoids are generally identified as pro-inflammatory, 
whereas their O3FA derived counterparts are anti-inflammatory. In the presence 
of EPA there is decreased production of the ‘pro-tumorigenic’ prostaglandin E2 
(PGE2) which is generated by AA interaction with COX enzymes (Hawcroft et al., 
2010). PGE2 is identified at higher concentrations in CRC tissue compared to 
normal tissue (Chulada et al., 2000). Reductions in other pro-inflammatory 
cytokines, including tumour necrosis factor (TNFα) and interleukin 1β (IL-1β) also 
occur following EPA supplementation (Caughey et al., 1996). In CRC patients a 
RCT examining the effects of EPA in the treatment of colorectal cancer liver 
metastases (CRCLM) found a statistically significant reduction in prostaglandin 
metabolite levels, which may be considered a surrogate marker for PGE2 
production (Cockbain et al., 2014). O3FA supplementation also results in 
displacement of AA from cell membranes (Crawford et al., 2000). Additionally, 
EPA specifically exhibits a higher affinity for elongase enzymes than LA, leading 
to competitive inhibition and thus reducing the conversion of LA to AA (Rose & 
Connolly, 1999). Therefore supplementation with ALA, EPA or DHA results in a 
significant decrease in the concentration of AA as shown in a number of studies 
in healthy individuals (Yaqoob et al., 2000; Thies et al., 2001).  
There is increasing evidence to suggest O3FAs influence the production of other 
inflammatory mediators including resolvins (Moro et al., 2016). Biosynthesis of 
20 
 
these inflammatory mediators from O3FAs is modulated by lipoxygenase 
enzymes (LOX) (Serhan et al. 2015). The Resolvin RvE-1 is postulated to inhibit 
CRC carcinogenesis via activation of the ChemR23 protein coupled receptor and 
inhibition of nuclear transcription factor Kb (NF-κB) as demonstrated in mouse 
models (Kure et al., 2010; Janakiram et al., 2011). NF-κB is a transcription factor 
vital for propagating inflammatory pathways and tumour development (Clevers, 
2004). There is also evidence to suggest that EPA acts as an alternative 
substrate for COX to generate the anti-inflammatory prostaglandin E3 (PGE3) 
(Smith, 2005; Hawcroft et al., 2010). Mouse models of colorectal carcinogenesis 
exhibit preferential production of anti-inflammatory PGE3 in the presence of EPA 
(Vanamala et al., 2008). Examples of the enzymatic generation of both 
eicosanoids and docosanoids from EPA, DHA and AA are briefly summarised in 
figure 3. 
Incorporation of O3FAs into the cellular membrane may also affect cell 
membrane structure and integrity, thus influencing CRC development (Chapkin 
et al., 2002). EPA and DHA are implicated in maintaining intestinal epithelial cell 
integrity via direct incorporation into the phospholipid membrane (Rees et al., 
2006; Nieto et al., 2002). Of particular interest is the effect on ‘lipid rafts’ that are 
associated with cell membrane proteins identified in signalling pathways, which 
may subsequently promote tumour growth (Ibarguren et al., 2014). Mouse 
models confirm that DHA supplementation results in decreased presence of the 
epidermal growth factor receptor (EGFR) protein within lipid rafts and a 
concomitant reduction in tumour weight compared to controls (Rogers et al., 
2010). O3FAs also interact with G-protein-coupled receptors (GPCR) located in 
cell membranes. There are multiple mechanisms of action via which O3FAs are 
reported to suppress inflammatory pathways, including activation of the GPR120 
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receptor in macrophages and dendritic cells, and also via production of 
inflammatory mediators such as resolvins (Arita et al., 2005; Oh et al., 2010). Oh 
et al. reported that DHA inhibits TNFα inflammatory signalling pathways in both 
in-vitro and in-vivo studies, where inhibition of the TNFα inflammatory gene is 
completely abrogated in GPR120 knockout mice (Oh et al., 2010). The 
peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear 
receptors are also activated by O3FAs and there is some evidence that this may 
modulate NF-κB inflammatory pathways (Krey et al., 1997; He et al., 2017). 
However, the mechanism by which this occurs is not fully understood as in the 
presence of PPAR inhibitors there continues to be O3FA-induced inhibition of 
NF-κB mediated inflammatory cytokine production (Draper et al., 2011; Magee 
et al., 2012).   
The presence of a methylene group between two double bonds in the chemical 
structure of O3FAs makes them highly prone to attack by free radicals, even 
more so DHA which contains five methylene groups. The process of non-
enzymatic lipid peroxidation by reactive oxygen species (ROS) results in the 
generation of highly toxic products such as aldehydes (Siddiquia et al., 2008). In 
the context of CRC, lipid peroxidation increases the activation of apoptotic 
pathways by potentiation of caspase-3 activity in multiple CRC cell lines and 
presents a potential avenue for CRC treatment (Hossain et al., 2008). 
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1.5.3 Animal studies exploring the effect of O3FAs on CRC carcinogenesis 
The effect of O3FAs on CRC carcinogenesis in mouse models is well 
documented and provides evidence for the consideration of O3FA 
supplementation in both chemoprevention and as a CRC adjuvant treatment. 
There are a number of studies that report both decreased tumour multiplicity and 
Pro-inflammatory eicosanoids 
COX-2 enzyme 
DHA EPA AA 
Anti-inflammatory 
eicosanoids and docosanoids 
LOX enzymes 
e.g. 5-LOX 
PGE2 LTE4 PGE3 RvE RvD 
Pro-inflammatory eicosanoid PUFA conversion  
Anti-inflammatory eicosanoid and docosanoid PUFA conversion  
Competitive substrate inhibition  
Figure 3. Diagrammatic representation of the enzymatic conversion of EPA, DHA and AA by 
COX-2 and LOX enzymes to generate pro-inflammatory and anti-inflammatory eicosanoids 
and docosanoids. Anti-inflammatory eicosanoids and docosanoids include PGE3 and both D 
and E series resolvins (RvD and RvE). Pro-inflammatory eicosanoids include Leukotriene 4 
(LTE4) and PGE2  
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size following various O3FA containing diets (Petrik et al., 2000; Boudreau et al., 
2001; Reddy et al., 1991). The Apc(Min/+) mouse model data reported by Petrick 
et al. illustrated a reduction in both tumour number and size after 
supplementation with EPA and DHA (Petrik et al., 2000). There was also 
concomitant reduction in mucosal PGE2 tissue levels following O3FA 
supplementation. In the Apc(Min/+) mouse model Fini et al. reported that animals 
fed an EPA-containing diet had a 78% reduction in polyp numbers compared to 
animals fed a predominantly O6FA containing diet (Fini et al., 2010). The animals 
fed an EPA rich diet also exhibited lower levels of mucosal AA and a reduction 
in COX-2 expression. These animal studies are of interest in the application of 
O3FAs as a method of chemoprevention as they provide evidence to suggest 
O3FAs impair the transition of normal colonic tissue to pre-malignant adenomas.  
EPA and DHA are proposed to impair colorectal carcinogenesis via promotion of 
apoptosis (Fukunaga et al., 2008). In an Azoxymethane (AOM) induced rat 
model of CRC, rats fed a combination of O3FAs and pectin exhibited a lower 
incidence of colorectal tumours compared to animals fed corn oil (Cho et al., 
2011). These animals also showed a concomitant increase in the apoptotic index 
within the colon, and there was also lower expression of genes associated with 
cell adhesion. Kansal et al. reported induction of apoptosis and suppression of 
cellular proliferation via inhibition of Ras-mediated cellular pathways in mice fed 
a combination of EPA and DHA (Kansal et al., 2012). Ras controls the growth 
and differentiation of colonic cells and is of significant importance in colorectal 
carcinogenesis, in which mutations in the Ras oncogene are identified in a 
significant proportion of CRCs (Shirasawa et al., 1993; Worthley et al., 2007). 
The p53 tumour suppression gene is important in the regulation of apoptosis and 
maintenance of the cell cycle. Mutation of the p53 gene is accompanied by a loss 
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of function and is implicated in colorectal carcinogenesis (Hainaut et al., 1998).  
A mouse study comparing the effects of EPA and DHA supplementation in two 
CRC cell lines, one possessing a p53 mutation (WiDr), the other with wild type 
p53 (COLO 205), showed decreased cell proliferation in both cell lines following 
O3FA treatment (Kato et al., 2007). Interestingly, the degree to which tumour cell 
proliferation was inhibited was dependent on the type of O3FA supplementation, 
with DHA exhibiting a significantly increased inhibitory effect in wild type p53 cell 
lines compared to mutated p53 cell lines. This was not apparent in animals fed 
EPA, where the inhibitory effects of EPA were similar across both cell lines. The 
authors concluded that the anti-cancer effects of DHA are more profound than 
EPA and that the mechanism of DHA inhibition of colorectal carcinogenesis is 
p53 dependent, whereas EPA mechanisms are independent of p53 function.  A 
GCPR mechanism of inhibiting colorectal carcinogenesis by EPA and DHA has 
been demonstrated in an AOM/DSS-induced CRC mouse model, in which there 
was significantly reduced tumour incidence and volume (Zhang et al., 2016). 
There was also evidence of an O3FA dose-dependent reduction in cellular 
proliferation and an increase in apoptotic cells in an in-vitro study (Zhang et al., 
2016). 
There is emerging evidence to suggest O3FAs ameliorate CRC carcinogenesis 
via epigenetic mechanisms, including methylation of DNA promoter regions, 
which subsequently inhibit gene transcription. A mouse study identified higher 
levels of 5-methylcytosine, a form of methylated DNA in mice treated with 
O3FAs, which corresponded with a statistically significant lower tumour 
incidence (Huang et al., 2016). The Bcl-2 protein is an anti-apoptotic mediator 
which is upregulated in a variety of cancers including CRC (Kirkin et al., 2004). 
Expression of the Bcl-2 protein is suppressed by methylation of the promoter 
25 
 
region of the BCL-2 gene, thus enhancing apoptosis (Cory & Adams, 2002). In 
an AOM-induced CRC rodent model, animals fed a combination of EPA and DHA 
exhibited decreased tumour incidence (Cho et al., 2012). The study also 
identified a higher apoptotic index in O3FA fed animals, which corresponded with 
elevated Bcl-2 promoter methylation and lower levels of Bcl-2 transcripts. The 
downregulation of Bcl-2 expression and concurrent enhancement of apoptosis 
in the presence of O3FA supplementation has been replicated in other animal 
models (Hong et al., 2003).     
Angiogenesis, the development of new blood vessels, is stimulated in colorectal 
tumour tissue by the generation of vascular endothelial growth factor (VEGF) 
(Takahashi et al., 1995). In a CRC mouse model, animals fed EPA or DHA 
exhibited a statistically significant reduction in tumour volume, tumour weight and 
microvessel density (Calviello et al., 2004). These findings coincided with 
decreased expression of both VEGF and COX-2. The inhibition of angiogenesis 
by O3FA supplementation may be most relevant in the treatment of CRC or the 
adjuvant treatment of metastatic disease, since VEGF is produced by tumour 
tissue to stimulate neovascularisation and tumour growth (Guba et al., 2004). 
The effect of the ratio of O3FA to O6FA on colonic inflammation and CRC 
carcinogenesis has been demonstrated in mouse models where animals are fed 
a 2.5:1 ratio of O3FAs:O6FAs. There was a reduction in the number of N,N'-
dimethylhydrazine-induced plaque lesions compared to mice fed a 1:1 
O3FA:O6FA diet (Sarotra et al., 2012). The role of the O3FA to O6FA ratio has 
also been demonstrated in fat-1 transgenic mice. These mice contain a fat-1 
gene that encodes for an O3FA desaturase which enables the conversion of 
O6FAs to O3FAs (Kang et al., 2004). In fat-1 transgenic mouse studies of DSS 
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induced chronic inflammation, the ratio of O6FAs to O3FAs was lower than wild-
type mice, with concurrent significant reduction of a variety of inflammatory 
cytokines (Gravaghi et al., 2011). Similar findings of a suppressive effect on 
colonic inflammation were identified in a trinitrobenzenesulfonic acid (TNBS)-
induced colitis model of fat-1 transgenic mice, with significant reductions in 
markers of oxidative stress, pro-inflammatory NF-κB activity and COX-2 
expression (Yum et al., 2017). Although the aforementioned studies were 
primarily focused on the interplay between PUFAs and inflammatory pathways, 
they are of importance in the consideration of O3FA supplementation as a 
method of chemoprevention, as inflammation is inextricably linked to colorectal 
carcinogenesis. In a fat-1 transgenic mouse model of DSS/AOM induced 
colorectal carcinogenesis there were both a lower number and volume of 
colorectal tumours, with down regulation of NF-κB activity and COX-2 inhibition 
(Nowak et al., 2007). The O6FA:O3FA ratio was also significantly lower in fat-1 
transgenic mice compared to wild type controls, suggesting the endogenously 
generated O3FAs garnered a protective effect. Similar findings have been 
reported in another study using fat-1 transgenic mice where there were a 
reduced number of colorectal tumours and lower levels of PGE2  (Jia et al., 2008).  
There were also higher levels of the anti-inflammatory EPA-derived eicosanoid 
PGE3.   
1.5.4 The effect of O3FAs on CRC metastasis 
Of relevance for consideration of O3FAs as a potential adjunct in the treatment 
of CRC, is any effect on metastatic disease. An in-vivo study exploring colorectal 
lung metastases identified a reduction in the number of lung metastases in mice 
treated with EPA and DHA, which the authors accounted for as being secondary 
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to alterations in cell membrane structure (Ligo et al., 1997). The liver is the most 
common site of metastatic spread in CRC. In a mouse model of CRCLM 
Hawcroft et al. reported that EPA treatment was associated with a significant 
decrease in liver tumour burden (Hawcroft et al., 2012). There was also evidence 
of a reduction in pro-inflammatory PGE2 levels, with a reciprocal increase in the 
anti-inflammatory prostaglandin PGE3. As previously described, PGE2 is a 
cytokine associated with colorectal carcinogenesis (section 1.5.2). The effect of 
O3FA supplementation on CRCLM is also reported in other studies where 21% 
of mice fed an O3FA-rich diet exhibited tumours in the liver, compared to 70% in 
the control group that were fed coconut oil (Gutt et al., 2007). It is therefore 
feasible that O3FAs may have a role in the adjuvant treatment of CRC 
metastasis. However there is a lack of evidence as to whether the effects on 
CRCLM exhibited in animal models would be reproducible in other anatomical 
sites of metastasis or circulating micrometastases, as it may be that the 
concentration of O3FAs is significantly higher in the liver due to absorption from 
the gastrointestinal tract directly into the portal circulation. 
1.5.5 Clinical studies exploring the effect of O3FAs in CRC as a potential method 
of chemoprevention 
Chemoprevention is defined as primary, secondary or tertiary. Primary and 
secondary prevention pertain to the implementation of treatments to disrupt the 
process of carcinogenesis in the general population and those deemed at 
increased risk of carcinogenesis secondary to the presence of pre-malignant 
lesions such as colonic polyps (Landis-Piwowar & Iyer, 2014). Tertiary 
chemoprevention refers to prevention of recurrent or secondary malignancy.  
There is limited scientific literature pertaining to O3FAs for the purposes of CRC 
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chemoprevention. Most study outcomes are focussed on biomarkers associated 
with inflammation and colorectal carcinogenesis, rather than clinical outcomes 
or the incidence of CRC as a primary endpoint.  
In the context of chemoprevention, many of the studies exploring CRC risk are 
retrospective, do not implement an O3FA intervention and fail to provide details 
of O3FA bioavailability. Tokudome et al. undertook a randomised control trial 
over a two year period in Japanese participants who had undergone previous 
removal of colonic polyps and therefore most relevant to the purpose of 
secondary chemoprevention (Tokudome et al., 2015). The O3FA intervention 
was achieved via both modification of dietary intake and O3FA supplementation. 
PUFA bioavailability was measured by analysing RBC membranes. Although 
there were multiple confounding factors, there were statistically significant 
elevations in EPA and DHA levels, with concomitant reductions in AA levels in 
RBC membranes. However this did not translate to a decrease in CRC incidence. 
There are a number of randomised placebo-controlled trials implementing 
various concentrations and formulations of EPA and DHA that show a reduction 
in the proliferation index within colonic mucosa, a surrogate marker of the 
likelihood of tumour development (Cockbain et al., 2012). Given the adenoma-
carcinoma sequence via which CRC develops, polyp prevention trials have been 
undertaken to ascertain the feasibility of O3FAs in chemoprevention (Fearon & 
Vogelstein, 1990; Cotton et al., 1996). West et al. reported a reduction in both 
the number and size of colonic polyps in a RCT of 58 patients given 2g of EPA 
daily for 6 months (West et al., 2010). However this trial was performed in 
patients with a diagnosis of FAP and therefore may not translate to the 
development of sporadic adenomas or CRC in the general population. A 
retrospective case-control study examining 363 cases with adenomas reported 
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an inverse relationship between the highest levels of serum O3FAs and 
colorectal adenoma risk (Pot et al., 2008). There was also a statistically 
significant increased risk of developing colorectal adenomas with higher O6FA 
serum levels. The most recent data providing evidence for the implementation of 
O3FAs as a method of secondary chemoprevention is from the Systematic 
Evaluation of Aspirin and Fish Oil (SEAFOOD) polyp prevention trial. This was a 
multicentre, randomised, double-blind, placebo-controlled, 2x2 factorial trial in 
patients aged 55 to 73 years of age with previously identified colonic polyps (Hull 
et al., 2018). Of the 709 patients recruited into the study, 153 were given 2g EPA 
per day over a 12 month period at which point a surveillance colonoscopy was 
undertaken. Although there appeared to be no overall reduction in the 
development of colonic adenomas after 12 months treatment with EPA, there 
was evidence of a risk-reduction in the development of left-sided colonic 
adenomas. The aforementioned studies are the most convincing evidence for 
the application of O3FA supplementation in CRC chemoprevention, although the 
potential protective benefits are most apparent in ‘at risk’ patients with previously 
identified colonic polyps. 
1.5.6 Clinical studies exploring the effect of O3FAs in CRC as a potential method 
of treatment  
Clinical studies examining the effects of O3FAs in CRC patients are limited and 
primarily focus on nutritional outcomes and measurement of inflammatory 
markers (Moldawer & Copeland, 1997; Gee et al., 1999; Liang et al., 2008; 
Sorensen et al., 2014). A RCT in 148 patients awaiting surgical resection of 
colorectal tumours showed decreased levels of inflammatory markers compared 
to controls (Sorensen et al., 2014).  A smaller RCT in 42 patients undergoing 
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colorectal resections also exhibited decreased levels of inflammatory markers, 
but these findings did not translate into any clinical benefit related to mortality or 
morbidity (Liang et al., 2008). It is of note that both studies were relatively small 
and undertook O3FA supplementation over a relatively short period (seven 
days), with the study by Liang et al. administering the O3FA intravenously.  Due 
to the anti-inflammatory nature of O3FAs there has been some interest into 
whether short-term provision of O3FA supplementation would be of any clinical 
benefit in the post-operative period. A meta-analysis of eleven studies (n=694) 
identified statistically significant reductions in both length of stay and infectious 
complications in patients that had received either enteral or parenteral O3FA 
treatment in the peri-operative period (Xie & Chang, 2016).  
With regard to metastatic disease Cockbain et al. examined the effect of EPA 
treatment in a RCT of patients awaiting resection of CRCLM (Cockbain et al., 
2014). Although there was no evidence of increased apoptotic activity or reduced 
cellular proliferation, the study did suggest impairment of vascularity in tumour 
tissue and even possible improved overall survival. Further examination of the 
RBC samples from the aforementioned study is undertaken in this thesis to 
ascertain whether RBC membrane incorporation of EPA has an association with 
incorporation of PUFAs into CRCLM tissue or patient survival outcomes.  
One of the potential applications of O3FAs in the adjuvant treatment of CRC is 
in combination with standard chemotherapy agents. The mechanisms via which 
the synergistic effects of O3FA and chemotherapy drugs might take effect have 
not been fully elucidated. Both in-vitro and mouse studies, using a combination 
of O3FAs and 5-fluorouracil, indicate potentiation of pro-apoptotic effects via a 
number of mechanisms including downregulation of Bcl-2 expression (Calviello 
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et al., 2005; Rani et al., 2017). Clinical outcomes including disease-free survival 
are reported in an adjuvant chemotherapy study of 1011 patients with lymph 
node positive CRC following surgical resection (Van Blarigan et al., 2018).  
Dietary marine O3FA intake was measured using a food frequency questionnaire 
and participants followed up for seven years. There was an association between 
patients receiving adjuvant chemotherapy and intake of marine O3FAs, with 
patients in the highest quartile of marine O3FA consumption exhibiting both 
statistically significantly increased recurrence-free and disease-free survival. Of 
note was that the estimated median marine O3FA intake in the highest tertile 
(0.4g/day) was far lower than the dosages used in most O3FA intervention 
studies. O3FA intervention studies in combination with standard chemotherapy 
regimens are limited by relatively small numbers of patients (maximum, 23 
patients), with treatment periods between 9 to 12 weeks. (Silva et al., 2012; 
Mocellin et al., 2013; Trabal et al., 2010). These studies indicate a reduction in 
inflammatory marker levels and improved nutritional outcomes including gains in 
body weight, which in the setting of adjuvant chemotherapy may be of clinical 
benefit. These findings are of particular interest with respect to cancer-
associated cachexia, which is mediated by a number of inflammatory cytokines 
and is associated with poor quality of life and increased mortality (Moldawer & 
Copeland, 1997; Tisdale, 2002).                     
1.6 O3FAs and the gut microbiome 
1.6.1 The colonic microbiota 
The microbiota is defined as the collection of microorganisms in a specified 
location, for instance the colonic microbiota (Claesson et al., 2017). There is an 
important symbiotic relationship between the colonic microbiota and human host. 
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Microorganisms are involved in multiple biological processes that contribute to 
maintaining homeostatic conditions, including production of metabolites that aid 
healthy gut and immune function (Kau et al., 2011; Clemente et al., 2012). 
Bacteria residing within the large intestine are predominantly anaerobic, although 
there are variations throughout the colon according to various factors including 
pH and bile salt concentration (Neish, 2009). The most abundant phyla within 
the large intestine are gram-positive Firmicutes and gram-negative 
Bacteroidetes (Hollister et al., 2014; Kurokawa et al., 2007). There is evidence 
to suggest that the gut microbiota influences both mucosal barrier integrity and 
inflammatory processes within the colonic epithelium. Imbalance of the 
constituent bacteria within the colon, a so-called ‘dysbiosis’ is believed to 
influence multiple disease processes. There is emerging evidence implicating 
the gut microbiota in colonic inflammation, colorectal carcinogenesis and 
systemic metabolic dysfunction including insulin resistance and diet induced 
obesity (Ding et al., 2010; Delzenne et al., 2011; Irrazábal et al., 2014; Sears & 
Garrett, 2014; Sherafat et al., 2018). The generation of short chain fatty acids 
(SCFA) including butyrate, proprionate and acetate via bacterial fermentation of 
fibre is relevant to maintaining intestinal health and is proposed to be protective 
against colorectal carcinogenesis (Song & Chan, 2019; Wu et al., 2018). 
Butyrate is also the primary energy source of the intestinal epithelium, again 
highlighting the synergistic role of the colonic microbiota in maintaining intestinal 
homeostasis (Wu et al., 2018). Despite mounting evidence to show that dietary 
modification influences the colonic microbiota and subsequent CRC risk there is 
limited data to explore whether O3FAs have any effect (Yang & Yu, 2018). This 
is of particular relevance in relation to the application of O3FA supplementation 
as a method of chemoprevention. 
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1.6.2 Microbiome analysis 
The advent of microbiome analysis has led to research examining the microbiota 
residing within the gastrointestinal tract, in particular the colon. The colonic 
microbiome is defined as the collective genome of the microorganisms residing 
within the colon (Zoetendal et al., 2004). The technique of microbiome analysis 
utilises molecular sequencing to identify microorganisms within different 
environments, allowing identification of bacterial species previously not possible 
with traditional culture techniques.  
Taxonomy and phylogeny are important concepts for classification of bacteria in 
the process of microbiome analysis. Taxonomic classification of bacteria is a 
hierarchical system that classifies bacteria according to common characteristics 
(figure 4) (Washburne et al., 2018). Microbiome analysis identifies bacteria at 
various taxonomic levels including individual species. Phylogenetic classification 
is also implemented in microbiome analysis, particularly to measure the diversity 
of bacteria present within an environment. Phylogeny classifies bacteria 
according to their evolutionary relatedness and is therefore able to trace bacterial 
species to common bacterial ancestors (Washburne et al., 2018).  
Microbiome analysis utilises the presence of a highly preserved 16S ribosomal 
RNA subunit in bacterial genomic DNA, enabling polymerase chain reaction 
(PCR) amplification of bacterial DNA for subsequent genetic sequencing and 
identification of bacterial species (Zoetendal et al., 1998; Vaughan et al., 2000). 
The 16S rRNA gene is used for microbiome analysis as it contains both highly 
conserved regions surrounded by hyper-variable regions which provide optimal 
species identification (Neefs et al., 1990; Claesson et al., 2017). Ideally the 
entirety of the 16S rRNA gene would be sequenced, but due to the limited read 
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length of next generation sequencing a hyper-variable region is selected 
(Santamaria et al., 2012). The 16S rRNA subunit gene contains conserved sites 
for binding of universal primers to allow PCR amplification and DNA sequencing. 
The primer sites are flanked by regions that contain variable sequences that can 
be exploited to identify bacteria at different taxonomic levels (Claesson et al., 
2017).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There are nine hyper-variable regions within the gene coding for the 16S rRNA 
subunit, each exhibiting various degrees of conservation (Vetrovsky & Baldrian, 
2013). Each hyper-variable region is approximately 30 to 100 basepairs in length 
and therefore ideal for next generation sequencing. The degree of preservation 
across each hyper-variable region guides the taxonomic level to which 
microbiome analysis can be determined. Therefore hyper-variable regions 
displaying lower levels of sequence preservation can resolve bacteria at species 
Phylum Firmicutes 
Class Clostridia 
Clostridium Genus 
Species 
Clostridium  
perfringens 
Order 
Family 
Clostridiales 
Clostridiaceae 
Bacilli 
Lactobacillales 
 Lactobacillaceae 
Lactobacillus 
Lactobacillus 
acidophilus 
Clostridium  
difficile 
Lactobacillus 
casei 
Figure 4. Taxonomic classification of bacteria with examples from the phylum firmicutes. 
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level, whereas more highly preserved regions identify bacteria at genus and 
phylum levels (Jovel et al., 2016). The V4 hyper-variable region of the 16S rRNA 
subunit is often selected for PCR amplification and sequencing across reported 
microbiome studies (Caporaso et al., 2011). This region appears to be optimum 
for resolving bacteria at the phylum level but may fail to identify closely related 
bacteria at species level that exhibit high levels of sequence similarity (Yang et 
al., 2016; Jovel et al., 2016). Sequences derived from the same genome, often 
exhibit a degree of diversity, either due to evolutionary mutations or sequencing 
errors. To avoid classifying near identical sequences as different organisms a 
process of binning is performed whereby sequences of typically greater than 
95% similarity are clustered into a single Operational Taxonomic Unit (OTU) 
(Schloss, 2010; Matsen, 2014). This process is particularly important for 
assessing the bacterial diversity within an environment. α-diversity and β-
diversity are commonly quoted measures in microbiome analyses (Wagner et 
al., 2018). α-diversity is a measure of microbial diversity within a specific 
environment, for example a stool sample. β-diversity measures the degree to 
which taxa are shared between two different samples (Wagner et al., 2018). 
1.6.3 Gut microbiota and CRC 
There is increasing evidence to implicate the intestinal microbiota in playing a 
role in colorectal carcinogenesis. The concept of dysbiosis is of particular 
importance in relation to the associations between microbial composition and 
colorectal carcinogenesis. In the context of CRC, dysbiosis is broadly referred to 
as an alteration in microbial composition between cancer patients and healthy 
individuals. It is characterised by both overrepresentation and depletion of a 
variety of bacteria species that will be discussed later. There are a number of 
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rodent models that provide evidence of a complex interplay between the 
microbiota, colonic inflammation and carcinogenesis. In Apc(Min/+) mouse 
models, mice grown in a germ free environment exhibited a significant reduction 
in the occurrence of intestinal tumours (Dove et al., 1997; Li et al., 2012).  
The colonic bacteria indirectly influence colorectal carcinogenesis via alteration 
of mucosal integrity and production of inflammatory mediators (Arthur & Jobin, 
2011). There are numerous pattern recognition receptors covering intestinal 
epithelial cells which interact with microbial proteins, resulting in both initiation 
and regulation of various apoptotic, inflammatory and cellular proliferation 
pathways (Arthur & Jobin, 2011). Chronic inflammation is associated with 
development of CRC as shown in individuals diagnosed with inflammatory 
conditions such as ulcerative colitis (Eaden et al., 2001). Regulation of colonic 
inflammation is mediated by a single layer of intestinal epithelial cells that play a 
crucial role in the innate immune response. These cells possess the type I 
transmembrane glycoproteins, Toll-like receptors (TLR) (Li et al., 2014). 
Dysregulation of TLR mediated immunity is key in the process of inflammatory-
driven colorectal carcinogenesis. A number of TLR polymorphisms are 
implicated in both the onset and progression of CRC (Messaritakis et al., 2018). 
TLRs are pattern recognition receptors that respond to a range of ligands, so-
called pattern associated molecular patterns, including lipopolysaccharides 
derived from bacteria (Li et al., 2014; Pradere et al., 2014). Activation of TLRs 
by pathogenic bacteria activates inflammatory pathways, that if dysregulated 
may be lead to chronic inflammation and induction of carcinogenesis. TLRs 
promote carcinogenesis via MyD88 mediated activation of the NF-kB 
transcription factor, which inhibits apoptosis and initiates production of a variety 
of inflammatory cytokines including TNFα (Li et al., 2014; Pradere et al., 2014).   
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TLR4 has been shown in mouse models to be the key TLR implicated in 
inflammation-driven carcinogenesis, with TLR4 knockout mice showing 
decreased levels of inflammation and tumour burden in a (AOM)-DSS model 
(Fukata et al., 2009). Conversely in transgenic mice in which TLR4 is 
overexpressed, inhibition of TLR4 resulted in fewer polyps in a (AOM)-DSS 
model of colorectal carcinogenesis (Fukata et al., 2011).  The same study also 
identified that expression of TLR4 was higher in ulcerative colitis patients with 
CRC compared with patients with no evidence of dysplasia. Modulation of TLR 
mediated colonic inflammation via changes in the colonic microbiota is therefore 
of significant interest in colorectal carcinogenesis.      
A number of human studies highlight changes in the microbiome profiles of 
colorectal tumour tissue compared with colonic mucosa in healthy controls or 
non-tumour tissue from the same individual. These studies have sought to 
determine any association with CRC carcinogenesis (Chen et al., 2012; Kostic 
et al., 2012; Geng et al., 2013; Geng et al., 2014; Mira-Pascual et al., 2015; 
Nakatsu et al., 2015). The studies identify a variety of differences between 
normal colonic tissue and tumour tissue, thus inferring changes to the 
microbiome may be associated with colorectal carcinogenesis. However the 
results are varied and there is a lack of consensus across studies as to the 
specific changes to microbial composition that occur. The only commonality 
across any of the aforementioned studies are the results of diversity measures, 
which are representative of the dysbiosis that is purported to be associated with 
CRC. Three of the aforementioned studies report that there was an increase in 
measures of microbial diversity in CRC tissue compared to normal colorectal 
tissue in the same individual or adenomatous tissue (Mira-Pascual et al., 2015; 
Geng et al., 2013; Nakatsu et al., 2015). However the largest microbiome 
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analysis of CRC tissue (n=95) and paired normal tissue did not reveal any 
differences in microbial diversity (Kostic et al., 2012).   
In an effort to determine whether changes in microbial composition and diversity 
in faeces are associated with CRC, there are a number of human studies 
examining the microbial composition of faecal samples in CRC patients 
compared to healthy controls (Sobhani et al., 2011; Wu et al., 2013; Weir et al., 
2013; Wang et al., 2011). Again, similar to mucosal tissue studies there are 
differences between CRC patients and healthy volunteers, but there is significant 
variation as to the specific changes that occur. With regard to microbial diversity 
there are conflicting results, with Ahn et al. and Yu et al. suggesting reduced 
diversity in CRC patients, whilst other studies do not reveal any differences (Ahn 
et al., 2013; Yu et al., 2017; Wu et al., 2013; Weir et al., 2013; Wang et al., 2011). 
Feng et al. report that there are no differences in α-diversity across CRC patients, 
patients with advanced adenomas and healthy controls (Feng et al., 2015). 
However they did identify increased gene-richness in CRC stool samples 
compared to stool samples from patients with both advanced adenomas and 
healthy controls. The authors attribute this finding to the overgrowth of bacteria 
that may be associated with CRC.  
One bacterium that appears to be over-represented across a number of human 
studies in either faecal samples or CRC tissue is Fusobacterium nucleatum (Ahn 
et al., 2013; Wu et al., 2013; Liang et al., 2017; Yu et al., 2017). The significance 
of this bacterium in colorectal carcinogenesis will be discussed later.      
There is a question about whether the associations identified between the 
microbiome and CRC represent a causal relationship or if the changes in the 
microbiome reported are secondary to colorectal carcinogenesis and alterations 
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in the tumour microenvironment. Mouse studies have examined whether 
changes in the colonic microbiome result in the development of colorectal 
tumours or vice versa. One study exposed animals (Apc(Min/+)) to 
Fusobacterium nucleatum and reported both accelerated development and an 
increased number of colonic tumours (Kostic et al., 2013). A second mouse study 
suggested the relationship between changes to the intestinal microbiome and 
CRC carcinogenesis is more complex (Zackular et al., 2013). This study 
highlighted that not only did AOM-induced and DSS-induced inflammation and 
tumorigenesis induce changes to faecal microbiome profiles, but also conversely 
when the microbiota from tumour-affected mice was transferred to germ-free 
mice there was subsequent tumour development without carcinogenic exposure.   
1.6.4 Limitations of studies exploring the relationship between the colonic 
microbiome and CRC carcinogenesis  
The findings of studies analysing both faecal and tissue microbiome profiles at 
phylum, genus and species levels in CRC patients versus normal controls are 
varied, often without consensus. Differences across studies are in part likely due 
to variations in methodology. The bacterial changes identified in studies 
examining either cancerous or normal tissue cannot necessarily be interpreted 
as being representative of changes in the colonic faecal microbiome profiles. 
Microbiome analysis of luminal faecal samples compared to colonic tissue 
samples has shown significant differences in the composition of the three 
predominant phyla including Firmicutes and Bacteroidetes (Chen et al., 2012). 
The lack of standardised hyper-variable region selection for PCR amplification 
and sequencing is likely to result in differences seen in microbiome analysis 
results, given that the choice of hyper-variable region impacts on the ability to 
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identify bacteria at phylum, genus and species levels (Jovel et al., 2016). There 
are also methodological variations across studies with regard to sample storage 
and DNA extraction techniques which may account for some of the differences 
encountered in microbiome analysis in studies with otherwise similar designs. 
There are geographical variations across studies, with some evidence to suggest 
that the microbiome is influenced by ethnicity (Yazici et al., 2017).           
1.6.5 The effects of specific bacteria on CRC carcinogenesis 
Studies have shown an increase in the presence of pathogenic bacteria including 
Enterococcus and Escherichia coli in CRC patients (Swidsinski et al., 1998; 
Martin et al., 2004; Grivennikov et al., 2012; Bonnett et al., 2014). Escherichia 
coli is reported to increase polyp burden in mouse models with specific bacterial 
strains proposed to produce toxic proteins that can induce double stranded DNA 
breaks (Cuevas-Ramos et al., 2010). The gram-positive bacterium Enterococcus 
faecalis has been identified both in-vivo and in-vitro to promote CRC 
carcinogenesis via the generation of hydroxyl radicals that may induce point 
mutations and chromosomal instability (Huycke & Moore, 2002; Huycke et al., 
2001; Cooke et al., 2003; Evans et al., 2004).  
A number of human studies have shown depletion of Bacteroidetes and 
Clostridia in both stool and tissue samples (Kostic et al., 2012; Ahn et al., 2013; 
Weir et al., 2013; Wang et al., 2012). Other studies have shown an increased 
presence of the genus Bacteroides, which may be linked to the release of 
endotoxins causing direct DNA damage and the induction of cellular proliferation 
pathways such as NF-κB (Qin et al., 2010; Sobhani et al., 2011; Wu et al., 2009; 
Wu et al., 2013; Karrasch et al., 2007). 
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The presence of butyrate-producing bacteria such as Clostridia appears to be of 
significant importance (Van den Abbeele et al., 2013). The SCFA butyrate is a 
breakdown product of carbohydrate and fibre metabolism.  It is proposed to have 
various anti-inflammatory and anti-cancer properties, primarily the regulation of 
gene expression via inhibition of Histone deacetylase function (Donohoe et al., 
2012; McIntyre et al., 1993; Davie, 2003). A large case-control study comparing 
344 advanced CRC patients with a matched number of healthy controls 
illustrated an increased abundance of pathogenic bacteria including 
Enterococcus, whereas healthy controls were found to exhibit increased 
presence of butyrate-producing bacteria (Chen et al., 2013). Other bacteria 
which are proposed to be protective against inflammation and CRC 
carcinogenesis include the butyrate-generating bacteria Bifidobacteria and 
Lactobacillus (Wu et al., 2018). In a RCT of patients with a diagnosis of ulcerative 
colitis, patients treated with a Bifidobacteria probiotic exhibited reduced 
inflammation as measured by a reduction in the presence of inflammatory 
cytokines including TNF (Furrie et al., 2005). Lactobacillus and 
Bifidobacterium species are protective against colonic inflammation via 
suppression of both NF-κB and IL-8 (Li et al., 2019). Uronis et al. illustrated that 
pathogen free mice exhibited fewer tumours in AOM-initiated colitis associated 
CRC, when Bacteroides vulgatus was present (Uronis et al., 2009). 
The bacteria Fusobacterium nucleatum is widely reported to be associated with 
CRC both in mucosal and faecal samples (Kostic et al., 2012; Ahn et al., 2013). 
A case-control study identified the presence of Fusobacterium nucleatum in 32% 
of CRC subjects (n=47) compared with only 12% of healthy control samples 
(n=94) (Ahn et al., 2013).  The over-representation of Fusobacterium in faeces 
was also identified in a further study comparing CRC patients and healthy 
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controls (Feng et al., 2015). A study examining the normal colonic mucosa of 
adenoma patients and healthy individuals, not only identified that the abundance 
of Fusobacterium was higher in adenoma patients, but also that the magnitude 
of the abundance of the bacteria was correlated with the likelihood of the 
presence of adenomas (McCoy et al., 2013).   Other studies have examined the 
bacterial content of colonic tumour tissue to ascertain any relationship between 
specific bacteria and CRC. One study of 99 CRC subjects reported that the 
abundance of Fusobacterium was 415 times greater in tumour tissue than in 
normal colonic tissue of the same individual, adding weight to the argument that 
the tumour micro-environment may confer some benefit to the bacterium 
(Castellarin et al., 2012).  
There is evidence to suggest the presence of Fusobacterium is associated with 
particular subtypes of CRC that have specific molecular traits including 
microsatellite instability (Tahara et al., 2014).  There is also a study suggesting 
that Fusobacterium nucleatum specifically, is enriched in CRC metastases, 
perhaps indicating that the bacterium has an important role in specific molecular 
mechanisms of CRC carcinogenesis (Kostic et al., 2012).  
The largest study exploring the relationship between Fusobacterium and CRC 
was from a follow-up of health professionals in the United States which included 
1069 individuals with CRC (Mima et al., 2015). This study identified that the 
presence and burden of DNA representative of Fusobacterium nucleatum in 
colonic tumour tissue had a negative impact on CRC specific mortality.  
The molecular mechanisms of Fusobacterium-initiated CRC carcinogenesis are 
poorly understood. Fusobacterium nucleatum is proposed to generate proteins 
including Fap2 which inhibit natural killer cells and therefore contribute to 
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colorectal carcinogenesis (Gur et al., 2015). Other proteins including the 
adhesion Fad A are implicated in activating various cell signalling pathways 
including β-catenin and driving the activation of various transcription factors and 
oncogenes that stimulate CRC cell growth (Rubinstein et al., 2013). The bacteria 
may also have an effect on the ability of the immune system to inhibit 
carcinogenesis by increasing the presence of tumour permissive myeloid-
derived suppressor cells as exhibited in mouse models (Kostic et al., 2013). 
1.6.6 The effect of O3FAs on colonic inflammation, gut microbiota and CRC 
There is limited literature examining the effects of O3FAs on the gut microbiota. 
Most are studies examining the effects of O3FAs on mucosal integrity and 
intestinal inflammation rather than CRC carcinogenesis specifically (Rees et al., 
2006; Nieto et al., 2002). There are a number of mouse studies reporting 
alterations in the microbiome profiles of mice fed O3FA-rich diets. Myles et al. 
report an increase in the Firmicutes:Bacteroidetes ratio and anti-inflammatory 
effects including increased levels of the cytokine IL-10 (Myles et al., 2014). 
Interestingly, the same group report evidence of an increased inflammatory 
response when mice were fed high fat O6FA-rich diets. Ghosh et al. showed that 
mice fed an O6FA rich diet exhibited an increased presence of bacteria 
implicated in intestinal inflammation, namely Clostridia and Enterobacteriaceae, 
whereas mice fed an O3FA-rich diet showed an increased presence of 
Lactobacillus and Bifidobacteria, with a concomitant reduction in levels of 
bacteria associated with intestinal inflammation (Ghosh et al., 2013). Similar 
findings are also reported in a study of rats with chronic intestinal inflammation, 
whereby O3FA supplementation reduced the proportion of the inflammatory 
associated bacteria Esherichia coli and Bacteroides, whilst there was an 
44 
 
increase in Lactobacillales (Li et al., 2011). This corresponded with improved 
epithelial tight junction integrity in chronically inflamed intestinal mucosa. One of 
the limitations of studies examining the effects of O3FAs on the intestinal 
microbiome is that incorporation of O3FAs into tissues is rarely measured. This 
precludes any investigation of whether the effects of O3FAs on the intestinal 
microbiome might in fact be secondary to systemic incorporation of O3FAs into 
intestinal tissue rather than direct luminal exposure. A single study examining 
the effects of fish oil in mice identified that the microbiome was enriched with 
Bifidobacteria and importantly this corresponded with increased tissue levels of 
EPA and DHA (Patterson et al., 2011). A limitation of many animal studies 
examining the effects of O3FAs on the intestinal microbiome is the confounding 
factors associated with dietary O3FA supplementation. In order to negate these 
potential dietary confounding factors researchers have employed animal models 
using the fat-1 mouse that expresses the Caenorhabditis elegans fat-1 gene and 
therefore endogenously produces O3FAs from O6FAs (Kaliannan et al., 2016; 
Kaliannan et al., 2015). In one study elevated tissue levels of O3FAs resulted in 
attenuation of an antibiotic-induced increase in the Firmicutes:Bacteroidetes 
ratio seen in wild-type mice (Kaliannan et al., 2016). In a separate study the same 
authors reported lower quantities of Enterobacteriaceae, Escherichia coli, 
Fusobacterium and Clostridium in fat-1 mice than wild-type mice (Kaliannan et 
al., 2015). These bacteria are associated with intestinal inflammation and CRC 
carcinogenesis.  
A mouse study examining the caecal contents of mice fed a fish oil diet reported 
increases in Lactobacillus, Bifidobacteria and Akkermansia mucciniphilia 
(Caesar et al., 2015). As stated previously, both Lactobacillus and Bifidobacteria 
are proposed to have a protective effect against colonic inflammation. Any 
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protective role of Akkermansia associated with colorectal inflammation and 
carcinogenesis is unclear. Some studies suggest the presence of this bacteria is 
associated with colorectal inflammation via degradation of the protective mucus 
barrier within the colon and that O3FA supplementation reduces the presence of 
Akkermansia (Pusceddu et al., 2015).  A single human study in CRC patients 
which was limited by the small cohort size identified an increased presence of 
Akkermansia muciniphilia in the faecal samples of CRC patients (Weir et al., 
2013). There is a single comprehensive study exploring the effect of OF3As on 
the intestinal microbiota. A study of 867 individual female twins reported that 
serum O3FA levels correlated with microbiome diversity and that there was 
increased representation of the butyrate-producing bacteria Lachnospiraceae 
(Menni et al., 2017).  
There is very little evidence to identify any protective benefit of O3FA 
supplementation in relation to interaction between the intestinal microbiota and 
CRC carcinogenesis. Piazzi et al. reported that a diet containing EPA resulted in 
reduced number and size of colonic tumours in an AOM-DSS model of colitis-
associated CRC (Piazzi et al., 2014). These mice also showed increased 
presence of lactobacillus within microbiome profiles, although it is not possible 
to determine whether the altered microbiota was responsible for this protective 
effect as there was also increased activation of apoptotic pathways and inhibition 
of notch signalling pathways which have both been implicated in CRC 
carcinogenesis.     
The bacterial profile within the gastrointestinal tract may also affect the 
availability of O3FAs within the colon. It is reported that lactobacillus alters the 
proportion of PUFAs in-vitro, including EPA via metabolic conversion 
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(Kankaanpää et al., 2004).  This is of interest when considering if colonic 
exposure to O3FAs is secondary to systemic incorporation or via direct luminal 
exposure. 
The paucity of evidence regarding the effect of O3FAs on the gut microbiota 
highlights this as an area of interest, especially given there is increasing 
understanding of the role of the intestinal microbiota in inflammation and 
colorectal carcinogenesis. Although there are a number of animal studies that 
suggest beneficial effects of O3FAs on the intestinal microbiota it is unclear 
whether O3FAs result in changes to the gut microbiota that may be associated 
with reduced CRC risk. Amelioration of CRC risk via modulation of the colonic 
microbiota presents a potential avenue via which O3FA supplementation could 
be utilised as a form of chemoprevention.  
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Chapter 2: Aims and hypotheses 
2.1 Aims and hypotheses 
EPA and DHA are essential O3FAs required for multiple biological functions 
including cell signalling and gene expression. They are of particular interest due 
to their potential anti-inflammatory and anti-CRC activities. Therefore O3FA 
supplementation has a potential role in both CRC chemoprevention and adjuvant 
treatment as a so-called ‘nutraceutical’.  
Despite much research on O3FAs there is a lack of evidence exploring the effect 
of O3FAs on the intestinal microbiota. This is of significance as epidemiological 
and clinical evidence suggests a complex interplay between diet, the intestinal 
microbiota and a potential role in CRC carcinogenesis. Therefore I conducted a 
randomised, open-label, cross-over trial in healthy volunteers to test the 
hypothesis that O3FA supplementation alters the colonic microbiota as 
examined in faecal microbiome profiles from stool samples.  
Although naturally present in oily fish, O3FA capsules are usually administered 
in clinical studies. There are new preparations of O3FA supplements including 
juice drinks which are of potential clinical use in cancer patients who may also 
require calorific supplementation. There is a lack of scientific literature exploring 
bioavailability of these novel supplements. Therefore a secondary aim of the 
study was to test the hypothesis that an O3FA-containing drink supplement was 
not inferior to an equivalent O3FA daily dose given in soft-gel capsule form as 
measured by the change in relative RBC membrane levels of EPA and DHA 
following supplementation. 
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In summary the objectives of the study were as follows: 
1. To conduct a randomised, cross-over trial in healthy volunteers aged >50 
years randomised to O3FA supplementation for a period of eight weeks 
with either O3FA supplementation in a carton drink form or an equivalent 
dose in capsules.  
2. To determine the effect of O3FAs on the colonic microbiome through PCR 
amplification of the V4 hyper-variable region of the 16S rRNA gene in 
faecal samples. 
3. To compare the bioavailability of O3FAs in drink and capsule forms by 
measuring the change in RBC membrane percentage content of EPA and 
DHA at eight weeks compared with baseline using liquid chromatography 
tandem mass spectrometry (LC-MS/MS). 
4. To measure the difference in RBC membrane percentage content of AA 
at eight weeks compared with baseline using LC-MS/MS. 
5. To assess the acceptability, compliance, tolerability and adverse events 
related to each O3FA preparation. 
The molecular gastroenterology group published the Eicosapentaenoic Acid for 
Treatment of Colorectal Cancer Liver Metastases (EMT) study (Cockbain et al., 
2014). This was a Phase II randomised, double-blind, placebo-controlled trial 
examining EPA treatment in patients awaiting surgical resection of CRCLM. As 
part of this study, RBC samples were collected to measure baseline, post-
treatment and washout PUFA incorporation levels in RBC membranes, including 
EPA, DHA and AA. This was not performed at the initial analysis of the study due 
to financial constraints. As a further aim of his study I measured RBC membrane 
PUFA levels from the EMT study in order to determine the bioavailability and 
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PUFA profiles in patients with CRCLM and identify any relationship with clinical 
outcomes. The objectives were as follows: 
1. To measure the change in RBC membrane percentage content of EPA 
after O3FA treatment and washout using LC-MS/MS. 
2. To ascertain whether there is a correlation between RBC EPA 
membrane levels and CRCLM tumour tissue EPA levels. 
3. To perform survival analysis in order to determine whether there is an 
association between RBC EPA membrane levels and overall survival 
in patients undergoing curative resection of CRCLM. 
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Chapter 3: A randomised cross-over trial examining the bioavailability of 
O3FAs in capsules versus an equivalent dose in a drinks formulation and 
the effects of O3FA supplementation on faecal microbiome profiles. 
3.1 Introduction 
The potential application of O3FAs as a method of CRC chemoprevention or 
adjuvant treatment requires examination of the bioavailability of O3FAs in 
various forms of supplementation. There is limited data comparing RBC 
membrane PUFA incorporation following supplementation with O3FAs in a 
‘nutritional drink’ formulation and traditional capsule supplementation. Nutritional 
drinks are a potential alternative to capsule supplementation, and may be more 
acceptable to both healthy individuals and CRC patients with gastrointestinal 
disturbance. O3FA containing drinks may contain sufficient fat content to 
stimulate pancreatic lipase secretion which is required to facilitate absorption of 
triglyceride-bound O3FAs from the small intestine. 
There is an increasing recognition and interest in the intestinal microbiota and its 
role in health and disease. However there is a lack of published evidence 
studying the effect of oral O3FA supplementation on the human intestinal 
microbiome, in particular with relation to CRC risk. This is of particular 
significance with regard to utilising O3FA as a potential chemoprevention.   
3.2 Overview of study design 
An open label, randomised, cross-over trial in healthy volunteers aged >50 years 
randomised to O3FA supplementation for a period of eight weeks with either 
(figure 5): 
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- Two Smartfish™ Remune drinks per day (2000mg EPA and  2000mg 
DHA per day; see Appendix 1 for full contents) 
- Four O3FA capsules twice daily taken with food (2000mg EPA and 
2000mg DHA per day) 
A minimum 12-week ‘washout’ period followed each intervention period (figure 
5). Participants over 50 years of age were selected to reflect the population in 
which CRC incidence is highest.   
3.3 Primary outcome measure 
- Change in RBC membrane percentage content of EPA and DHA  at eight 
weeks compared with baseline 
The cross-over trial design allowed intra-individual comparison of both changes 
to faecal microbiome profiles and O3FA RBC membrane levels after 
supplementation with capsules and O3FA-containing nutrition drinks. An eight 
week intervention period was chosen as this would allow steady-state RBC 
membrane O3FA levels to be reached (Scaioli et al., 2015; Cao et al., 2006; 
Stonehouse et al., 2011). The intervention period would also be sufficient for 
changes in microbiome profiles to be apparent as highlighted in studies where 
rapid reversible changes to the intestinal microbiome have been noted following 
short-term dietary modifications of between 24 hours and two weeks (Wu et al., 
2011; Klimenko et al., 2018).  A 12-week ‘wash-out’ period was adequate for a 
return to baseline O3FA RBC membrane levels. 
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Figure 5. Timing and nature of study visits 
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  3.4 Secondary outcome measures 
- Change in faecal microbiome profiles after eight weeks O3FA 
supplementation  
- Difference in RBC membrane percentage content of AA at 8 weeks 
compared with baseline   
- Acceptability  and compliance with each O3FA preparation 
- Tolerability and adverse events related to each O3FA preparation  
3.5 Ethical and regulatory approval 
The Medicines and Health Products Regulatory Authority (MHRA) confirmed that 
the use of O3FA supplement capsules was not considered a Clinical Trial of an 
Investigational Medicinal Product (13/02/2015; Appendix 2). Ethical approval 
from the South Yorkshire Research Ethics Committee (REC) was received on 
April 29th 2015 (REC reference 15/YH/0142; Appendix 3). The trial was 
registered on the International Standard Randomised Controlled Trial Number 
(ISRCTN) database on 22nd June 2015 (ISRCTN: 18662143).  
3.6 Trial design 
3.6.1 Timing and nature of study visits (figure 5) 
Following an initial screening visit to check eligibility for enrolment into the study, 
participants were required to attend five scheduled study visits over a 10-month 
study period. There were two eight week intervention periods followed by a 12-
week washout period. Exact timing of the eight week visits during both 
intervention periods were adhered to whenever possible, although a 24 hour 
window either side of all planned visit dates was permitted. If attendance at visits 
2 and 4 could not be guaranteed then the start of each intervention period (visits 
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1 and 3) was moved back to ensure the timing of the week eight visit, thus 
delaying the start of the study (intervention 1) or prolonging the first ‘wash-out’ 
period (prior to intervention 2). The washout period was a minimum of 12 weeks’ 
duration. If the first washout period was prolonged, the duration of the second 
washout period was matched (within one week either side).   
3.6.2 Screening visit assessments 
At screening, participants completed a questionnaire to check eligibility.  
Volunteers underwent a taste-test of the study drink. A score of five or above on 
a 10-point acceptability scale was required in order for the participant to remain 
eligible. Potential participants were also required to swallow two study O3FA 
capsules with a glass of water to increase confidence they were able to tolerate 
swallowing eight capsules per day (four capsules twice a day with meals). 
Participants were asked to provide written informed consent if eligible to take 
part in the study. A baseline health assessment was also carried out. 
3.6.3 Study visit assessments and sample collection 
Blood, urine and stool samples were collected at each study visit. Any adverse 
events were assessed at visit 2 and all subsequent study visits. Assessment of 
capsule and drinks carton acceptability using a questionnaire was performed at 
the end of each intervention period (visits 2 and 4). Volunteer height and weight 
were collected at visit 3.  
3.7 Inclusion & exclusion criteria 
The inclusion and exclusion criteria for the trial are listed in table 1. In order to 
reflect a relevant risk group for CRC chemoprevention, only individuals over the 
age of 50 years were invited for recruitment into the study. 
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3.8 Participant Recruitment 
Participants were identified from a database of potential volunteers available to 
the Human Appetite Research Unit (HARU) at the University of Leeds. Poster 
advertisement around the university campus and use of university approved 
electronic mailing lists were also employed to identify potential volunteers. 
Table 1. Inclusion and exclusion criteria for participating in the randomised cross-over trial. 
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3.9 Randomisation 
Participants were randomised to the order of which they received the O3FA 
intervention at visit one (capsules followed by cartons or vice versa). A 
randomisation schedule was produced by Leeds Teaching Hospitals Pharmacy. 
Allocation to either intervention order was concealed using envelopes.  
 
3.10 Sample size calculation 
There was no published data pertaining to the effects of O3FA supplementation 
on the human intestinal microbiota. Therefore the sample size calculation was 
based on the hypothesis that Smartfish™ Renume was not inferior to the 
equivalent O3FA daily dose given in soft-gel capsule form for the change in 
relative RBC membrane levels of EPA and DHA following O3FA 
supplementation. 
There were no data available in relation to percentage RBC membrane EPA and 
DHA levels in subjects consuming Smartfish™ Remune. Based on data from a 
study in healthy individuals consuming O3FA capsules that reported intra-
individual variability of four percent we set a non-inferiority margin of three 
percent (Harris & Thomas, 2010). Therefore, assuming a participant drop-out 
rate of 20%, we estimated a sample size of 20 patients was required to exclude 
a difference in levels of RBC DPA and EHA of three percent or greater with 90% 
power and at a significance level of 0.05. 
3.11 Adverse events and data monitoring  
Adverse events were classified as mild, moderate and severe. A mild adverse 
event was defined as a known side-effect associated with O3FA 
supplementation but which did not result in cessation of the trial supplementation 
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(e.g. diarrhoea, eructation, abdominal bloating or discomfort). A moderate 
adverse event was defined as requiring the participant to cease or reduce the 
dose of the trial supplementation, whereas a severe adverse event occurred if a 
participant required hospitalisation as a result of taking the trial O3FA 
supplements. A regular report was submitted to an independent 
Gastroenterologist to oversee any adverse events experienced during the study.  
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Chapter 4: Laboratory methods 
4.1 Sample collection and processing for storage 
4.1.1 Venous blood 
Venous blood samples were obtained using the S-Monovette 7.5 ml, K2 
Ethylenediaminetetraacetic acid (EDTA) Gel blood collection system (Sarsedt, 
Numbrecht, Germany). Blood samples underwent immediate centrifugation at 
1000 Relative Centrifugal Force (RCF) for five minutes at 4ºC. Using a 1ml 
Pasteur pipette, the plasma was aliquoted into two separate 2ml cryovials. The 
buffy layer containing leukocytes and platelets was carefully discarded. The 
bottom layer of RBCs was divided equally into two separate 2ml cryovials. All 
samples were stored at -20ºC prior to transfer on dry ice for storage in the HTA-
approved -80 ºC freezers at Leeds Institute of Medical Research (LIMR) at St. 
James University Hospital, Leeds.  
4.1.2 Stool samples 
Stool samples were collected using the Fe-Col™ faecal collection device 
(Alphalabs, Eastleigh, UK) and sent via post to LIMR using the Royal Mail 
Safebox™ system (Royal Mail, UK). Alternatively, patients were also able to 
provide a stool sample at the time of the scheduled study visit. A 250mg sample 
of participant faeces was weighed and aliquoted into a 1.5ml microcentrifuge 
tube. The microcentrifuge tubes were filled to 1.5ml with an appropriate volume 
of RNAlater stabilization solution (Thermo Fisher Scientific, MA, USA) and stored 
in a secure -20ºC freezer at LIMR. The remaining sample was stored in the 
original stool collection tube at -80ºC in the HTA-approved freezer in LIMR.  
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4.1.3 Urine samples 
Urine samples were collected into a single 20ml universal container and 
transferred on ice to LIMR. Samples were centrifuged at 1000RCF for five 
minutes prior to aliquoting in equal volumes into two separate 5ml universal 
containers for storage in the -80ºC freezer at LIMR.  
4.2 Microbiome analysis 
4.2.1 Faecal microbial DNA isolation, extraction and recovery 
Faecal microbial DNA extraction was adapted from Yu & Morrison (Yu & 
Morrison, 2004). Participant stool samples were removed from storage in -80°C 
freezers. A 250µg sample of participant faeces was weighed and aliquoted into 
a 1.5ml Pathogen Lysis tube to which 1ml of Buffer ASL (Qiagen, Hilden, 
Germany) was added. The samples were placed on a vortex shaker for 10 
minutes at 22000 revolutions per minute (rpm) and transferred to a shaker 
incubator with parameters set at 95°C and 850rpm for 15 minutes. The samples 
were centrifuged for one minute at 14000rpm to pool the beads within the 
pathogen lysis tubes. The supernatant was then aliquoted into a 2ml 
microcentrifuge tube and placed on ice. The aforementioned process was 
repeated using 300µl of Buffer ASL. The supernatant was added to the initial 
sample stored on ice.   
Two hundred and sixty microliters of 10M Ammonium Acetate was added to the 
supernatant contained in the microcentrifuge tube and vortexed to mix. The 
samples were placed on ice in a Biohazard Class 1 cabinet for five minutes after 
which samples were centrifuged for five minutes at 14000rpm. The supernatant 
was aliquoted in equal volumes into two separate 1.5ml microcentrifuge tubes. 
An equal volume of isopropanol was added to each microcentrifuge tube, 
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vortexed to mix and placed on ice in a Biohazard Class 1 cabinet for 30 minutes. 
The samples were centrifuged at 14000rpm for 10 minutes. The supernatant was 
discarded and 1ml of 70% (v/v) ethanol added to the remaining pellet within each 
of the 1.5ml microcentrifuge tubes. The samples were centrifuged at 14000rpm 
for three minutes and the ethanol then discarded. The process was repeated 
using 500µl of 70% (v/v) ethanol. The samples were left in the Biohazard Class 
1 cabinet for 30 minutes to ensure complete evaporation of the ethanol. One 
hundred microliters of 1x Tris EDTA (TE) Buffer (Invitrogen, California, USA) was 
added to each sample and vortexed to mix to re-suspend the DNA pellet. 
Purification of the faecal DNA was performed using the QIAGEN QIAamp DNA 
Stool Mini kit (Qiagen, Hilden, Germany). The two separate samples containing 
the re-suspended DNA pellet in 1xTE buffer were pooled into a single clean 1.5ml 
microcentrifuge tube to which 200µl of Buffer AL (Qiagen, Hilden, Germany) and 
15µl of Proteinase K (Qiagen, Hilden, Germany) were added. The sample was 
then vortexed to mix and transferred to the shaker incubator for 10 minutes, with 
parameters set at 70°C and 650rpm. Two hundred microliters of 100% ethanol 
was added to each sample and vortexed to mix, followed by centrifugation at 
3500rpm for five seconds. The supernatant was transferred to a QIAamp Mini 
Spin Column (Qiagen, Hilden, Germany) and centrifuged at 14000rpm for one 
minute. The column was then transferred to a clean 2ml collection tube to which 
500µl of Buffer AW1 (Qiagen, Hilden, Germany) was added and then then 
centrifuged at 14000rpm for one minute. The column was then transferred to a 
clean 2ml collection tube to which 500µl of Buffer AW2 (Qiagen, Hilden, 
Germany) was added and then then centrifuged at 14000rpm for three minutes. 
The column membranes were dried by transferring to a clean collection tube and 
centrifuging at 14000 rpm for one minute. The DNA bound to the column 
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membrane was eluted into 100µl of molecular grade water (Invitrogen, California, 
USA) in a clean 1.5ml microcentrifuge tube by centrifuging at 14000rpm for one 
minute. 
Quantification of faecal DNA was performed using the Nanodrop 
photospectrometer (Thermofisher Scientific, MA, USA). The ratio of sample 
absorbance at 260nm and 280nm is a measure of DNA purity. A 260/280 ratio 
of greater than 1.8 was accepted as representing adequate DNA purity with lower 
values indicating presence of contaminants from the DNA extraction process. 
The 260/230 ratio is a secondary measure of nucleic acid purity. 260/230 ratio 
values between 1.8 and 2.2 are accepted as representing pure DNA. Faecal 
DNA was stored at -80ºC.    
4.2.2 PCR amplification of the 16S rRNA gene 
16S rRNA V4 amplification and library preparation were adapted from Taylor et 
al. (Taylor et al., 2017). Thawed faecal DNA samples were diluted into molecular 
grade water (20ng/µl) and 1µl of sample added to individual wells in a sterile 96 
well plate. Two and a half microliters of both forward and reverse primers (10nM) 
specific to the V4 hyper-variable region of the 16S rRNA gene (V4F-5′-
AYTGGGYDTAAAGNG, V4R- 5′— TACNVGGGTATCTAATCC) were prepared 
into a reaction volume (50µl) containing 1µL of 20ng/µL template DNA, 10µL of 
5× QC Reaction Buffer, 0.5µL of Q5 Hot Start High Fidelity DNA Polymerase, 
10µL of 5× Q5 High QC Enhancer, 1µL of 10mM deoxynucleotides (all New 
England Biolabs, MA, USA) and 22.5µl molecular grade water and added to each 
well. Degenerate base symbols N, V and Y represent alternative bases that 
occupy a position in the DNA primer sequence. Both a negative control sample 
containing 1µl of C2020 DNA from a B-lymphoblastoid cell line and a positive 
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control containing 1µl of E. Coli DNA were added to two separate wells. A well 
containing 1µl of molecular grade water was also prepared as an additional 
negative control. The 96 well plate was vortexed to mix at 2500rpm for five 
seconds.  
The PCR reaction was undertaken in a Bio-rad C1000 thermocycler (Bio-rad, 
CA, USA). Initial denaturation was performed at 98ºC for a period of 30 seconds. 
This was followed by 30 cycles programmed to undergo denaturation at 98ºC for 
five seconds followed by a 10 second annealing step at 42ºC and a 20 second 
elongation step at 72ºC. A final elongation step was carried out at a temperature 
of 72ºC for a period of 120 seconds.  
To ensure successful PCR amplification of faecal DNA samples, gel 
electrophoresis was performed using a 3% agarose gel and 1x Tris-Borate-
EDTA (TBE) buffer (Thermo Fisher Scientific, MA, USA). The gel was run at 100 
volts for 25 minutes. Gels were stained using 0.05% ethidium bromide and 
visualised under ultraviolet (UV) light. A 50bp DNA ladder (New England Biolabs, 
MA, USA) was also run on the gel for size comparison. 
4.2.3 Purification of amplified 16S rRNA PCR product    
Purification of the PCR amplification product was performed using the Minelute 
PCR purification kit (Qiagen, Hilden, Germany). Fourty five microlitres of 
amplified PCR product was added to 225µl of PB buffer in a clean spin column. 
Samples were centrifuged at 13000rpm for one minute. The collection tube was 
discarded and 750µl of buffer PE added to the spin column and centrifuged at 
13000rpm for one minute. Spin column membranes were dried by further 
centrifugation at 13000rpm for one minute. Purified PCR product was eluted into 
10µl of buffer EB after centrifuging at 13000rpm for one minute.  
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4.2.4 Quantification of PCR product 
In order to determine the concentration of double stranded DNA following PCR 
amplification of the V4 hyper-variable region of the 16 rRNA gene the Quant-iT 
dsDNA Broad Range Assay Kit (Life Technologies, CA, USA) was employed. 
This requires Picogreen which is a cyanine dye that fluoresces upon binding to 
double stranded DNA despite the presence of various contaminants including 
RNA, single stranded DNA and free nucleotides. 
Firstly a standard curve was prepared using known quantities of double stranded 
DNA (5ng, 10ng, 20ng, 40ng, 60ng, 80ng, 100ng). Two microliters of purified 
PCR product from each participant sample was added to a well of a clean 96 
well plate.  One microliter of 2x Picogreen (Thermo Fisher scientific, MA, USA) 
reagent buffer was added to 197µl of 10x Quant-it buffer and aliquoted into each 
individual sample well. Fluoresence was measured using a Fluoroskan Ascent 
2.6 fluorometer (Thermofisher Scientific, MA, USA).  
4.2.5 Library Preparation 
In order to perform DNA sequencing a series of modifications to the purified PCR 
product from each participant sample were necessary. Library preparation was 
performed under the supervision of Dr. Morag Taylor at the University of Leeds 
using the NEBNext Ultra DNA Library Prep Kit for Illumina and NEBNext 
Singleplex Oligos for Illumina (New England Biolabs, MA, USA).  
4.2.5.1 End prep of PCR product 
Firstly the 3’-5’ and 5’-3’ cohesive overhangs of each DNA fragment were 
enzymatically removed to facilitate ligation of an adaptor. One hundred 
nanograms of purified PCR product from each participant sample was required 
64 
 
for library preparation. The amount of purified PCR product required for each 
participant was determined from the concentration of DNA calculated in the 
picogreen assay. The appropriate amount of purified PCR product for each 
participant sample was added to individual wells in a 96 well plate after vortexing 
to mix. Varying amounts of TE buffer (Invitrogen, CA, USA) were added to each 
well to make a total reaction volume of 55.5µl per well.  The NEBNext End Prep 
Enzyme Mix (3µl) was added to the NEBNext End Repair Reaction Buffer (6.5µl) 
which was subsequently aliquoted into each sample well containing 100ng of 
participant DNA (Total volume 65µl). The 96 well plate was placed on to the 
Biorad C1000 thermocycler at 20ºC for 30 minutes followed by period of 30 
minutes at 65ºC to denature the enzymes.  
4.2.5.2 Adaptor Ligation 
Oligonucleotide adapters were attached to the blunt ended DNA fragments to 
facilitate binding to the flow cell of the Illumina next generation sequencer. Firstly 
the NEBNext Adaptor for Illumina (New England Biolabs, MA, USA) was diluted 
in molecular grade water.  Each blunt ended DNA sample (65µl) was added to 
an individual well of a clean 96 well plate. A mix of 15µl of Blunt/TA ligase master 
mix, 2.5µl of NEBNext adaptor for Illumina and 1µl ligation enhancer were 
aliquoted into each well to make a total volume of 83.5µl per sample. The plate 
was then vortexed to mix and centrifuged at 3700 rpm for 10 seconds followed 
by a period of incubation at 20°C for 15 minutes on a thermal cycler. The plate 
was subsequently centrifuged at 3700rpm for one minute before adding 3µl of 
USER enzyme (New England Biolabs, MA, USA) to each sample, vortexed to 
mix and centrifuged at 3700 rpm for 10 seconds. The plate was incubated for a 
period of 15 minutes at 37°C.  
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4.2.5.3 Purification of ligated PCR product 
Following ligation of the adaptor to the blunt ended DNA, a purification process 
was required to remove various contaminants and ligation enzymes. Solid Phase 
Reversible Immobilisation (SPRI) beads are para-magnetic beads activated by 
a magnetic field and to which DNA reversibly binds in the presence of certain 
chemicals. AMPure XP Beads (Beckman Coulter, CA, USA) were added to the 
ligated DNA samples in the 96 well plate in a ratio of 0.8 of the volume of modified 
DNA mixture. The beads were mixed by gentle pipetting and incubated at room 
temperature for five minutes. The 96 well plate was placed on a magnetic rack 
to activate the magnetic beads and facilitate movement out of solution to the 
base of the plate. The supernatant was removed using a pipette and disposed 
of. The beads were washed with 200µl of 80% (v/v) ethanol, incubated at room 
temperature for 30 seconds and the ethanol then removed. The process of 
washing the beads with ethanol was then repeated. In order to remove the ligated 
DNA from the SPRI beads 17µl of Buffer EB (Qiagen, Hilden, Germany) was 
added to each well and mixed by pipetting. To separate the SPRI beads from the 
purified ligated DNA product the 96 well plate was placed on the magnetic rack 
for five minutes. Fifteen microliters of purified ligated DNA product was aliquoted 
from each well into a clean 96 well plate ensuring the SPRI beads were not 
disturbed.   
4.2.5.4 Enrichment of ligated PCR product 
PCR amplification of the ligated PCR product was performed in order to facilitate 
successful sequencing. A reaction mixture of 25µl NEBNext Q5 Hot Start (2X) 
plus 5µl Universal PCR Primer (10µM) was added to each well of the 96 well 
plate containing 15µl of purified ligated DNA product from each participant 
66 
 
sample. Each sample was mixed by gentle pipetting. Five microliters of unique 
in-house designed index primers (Integrated DNA Technologies, IA, USA) were 
added to enable amplification of the ligated adaptor sequence of the modified 
PCR product. Each unique index primer corresponded to an individual participant 
stool sample. The 96 well plate was sealed and vortexed to mix followed by 
centrifugation at 3000rpm for five seconds. The PCR reaction was undertaken in 
a Biorad C1000 thermocycler. Initial denaturation was performed at 98ºC for a 
period of 30 seconds. This was followed by 12 cycles programmed to undergo 
denaturation at 98ºC for 10 seconds followed by a 75 second annealing step at 
65ºC. A final elongation step was carried out at a temperature of 65ºC for a period 
of five minutes.  
The enriched PCR library preparation then underwent purification using SPRI 
beads. AMPure XP Beads (Beckman Coulter, CA, USA) were added to the 
ligated DNA samples in the 96 well plate in 1:1 ratio to the volume of enriched 
library preparation PCR product. The beads were mixed by gentle pipetting and 
incubated at room temperature for five minutes. The 96 well plate was placed on 
a magnetic rack to activate the magnetic beads and move out of solution to the 
base of the plate. The supernatant was removed using a pipette and disposed 
of. The beads were washed with 200µl of 80% (v/v) ethanol, incubated at room 
temperature for 30 seconds and the ethanol then removed. The process of 
washing the beads with ethanol was then repeated. In order to remove the ligated 
DNA from the SPRI beads, 33µl of Buffer EB (Qiagen, Hilden, Germany) was 
added to each well and mixed by pipetting. To separate the SPRI beads out of 
solution from the purified ligated DNA product the 96 well plate was placed on 
the magnetic rack for five minutes. Twenty eight microliters of purified ligated 
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DNA product was aliquoted from each well into a clean 96 well plate ensuring 
the SPRI beads were not disturbed.  
4.2.5.5 Quantification of the library preparation product 
Quantification of the library preparation product was performed using the Quant-
iT dsDNA Broad Range Assay Kit as described previously. The Tapestation 
D1000 (Agilent technologies, CA, USA) was used to ensure the appropriate size 
of enriched library preparation product. Two microliters of D1000 sample buffer 
was added to an equal volume of enriched library preparation product from each 
sample.  
4.2.6 Library sequencing 
Next generation sequencing was performed on the Ilumina miseq sequencer 
(Illumina, CA, USA). Sample sequencing was undertaken by Carolina Lascelles 
and Sally Harrison at the University of Leeds. This sequencing technology 
utilises ‘sequencing by synthesis’ to both amplify and determine the sequence of 
DNA fragments of interest. The library preparation detailed earlier results in the 
addition of adaptor fragments to sample DNA fragments. During sequencing the 
adapted fragments bind to complementary sequences on a flow cell. A DNA 
polymerase reaction is initiated whereby sequences are amplified to generate a 
series of clusters, each with numerous copies of the same sequence within each 
cluster. Each cluster then undergoes simultaneous sequencing whereby a 
complementary fluorescently labelled base is added to the sequence of interest. 
The flow cell is excited by light to generate a specific signal corresponding to the 
fluorescently labelled base in each sequence cluster. This cycle is repeated to 
sequence the entirety of each cluster.   
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4.2.7 Bioinformatics microbiome analysis 
Analysis of the stool microbial DNA sequences was undertaken with Dr. Henry 
Wood and Dr. Suparna Mitra at LIMR. FASTQ data files generated by the 
Illumina sequencing platform were separated according to the unique index 
primer associated with individual participant samples. The adapter sequences 
were removed using cutadapt. Phylogenetic classification was performed using 
the Ribosomal Database Project (RDP) Naive Bayesian Classifier. The RDP 
database contains data pertaining to all known bacterial 16S rRNA gene 
sequences, thus allowing alignment of sequencing data from microbiome 
analysis to known bacterial sequences within the database. Using MOTHUR 
computer software additional analyses were performed including assessment of 
α-diversity and β-diversity.  
4.3 Measurement of RBC membrane PUFA content  
Extraction of fatty acids from RBC membranes and subsequent LC-MS/MS were 
performed by Jade Spencer and Professor Paul Loadman at the Institute of 
Cancer Therapeutics at the University of Bradford (Volpato et al., 2017; Rose & 
Oklander, 1965).  
4.3.1 PUFA extraction from RBC membranes 
RBC samples were removed from storage in -80 ºC freezers and thawed. RBCs 
were washed using five volumes of 0.89% (w/v) sodium chloride by mixing by 
inversion and centrifuging at 5000RCF for five minutes. The supernatant was 
removed and the process of washing repeated twice. Fifty microliters of washed 
RBCs were transferred into a clean Eppendorf tube to which was added an equal 
volume of distilled water containing deuterated ALA (LNA-d14) as an internal 
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standard at a concentration of 2μg/ml. The samples were allowed to stand at 
room temperature for 15 minutes. A 550µl volume of isopropanol was added to 
the washed RBCs, mixed and incubated at room temperature for one hour, 
occasionally vortexing to mix.  A volume of 350µl of chloroform was added to 
each sample, incubated at room temperature for one hour and centrifuged at 
10000RCF for five minutes. The supernatant was then evaporated to dryness in 
a rotary evaporator (EZ-2 plus rotary evaporator, Genevac Ltd, Suffolk, UK). A 
proportion of PUFAs are found in triglyceride-bound form. In order to measure 
total PUFA levels, a process of saponification was required, whereby fatty acids 
were cleaved from the glycerol backbone by the addition of hydrochloric acid and 
neutralised with sodium hydroxide. Each sample was then reconstituted in 500µl 
of acetonitrile and 50µl of 5M Hydrochloric acid. The samples were incubated at 
80ºC for one hour and then allowed to cool at room temperature for five minutes.  
A volume of 50µl of 5M sodium hydroxide was then added to each sample and 
mixed by vortexing, followed by the addition of 350µl of chloroform. The samples 
were left to stand for five minutes and the top 800µl of sample removed, leaving 
a layer of water behind.  The sample was then evaporated to dryness in a rotary 
evaporator and subsequently reconstituted in 50µl of methanol.   
4.3.2 LC-MS/MS 
Identification and measurement of relative quantities of individual PUFAs was 
performed using LC-MS/MS. Although gas chromatography-mass spectrometry 
(GC-MS) has traditionally been the method of choice for quantification of PUFAs 
in biological samples, LC-MS/MS is a valid alternative (Volpato et al., 2017). 
Particular benefits of LC-MS/MS over GC-MS include high throughput and the 
ability to measure non-volatile and thermally fragile molecules, thus avoiding 
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thermal degradation of PUFAs (Perez et al., 2016). LC-MS/MS is a two stage 
technique for identification and measurement of PUFA with the synergism of the 
two analytical techniques being both highly sensitive and specific.  
In high performance liquid chromatography (HPLC) a sample mixture is 
dissolved in a solvent (mobile phase) that transits through an adsorbent column 
(stationary phase) at high pressure. Compounds are separated within the mobile 
phase at varying rates due to differential polarity and interactions with the 
stationary phase. Analytes are subsequently analysed based on absorption of 
light from the UV spectrum and time taken to transit through the column 
(retention time). When used in combination with tandem mass spectrometry 
analytes of interest can be diverted from the chromatography column for spectral 
analysis.    
Tandem mass spectrometry identifies molecules according to their mass to 
charge ratio (m/z). Parent molecules injected into a mass spectrometer are 
ionised using various high energy sources, thus generating charged ions which 
transit through a magnetic field striking a detector to create an electrical current. 
Tandem mass spectrometry utilises a second ionisation process which further 
ionises parent molecule ions to create ‘daughter’ ions. This second ionisation 
process increases specificity of detection by enabling differentiation between 
molecules of similar m/z. The combination of tandem ionisation processes and 
the time taken to transit through the magnetic field and strike the detector 
produces specific spectra which correspond to specific molecular structures. The 
relative ion intensities generated during the mass spectrometry analysis 
correspond to the abundance of that molecule within a sample.  
  
71 
 
4.3.2.1 Derivatisation  
Derivatisation is a process of chemically altering sample molecules to enhance 
the sensitivity of the LC-MS/MS analysis. The chemical alteration increases 
specificity and sensitivity of LC-MS/MS by optimising the ionisation process and 
may also increase limit of detection, where low amounts of analyte that may 
otherwise not be distinguished from zero can be detected (Thompson et al., 
2002).  Derivatisation was performed using the derivatising agent 4-[2-(N.N-
dimethylamino)ethylaminosulfonyl]-7-(2-aminoethylamino)-2,1,3-
benzoxadiazole (DAABD-AE). Fifty microliters of derivatising agent was added 
to 50μl of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide HCl (EDC) and 50μl 
of 4-(dimethylamino) pyridine (DMAP). This was then mixed with the fatty acid 
extracted from each participant RBC sample (50μl) and incubated in amber glass 
HPLC vials for 24 hours.  
4.3.2.2 LC-MS/MS protocol 
LC-MS/MS was performed using a Waters Alliance 2695 High Pressure LC 
separations module in combination with a Waters Micromass Quattro Ultima 
triple quadrupole mass spectrometer (Waters UK, Hertfordshire). A two microliter 
derivatised sample from each participant was separated on a HiChrom RPB 
column (2.1mm× 250mm, 5μm) (HiChrom Ltd, Berkshire, UK). Mobile phase 
(MP) A consisted of 90% dH2O, 10% MeOH, 0.1% formic acid and MPB 
consisted of 90% MeOH, 10% dH2O and 0.1% formic acid. Gradient conditions 
were as follows: Starting at 80% MPB changing to 83% MPB over 8 min, then 
increasing to 95% MPB at 15 min, remaining at 95% MPB until 17 min before 
returning to starting conditions at 18 min. The overall run time was 25 min. The 
flow rate was set at 0.5ml/min and split post-column with 0.3ml/min delivered to 
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the mass spectrometer. Samples were analysed in multiple reaction monitoring 
(MRM) mode for the following fatty acids: EPA, DPA, DHA, ALA, AA, LA, SA, 
OA, PA and internal standard LNA-d14. The instrument settings were as follows: 
Capillary voltage, 3kV; Cone energy, 15eV; collision energy, 25eV; source 
temperature, 120°C and desolvation temperature, 300°C.  
Results for each of the aforementioned PUFAs were reported as the percentage 
of the total analysed fatty acid content for that sample. This was calculated as 
the sum of the ratio of each fatty acid peak area to the internal standard LNA-
d14 peak area (%FA). 
4.4 Statistical analysis 
Statistical analysis was undertaken with Graphpad version 7 (Graphpad, CA, 
USA) and SPSS software (IBM, NY, USA). Normality of data was tested using 
the D’Agostino & Pearson normality test.  Correlations were assessed using the 
Pearson’s correlation co-efficient. The one sample t-test was used to assess 
changes to RBC PUFA membrane levels from baseline. For paired data the 
paired t-test or Wilcoxian test were used to compare interventions. For unpaired 
data the Student’s un-paired t-test or Mann Whitney U test were employed.  
Multivariate analysis was carried out using multivariate linear regression. 
Survival analysis was performed with Kaplan-Meier curves and the log rank test. 
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Chapter 5: Results of the randomised cross-over trial exploring PUFA 
RBC membrane levels and tolerability of equivalent doses of EPA and 
DHA in a drink versus capsule formulation 
5.1 Introduction 
The following chapter details the results of the randomised cross-over trial in 
healthy volunteers. There is specific focus on comparing the bioavailability of 
EPA and DHA, as measured by RBC membrane levels, following capsule and 
drink supplementation. This was performed in order to determine whether O3FA-
containing drinks are a valid alternative to traditional capsule supplementation, 
which therefore may have a clinical application as either an adjunct in CRC 
treatment or chemoprevention.    
5.2 Patient recruitment 
Twenty two individuals expressed an interest to take part in the study and 
subsequently attended the HARU to undertake a screening visit. All 22 
individuals fulfilled the inclusion criteria and were therefore eligible to consent to 
enter the study. The first study participant attended visit 1 on 15th July 2015. 
There was a period of approximately three months between the first and final 
participant entering the study, with the final participant attending visit 1 on 21st 
October 2015. The study finished on 16th December 2015 after the final study 5 
visit.      
The consort diagram outlined in figure 6 details recruitment through the study. At 
visit 1, 12 participants were randomised to the capsule followed by drinks 
intervention group (C/D). Ten participants were randomised to consume drinks 
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followed by capsules (D/C). Withdrawals throughout the study period are 
discussed later.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3 Baseline characteristics 
Twelve of the 22 (55%) participants recruited into the study were female. 
Following withdrawal of two female participants early in the first intervention 
period, the sex distribution within the study was balanced (10 male; 10 female). 
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Figure 6. Consort diagram of recruitment, participant flow and withdrawals throughout the 
study period. *Participant ceased carton intervention early (remained in study), **Participant 
that ceased carton intervention early recommenced intervention period 2 (capsules), *** 
Participant ceased carton intervention early (remained in study). 
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The median age across all 22 participants in the study was 57 years (range; 51 
to 65 years). The median BMI was 27kg/m2 (range; 22.0 kg/m2 to 33.8kg/m2).  
Prior to starting the first intervention period, participants were assessed with 
regard to any symptoms that might be associated with O3FA supplementation 
(table 2). Of the three participants in the first capsule intervention group that 
experienced loose motions prior to entering the study, two had been formally 
diagnosed with irritable bowel syndrome (IBS).   The single participant in the D/C 
intervention group that experienced loose motions prior to entering the study had 
a previous cholecystectomy which may be associated with chronic diarrhoea, 
particularly in the presence of bile salt malabsorption. Only one individual in the 
C/D intervention group experienced any other recognised O3FA-related 
symptoms, specifically abdominal discomfort in an individual with a known 
diagnosis of IBS.  
 
CAPSULES (n = 12) DRINKS (n = 10) 
Loose stools 3 (IBS - 2) 1 (cholecystectomy) 
Abdominal discomfort  1 (IBS) 0 
Burping 0 0 
Indigestion 0 0 
Nausea/Vomiting 0 0 
 
  
Table 2. Symptoms associated with O3FA supplementation reported by study participants 
prior to commencing O3FA supplementation at visit 1. 
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5.4 Withdrawals 
Of the 22 patients that commenced the study, two female participants withdrew 
from the first intervention group randomised to initially consume capsules (C/D) 
after 49 days and 7 days respectively. These individuals withdrew due to 
experiencing gastrointestinal symptoms associated with O3FA supplementation. 
A third patient (male) withdrew after visit 3, completing both the initial intervention 
and washout periods (randomised to C/D). He withdrew due to concerns 
regarding the calorific content of the O3FA drinks. 
Seventeen of the 22 participants that enrolled in the study completed both eight 
week intervention and 12-week washout periods. Nineteen participants 
commenced both intervention periods with 20 participants completing at least 
one intervention and corresponding washout period.  One participant attended 
all planned study visits providing both venous blood and stool samples, but 
ceased O3FA drink supplementation 14 days prior to the planned intervention 
study visit (visit 4).  Therefore, 16 participants took O3FA supplements as per 
protocol during both intervention periods up until the relevant study visits (2 and 
4).     
5.5 Duration of supplementation and compliance  
The median duration of capsule supplementation across the 22 participants that 
commenced the capsule intervention period was 57 days (range 7 to 63 days). 
When adjusting for the two participants that withdrew from the study in the first 
intervention period (at 7 and 49 days) the median duration of capsule 
supplementation was 57 days (range 55 to 63 days). Nineteen participants 
commenced the drinks intervention period with a median duration of 
supplementation of 57 days (range 7 to 59 days). Adjusting for participants that 
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provided RBC samples at the planned end of intervention study date, median 
duration of supplementation was 57 days (n=20, range 55 to 63 days) and 57 
days (n=16, range 54 to 57 days) for capsules and drinks respectively. 
Compliance was measured by counting the number of capsules or drinks 
returned by a participant at the end of each intervention period. Median 
compliance across the 20 participants that completed the capsule intervention 
period was 100% (range 93% to 108%) versus 98% in the 16 participants that 
completed the drinks intervention period (range 85% to 106%). Compliance 
greater than 100% was due to participants returning fewer capsules or drinks 
than expected from the excess number given at the initial study visit. 
5.6 Acceptability and adverse events 
Adverse events were examined across the 22 and 19 participants that 
commenced the capsule and drink intervention periods respectively. Overall 
there were 29 adverse events recorded in 14 participants during the capsule 
intervention period versus 17 adverse events in 10 participants consuming 
drinks. The specific symptoms associated with O3FA supplementation are 
detailed in table 3. Although there were a greater number of adverse events 
experienced in the capsule intervention group there was no statistically 
significant difference identified between each intervention as measured by 
Fisher’s exact test. All 14 participants that experienced symptoms during the 
capsule intervention period reported resolution of the symptoms during the 
corresponding washout period, compared with nine of 10 participants in the 
drinks intervention. 
With regard to classification of severity of O3FA related symptoms, three 
participants in both capsule and drink interventions developed symptoms defined 
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as ‘moderate’, thus requiring cessation of supplementation either temporarily or 
permanently. Two participants (2/22) experienced symptoms that required 
cessation of capsule supplementation and subsequent withdrawal from the study 
after seven and 49 days. The third participant ceased capsule supplementation 
for a period of two days after experiencing flu-like symptoms which were deemed 
unrelated to the capsules. All three participants that experienced O3FA related 
symptoms defined as moderate during the drink intervention period ceased 
supplementation after seven, 10 and 43 days.   
Of the 10 participants that were randomised to commence capsules during the 
first intervention period (C/D), four participants also experienced symptoms 
associated with O3FA supplementation during the second intervention period 
when consuming drinks.  Four of nine participants that were initially randomised 
to the drink intervention (D/C) also experienced O3FA-related symptoms during 
the second capsule intervention period.  
 
CAPSULES (n = 22) DRINKS (n = 19) p value** 
Total number of 
adverse events 
during intervention 
periods 
29 (14*) 17 (10*) 0.54 
Diarrhoea 5 5 1.00 
Abdominal discomfort 6 3 0.47 
Burping 10 4 0.19 
Indigestion 5 1 0.19 
Nausea/vomiting 3 4 0.68 
 Table 3.  Number of adverse events associated with O3FA supplementation reported by study 
participants at the end of either capsule or drink supplementation irrespective of intervention 
order.  * Total number of participants reporting adverse events. * * Fisher’s exact test, p <0.05 
statistically significant. 
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Acceptability was measured for both capsule and drink interventions. An adapted 
questionnaire provided by the drinks manufacturer SmartfishTM was used to 
assess carton acceptability. The questionnaire measured four domains, 
specifically, smell, taste, texture and tolerability. Each domain was measured 
using a visual analogue scale with a maximum score of seven points for each 
domain (1; I dislike it very much, 7; I like it very much) and maximum total score 
of 28 points across all four domains. The median drinks acceptability score 
across the 17 participants that completed the questionnaire was 21/28 (range 13 
to 28). For a direct comparison of drinks and capsule O3FA supplementation, 
study participants were asked whether they would consider continuing the 
relevant supplementation following completion of the study. Of the 19 
participants that commenced drinks supplementation, 11 (58%) stated they 
would consider continuing the drinks supplementation at the end of the study, 
compared to 15 of 22 (68%) participants that commenced the capsule 
supplementation. There was no statistically significant difference between 
whether participants would consider continuing either type of O3FA 
supplementation (p=0.53).  
5.7 Measurement of PUFA RBC membrane levels 
Ninety seven RBC samples from 20 of the 22 participants that enrolled into the 
study successfully underwent LC-MS/MS PUFA analysis. Two participants that 
withdrew from the study during the first intervention period and therefore only 
supplied an initial visit 1 pre-supplementation venous blood sample were 
excluded from analysis. A participant that ceased the drink intervention early 
during the first intervention period did not supply a post-intervention period 
venous blood sample (visit 2). A second individual completed the initial capsule 
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intervention and washout period, but elected not to start the drinks intervention 
period and therefore did not provide blood samples from visits 4 and 5.  
Levels of individual PUFAs in RBC membranes were analysed and expressed 
as a percentage of the total RBC membrane fatty acid content.  The absolute 
change in percentage values between baseline and post-supplementation or 
washout was calculated for individual PUFAs. The one sample t-test was 
employed to assess absolute percentage RBC membrane PUFA change in 
individuals at post-supplementation and washout. The paired t-test was used to 
compare absolute change post-supplementation and at the end of the washout 
period across both interventions. The Wilcoxon matched-pairs signed rank test 
was used when data were not normally distributed.  
5.7.1 Treatment intervention order 
Analysis of PUFA RBC levels based on the intervention order to which 
participants were randomised was performed to determine whether the 12-week 
washout period ensured a return to baseline RBC membrane levels (Figure 7).    
The 12-week washout period was of satisfactory length to return EPA RBC 
membrane levels to near baseline measurements irrespective of capsule 
intervention order. Baseline EPA levels in participants randomised to receive the 
capsule intervention first (C/D, n=10) were similar to EPA levels in patients 
randomised to receive capsule supplementation during the second intervention 
period (D/C, n=10) with mean EPA RBC membrane levels of 0.72% and 0.83% 
respectively (p=0.52). Although DHA levels in participants randomised to 
consume capsules during the first intervention period (C/D) remained elevated 
after the 12-week washout period, this had no effect on baseline levels with 
regard to intervention order (C/D: 2.73% versus D/C: 3.32%, p=0.21). There was 
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no difference between the absolute change in eight week post-supplementation 
EPA RBC membrane levels based on the order to which the capsule intervention 
was received (C/D: 1.52% points,  D/C: 1.54% points, p=0.52), which was also 
similar when examining DHA RBC membrane levels (C/D: 1.51% points, D/C: 
1.31% points, p=0.63).  
Nine individuals (9/10) randomised to consume drinks during the first intervention 
period (D/C) completed eight weeks of supplementation compared to seven 
participants taking the drink supplements during the second intervention period 
(C/D).  EPA RBC membrane levels were higher at baseline in patients 
randomised to receive drinks during the second intervention period (D/C: 0.67%, 
C/D: 1.13%, p = 0.05). There were similar findings exhibited in DHA RBC 
membrane levels with mean levels at baseline of 3.36% and 4.15% in 
participants randomised to taking drinks during the first and second intervention 
periods respectively, although this difference was not statistically significant. The 
adequacy of the 12-week washout period was confirmed by examination of the 
absolute change in EPA and DHA levels after 12 weeks’ washout, neither of 
which were statistically significant regardless of intervention order.  
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Figure 7. Comparison of RBC EPA and DHA levels depending on the intervention order to 
which either the drinks or capsules were received (first or second). A,B: EPA and DHA RBC 
membrane levels in participants randomised to receive capsules during the first intervention 
period (n=10) versus the second intervention period (n=10). C,D: EPA and DHA RBC 
membrane levels in participants randomised to receive drinks during the first intervention 
period (n=9) versus the second intervention period (n=7).  The left y-axis is the absolute mean 
percentage PUFA content measured for each supplementation type prior to either intervention 
period (visits 1 or 3). The right y-axis is the absolute mean change from baseline following the 
intervention period and washout dependant on whether the supplementation was received 
during the first or second intervention period. Error bars denote the standard error (SE) of the 
mean 
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5.7.2 Primary outcome measure 
To test the hypothesis that O3FA supplement drinks were non-inferior to an 
equivalent dose of O3FAs in capsule form the difference between absolute eight 
week post-supplementation O3FA RBC membrane levels (EPA + DHA) in both 
interventions were examined. Across the 16 participants that completed and 
provided a venous blood sample at the planned eight week study visit, seven 
participants exhibited lower O3FA RBC membrane levels following drinks 
compared to capsules. Measured absolute O3FA RBC membrane levels were 
0.12% points lower in drinks than capsules, although the 95% confidence interval 
of -1.84% points to 1.61% points revealed that this difference was not significant 
and therefore O3FA supplementation with SmartfishTM drinks was non-inferior to 
an equivalent dose of O3FAs in capsule form.   
5.7.3 EPA (figure 8a) 
Comparison of baseline EPA RBC membrane levels revealed no difference 
between participants randomised to either intervention (drinks; 0.88%, caspules; 
0.77%, p=0.47). At the end of the eight week intervention period, both drink and 
capsule interventions exhibited similar statistically significant elevations in  EPA 
RBC membrane levels from baseline of  1.54% points and 1.53% points 
respectively (both p<0.0001). However, there was no difference with regard to 
absolute change in EPA RBC membrane levels between capsule and drink 
interventions (p=0.93). After the 12-week washout period EPA RBC membrane 
levels in both interventions returned to baseline levels (absolute change from 
baseline; drinks, 0.04% points; capsules, 0.14% points, p=0.63).  
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5.7.4 DPA (figure 8b) 
Mean DPA RBC membrane levels were similar across both interventions at 
baseline (drinks; 1.95%, capsules; 1.65%, p=0.20). Post-supplementation DPA 
RBC membrane levels were higher following the capsule intervention period, 
although this did not reach statistical significance when compared to the drinks 
intervention period (absolute change from baseline; capsules, 0.35% points; 
drinks, -0.01% points, p=0.16). After the 12-week washout period mean DPA 
RBC membrane levels in the drinks intervention were 0.33 percentage points 
lower than those measured at baseline (one sample t-test; p=0.04). However a 
difference between capsule and drink intervention DPA RBC membrane levels, 
as measured by absolute change failed to reach statistical significance in a 
paired analysis (drinks; -0.33% points, capsules; 0.26% points, p=0.07).     
5.7.5 DHA (figure 8c) 
Mean DHA RBC membrane levels were similar across both interventions at 
baseline (drinks; 3.70%, capsules; 3.03%, p=0.32). At the end of the eight week 
intervention period, both drink and capsule intervention groups exhibited 
elevations in  DHA RBC membrane levels from baseline of  1.05% points 
(p=0.02) and 1.41% points (p<0.0001) respectively. However the difference 
between interventions failed to reach statistical significance (p=0.86). Following 
the 12-week capsule washout period, DHA RBC membrane levels remained 
elevated from baseline (absolute change from baseline 0.73% points, p=0.04). 
The same elevation was not exhibited following the drink washout period where 
DHA RBC membrane levels returned to near baseline levels (absolute change 
from baseline -0.14% points, p=0.63). However the difference between capsule 
and drink interventions was not statistically significant (p=0.38). 
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5.7.6 AA (figure 8d) 
Baseline AA RBC membrane levels were similar across both interventions 
(drinks; 7.42%, capsules; 6.61%, p=0.42). There was a significant decrease from 
baseline in AA RBC membrane levels post-supplementation in the drinks 
intervention (-1.58% points, p<0.01), which was not apparent following the 
capsule intervention (-0.31% points, p=0.68). However this difference failed to 
reach statistical significance (p=0.23). Following the washout period AA RBC 
membrane levels remained lower than baseline levels in the drinks intervention 
(-1.27% points, p=0.05). However AA RBC membrane levels returned to near 
baseline levels in the capsule intervention (0.19% points, p=0.80).The difference 
between capsule and drinks interventions was not statistically significant.  
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Figure 8. Individual RBC PUFA levels comparing pooled data from the drink versus capsule 
intervention independent of intervention order (A: EPA, B: DPA, C: DHA, D: AA). Number of 
participants completing drinks intervention (n=16), number of participants completing capsule 
intervention period (n=20). The left y-axis is the absolute percentage PUFA content measured 
for capsule and drink interventions at baseline (visits 1 or 3). The right y-axis is the absolute 
change from baseline following the intervention period and washout dependent on the 
intervention type. Error bars denote the SE of the mean. 
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5.7.7 O3FA index (figure 9) 
The total EPA and DHA RBC membrane levels were analysed to reflect the 
combined O3FA composition of both the capsule and drink interventions. There 
was no significant difference between baseline EPA+DHA RBC membrane 
levels (drinks, 4.58%; capsules, 3.81%, p=0.43). Both capsule and drink 
interventions exhibited a statistically significant increase in EPA+DHA RBC 
membrane levels from baseline of 2.94% points (range: 0.33% points to 12.38% 
points, p=0.0001) and 2.60% points (range: -1.94% points to 5.68% points, 
p=0.0001) respectively. Post-supplementation there was no statistically 
significant difference between intervention types (p=0.90). Following the 12-
week washout period EPA+DHA RBC membrane levels remained elevated in 
the capsule intervention (0.87% points, p = 0.06) compared to the drinks 
intervention (-0.10% points, p=0.78), however this difference failed to reach 
statistical significance (p=0.40).  
5.7.8 O3FA:O6FA ratio (figure 10) 
The ratio of O3FAs to O6FAs is often quoted to reflect the proposed anti-
inflammatory role of EPA and DHA in comparison to pro-tumorigenic AA 
(DiNicolantonio & O'Keefe, 2018; Simopoulos, 2008). The ratio was defined as 
(EPA+DHA)/AA. At baseline, the mean O3FA:O6FA ratio was similar for both 
capsule and drink interventions (0.61 versus 0.63). Following eight weeks 
supplementation, the O3FA:O6FA ratio was higher for both capsule and drink 
interventions compared to baseline. Comparison of intervention type revealed 
that the increase in the O3FA:O6FA ratio from baseline was significantly higher 
following drinks (0.64) compared with capsules (0.48) (p=0.02). Following the 
12-week washout period the O3FA:O6FA ratio fell but remained elevated 
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compared to baseline for both capsule and drink interventions with mean 
absolute change from baseline of 0.13 and 0.09 respectively (p<0.0001 in both 
capsule and drink interventions). 
5.7.9 Individual participant analysis  
All participants (n=20) exhibited elevated EPA RBC membrane levels following 
eight weeks capsule supplementation. With the exception of one individual that 
ceased drink intervention two weeks prior to the planned eight week study visit 
(participant 007), the remaining participants that provided a post-intervention 
venous blood sample exhibited a rise in absolute EPA RBC membrane levels 
following drinks supplementation.   
Nineteen of the 20 participants showed increased DHA RBC membrane levels 
post-O3FA capsule supplementation (participant 005 – decreased RBC DHA 
membrane levels). DHA RBC membrane levels fell in three individuals 
(participants 006, 007 and 018) following eight weeks supplementation with 
O3FA containing drinks. Participant 007 ceased O3FA drinks supplementation 
two weeks prior to providing a venous blood sample. Irrespective of intervention 
type, the remaining three participants (capsules n=1, drinks n=2) with a decrease 
in measured post-supplementation RBC DHA membrane levels were all 
apparent following the second intervention period.  
Examination of individual PUFA profiles throughout the course of the trial 
revealed significant inter-individual variation. Absolute change in EPA RBC 
membrane levels post-capsule supplementation ranged from 0.56% points to 
3.28% points. This variation was also apparent following drinks supplementation 
(0.37% points to 3.57% points). Absolute change in DHA capsule RBC 
membrane levels ranged from -0.23% points to 7.86% points. There was also 
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variation following drinks supplementation although to a lesser degree (-2.32% 
points to 2.70% points).  
Measured AA RBC membrane levels were lower following O3FA drinks 
supplementation in 14 of 17 individuals (82%) that provided venous blood 
samples. Across the 17 participants, absolute change in AA RBC membrane 
levels post-supplementation ranged from -6.27% points to 0.75% points. 
Comparatively only 13 of 20 individuals (65%) showed a decrease in AA RBC 
membrane levels following capsule supplementation. Absolute change post-
supplementation in capsules ranged from -5.85% points to 10.47% points across 
the 20 participants. When taking into account intervention order, 9 of 10 
individuals randomised to capsules first exhibited a reduction in RBC AA 
membrane levels compared to 4 of 10 randomised to the capsules during the 
second intervention period.   This difference is likely due to the previously 
described finding that following washout in the drinks intervention, AA RBC 
membrane levels persisted to be lower than baseline. 
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Figure 10. Measurement of the O3FA:O6FA ratio ([EPA + DHA]/AA) in drinks versus capsules 
independent of intervention order. Number of participants completing drinks intervention (n=16), 
number of participants completing capsule intervention period (n=20). The left y-axis is the 
absolute O3FA index measured for capsule and drink interventions at baseline (visits 1 or 3). 
The right y-axis is the absolute change from baseline following the intervention period and 
washout dependant on intervention type. Error bars denote the SE of the mean. 
  
Figure 9. Measurement of the O3FA index (EPA + DHA) in drinks versus capsules 
independent of intervention order. Number of participants completing drinks intervention 
(n=16), number of participants completing capsule intervention period (n=20). The left y-axis 
is the absolute O3FA index measured for capsule and drink interventions at baseline (visits 
1 or 3). The right y-axis is the absolute change from baseline following the intervention 
period and washout dependant on intervention type. Error bar denote the SE of the mean. 
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5.7.10 Relationship between compliance and O3FA RBC membrane levels 
(Figure 11) 
In order to ascertain whether there was a relationship between O3FA RBC 
membrane levels and compliance with taking either supplementation, the 
Pearson correlation coefficient was calculated. The O3FA index was used for 
analysis as both capsule and drink preparations contained a combination of EPA 
and DHA. Compliance was based on the number of drinks cartons or capsules 
returned as described previously. There was no correlation between percentage 
compliance and measured post-supplementation O3FA RBC membrane levels 
(EPA + DHA) for either drinks (r=-0.13, 95% CI -0.54 to 0.33) or capsules (r=-
0.10, 95% CI -0.57 to 0.42) interventions. This analysis is limited by the inability 
to verify whether the capsule and drinks carton counts were accurate. 
5.7.11 Relationship between baseline O3FA RBC membrane levels and post-
supplementation O3FA RBC membrane levels (Figure 12)   
To determine whether there was a relationship between baseline O3FA RBC 
membrane levels and post-supplementation EPA or DHA RBC membrane levels 
following either capsule or drink interventions the Pearson correlation coefficient 
was calculated. There was no correlation between baseline and post-
supplementation RBC membrane levels for either EPA or DHA following capsule 
supplementation. However there was a statistically significant correlation 
between baseline and post-supplementation DHA RBC membrane levels 
following drinks supplementation (r=0.52, 95% CI 0.03 to 0.81, p=0.04).  
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Figure 11. Correlation between post-treatment O3FA (EPA + DHA) RBC membrane content 
(%) and compliance in each intervention type. A: capsules (n=20, r=-0.13), B: drinks (n=16, 
r=-0.10).    
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5.8 Discussion 
The randomised cross-over trial confirmed the hypothesis that EPA and DHA 
supplementation with drinks was non-inferior to an equivalent dose in capsule 
form as measured by RBC PUFA membrane levels. The cross-over trial design 
and adequacy of the 12-week washout period were validated by the finding that, 
irrespective of intervention order, baseline RBC membrane levels of both EPA 
 
Figure 12. Correlation between baseline O3FA RBC membrane content (%) and post 
treatment O3FA RBC membrane levels (%). A: EPA-capsules (n =20, r=0.25), B: EPA-drinks 
(n=16, r=0.28), C: DHA-capsules (n=20, r=0.23), D: DHA-drinks (n=16, r=0.52, p=0.04). 
*denotes statistically significant result (p<0.05)   
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and DHA were similar. Baseline EPA and DHA levels were comparable to 
published healthy volunteer studies (Kohler et al., 2010; Scaioli et al., 2015).  
Both capsule and drinks O3FA preparations were in triglyceride form, thus 
requiring hydrolysis by pancreatic lipases in the small intestine (see section 
1.3.3). The drinks cartons contained adequate fat content to stimulate secretion 
of pancreatic lipases and subsequent absorption of triglyceride-bound EPA and 
DHA.  Due to the lack of dietary assessment over the course of the study it could 
not be ascertained whether participants took the drinks with or without food and 
if they consumed additional dietary fat. This would potentially affect both 
absorption and subsequent incorporation of EPA and DHA into RBC 
membranes. 
The findings of the present study are in agreement with an eight week placebo-
controlled trial of another ‘convenience’ drink containing a total of 500mg 
combined EPA and DHA developed by the same manufacturer used in the 
present study. Interestingly, despite the aforementioned study employing a far 
lower daily dose of EPA and DHA (500mg versus 4000mg) the authors reported 
similar increases to the O3FA index of 2.43% compared to the 2.60% increase 
reported here (Kohler et al., 2010). This would suggest that a daily dose of 
4000mg of EPA and DHA is far in excess of that required to achieve maximal 
RBC membrane incorporation levels. Given the timing of RBC membrane 
measurements it is not possible to determine whether the rate at which maximal 
RBC membrane levels were achieved was more rapid with this higher dose of 
EPA and DHA. Of note was that following drinks supplementation and washout 
there was a decrease in both RBC DPA and DHA levels which was not apparent 
following capsule supplementation. The reason behind this difference is unclear 
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but there may be additional ingredients within the drinks that effect enzymatic 
conversion of EPA to DPA and subsequent conversion to DHA.        
There was significant inter-individual variation with respect to individual healthy 
participant PUFA profiles across both capsule and drinks interventions. This was 
also evident in the individual RBC membrane PUFA profiles of patients in the 
study of CRCLM (chapter 7). These findings correspond with the previously 
described O3FA drinks formulation study, where there was significant post-
supplementation variability to the O3FA index ranging from -0.03% to 7.16% 
across 40 participants   (Kohler et al., 2010). There are a number of potential 
explanations for the variation exhibited across individual PUFA profiles in the 
present study. There is potential widespread variation across individuals in 
relation to the rate at which PUFAs entered various metabolic pathways, 
including β-oxidation and generation of ATP, fatty acid conversion, or entering 
into various lipid signalling pathways (Kanamori et al., 2018; Camões et al., 
2009). The metabolic fate of PUFAs is likely to affect the measurement of RBC 
membrane PUFA levels at any given time point. One might also expect 
compliance to have a significant influence on EPA and DHA RBC membrane 
levels, although this was not apparent in the present study. A possible 
explanation was that with compliance across both interventions of greater than 
98% there was insufficient variation to detect a relationship.  There are also likely 
differences across participants with respect to their ability to absorb EPA and 
DHA from the gastrointestinal tract, specifically variations in pancreatic lipase 
excretion and enzyme activity, which may also be influenced by unmeasured 
concomitant dietary fat intake (Schuchardt & Hahn, 2013).   
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The significant inter-individual variation of response to O3FA supplementation is 
of relevance in the potential clinical applications of O3FA supplementation. RBC 
membrane O3FA levels are accepted as a reflection of O3FA levels within 
multiple tissues, and as I report later there was a correlation between RBC EPA 
membrane levels and CRCLM tissue levels (Metcalf et al., 2007; Harris et al., 
2004; Tu et al., 2013; Brenna et al., 2018). If there is a potential clinical benefit, 
particularly in the context of treating CRC micrometastases and 
chemoprevention in healthy individuals, the efficacy of any anti-cancer effect 
may also vary according to an individual’s ability to incorporate EPA and DHA 
into target tissues. A major limitation of this trial was the inability to gather colonic 
tissue to confirm whether the changes in RBC membrane PUFA levels 
correspond to colonic mucosal PUFA levels. This is of significant importance as 
there is evidence that incorporation of O3FAs into cell membranes may influence 
CRC development via influencing cell membrane structure and integrity (Chapkin 
et al., 2002). It is also evident from the literature that many in-vivo and in-vitro 
studies examine the effect of O3FAs on colorectal carcinogenesis in both colonic 
and CRC tissue (Cockbain et al., 2012). Therefore changes to colonic PUFA 
tissue profiles would be of significant interest. Participants in this study were 
healthy volunteers and therefore it would have been deemed to pose an 
unacceptable risk to subject individuals to endoscopic biopsy to obtain colonic 
tissue.   
When examining individual PUFA levels, the relationship between EPA, DHA 
and AA was of significant interest. The ratio of O3FAs to O6FAs is quoted to 
reflect the proposed anti-inflammatory role of EPA and DHA in comparison to 
pro-inflammatory AA, via their competitive interactions with the COX family of 
enzymes (Smith, 2005). In this study the O3FA:O6FA was defined as 
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(EPA+DHA)/AA. Irrespective of intervention type, there were increases in the 
O3FA:O6FA following the eight week supplementation period. Similar findings 
are reported elsewhere (Young et al., 2005; Burns et al., 2007; Gibney et al., 
1993). Cao et al. do not state the RBC membrane O3FA:O6FA ratio following 
EPA/DHA supplementation (2000mg) but do report both an increase in O3FA 
RBC membrane levels with a reciprocal decrease in AA RBC membrane levels 
over a period of eight weeks supplementation (Cao et al., 2006). It is unclear 
whether O3FA supplementation has a dose-dependent effect on the 
O3FA:O6FA given that the present study reports higher O3FA:O6FA ratios than 
a study using a combined EPA/DHA daily dose of approximately 35g (Young et 
al., 2005). However, it is noted that the aforementioned study measures plasma 
PUFA levels rather than RBC membrane levels. The magnitude of the increase 
in the O3FA:O6FA ratio was statistically significantly higher in drinks compared 
to capsules, a likely reflection of the greater drop in AA RBC membrane levels 
during the drinks intervention period. The reason behind this difference is unclear 
given that EPA and DHA RBC membrane levels were similar across both 
interventions and therefore one would expect any potential membrane 
displacement of AA by EPA and DHA to follow suit. One possible explanation is 
that during the drinks intervention period participants may have substituted their 
regular dietary routine with the drinks carton, which they did not subsequently 
follow during the capsule intervention period. Therefore their dietary intake of AA 
from for example eggs may have been lower during the drinks intervention 
period. If an individual also substituted LA containing foods during the drinks 
intervention period this may have resulted in reduced amounts available for 
conversion to AA (Rose & Connolly, 1999). The drinks cartons may also have 
ingredients that affected AA metabolism, particularly given that the drinks 
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contained approximately 600mg to 1100mg of unspecified PUFAs in addition to 
the EPA and DHA contents.  
The O3FA:O6FA ratio is pertinent to the interaction of PUFAs with the COX 
family of enzymes. This is one of the key mechanisms via which O3FAs are 
proposed to have anti-cancer properties and therefore potential clinical 
applications (see section 1.5). COX-2 is overexpressed in 50-80% of colorectal 
tumours (Eberhart et al., 1994). In the presence of EPA, there is decreased 
production of PGE2 which is generated by AA interaction with COX enzymes 
(Hawcroft et al., 2010). PGE2 is identified at higher concentrations in CRC tissue 
compared to normal tissue (Chulada et al., 2000). It was also reported that PGE2 
levels were lower in CRCLM tissue following EPA supplementation (Cockbain et 
al., 2014). The production of pro-inflammatory eicosanoids such as PGE2 
promotes carcinogenesis via a number of mechanisms including suppression of 
apoptosis, promotion of angiogenesis and stimulation of cell proliferation (Cheuk 
et al., 2002; Tsutsumi et al., 2002; Leahy et al., 2002; Cianchi et al., 2001; Pai et 
al., 2001). It would be of interest to measure whether levels of the urinary 
prostaglandin metabolite (PGE-M) decreased following O3FA supplementation 
with both drinks and capsules (Cockbain et al., 2014). Although there was 
insufficient funding there is still scope to perform this analysis in the future, as 
urine samples were collected at each time point over the course of the study.  
Both drinks and capsule O3FA formulations were well tolerated as highlighted 
by the limited number of individuals that ceased supplementation during either 
intervention period (two individuals and three individuals from capsule and drinks 
respectively). There was no appreciable difference with regard to the adverse 
event and acceptability profiles of both the drinks and the capsules, with results 
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similar to data reported previously (Wang et al., 2006). It is not possible to 
determine whether there was a dose-related response with regard to O3FA 
supplementation in either capsule or drink preparations as no individual reduced 
the dose of O3FA intervention over the course of either intervention period. Of 
interest is that less than 50% of individuals that experienced adverse events 
during the first intervention period taking either capsules or drinks, reported any 
adverse events when taking the alternative intervention during the second 
intervention period. Given there was O3FA dose equivalence across both 
capsule and drink interventions, there may have been additional factors 
associated with both interventions responsible for adverse events. One measure 
that suggested participants preferred capsules to the drinks, was whether an 
individual would consider taking either supplement in the future. A greater 
number of participants answered they would consider continuing the capsules 
(68%) than the drinks (58%), although this was not statistically significant. It is 
clear that although the adverse event profile and acceptability of the drinks 
preparation was comparable to capsules, there continued to be hesitancy from 
this healthy study population as to whether long-term or indefinite 
supplementation would be tolerated. 
The strengths of the present study included a relatively low participant withdrawal 
rate and high concordance with both provision of RBC samples and consumption 
of O3FA supplements. The cross-over trial design allowed direct intra-individual 
comparison of O3FA supplement types in an effort to limit the effect of inter-
individual variability. 
The main limitation of the study was the lack of dietary assessment which 
precluded measuring the effect of dietary fat intake on the absorption of O3FAs 
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in either intervention type. This relatively small study was also insufficient to 
properly assess the difference in tolerability and acceptability between both 
forms of supplementation. The inability to assess for any correlation between 
PUFA incorporation into RBC membranes and colonic mucosal tissue is a 
significant limitation. Given that the colonic mucosa is the site at which colorectal 
carcinogenesis occurs, it is an important target for O3FA incorporation when 
considering O3FA supplementation as either a form of CRC chemoprevention or 
CRC treatment adjunct. 
5.9 Conclusion 
The findings of the present study provide evidence that O3FA containing drinks 
exhibit a similar O3FA RBC membrane incorporation profile to traditional O3FA 
containing capsules. Given the previously described anti-inflammatory and anti-
neoplastic properties associated with O3FAs, supplement drinks have a potential 
clinical application in chemoprevention or as an adjunct in CRC treatment. The 
non-inferiority of drinks compared to capsules with regard to bioavailability of 
O3FAs is of key significance in CRC patients. Many patients recovering from 
surgery have an impaired appetite and are unable to consume conventional 
dietary fats required for absorption of traditional O3FA capsule supplementation. 
In addition, fortified O3FA nutrition drinks may be of nutritional value in providing 
additional calories to patients who are unable to achieve adequate calorific input, 
as is already commonplace with the use of various calorific supplements. Further 
research in a population of CRC patients is required to ascertain whether there 
are similar bioavailability, acceptability and tolerability profiles to those exhibited 
in this study of healthy volunteers. 
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Chapter 6: Results of faecal microbiome analysis from the randomised 
cross-over trial following O3FA supplementation 
6.1 Introduction 
The following chapter describes the results of faecal microbiome profile analysis 
of healthy volunteer stool samples following O3FA supplementation in the 
randomised cross-over trial.  The effect of O3FA supplementation on bacteria at 
various taxonomic levels was examined, with particular attention to faecal 
microbiome profile changes associated with CRC carcinogenesis.   
6.2 Sampling (see section 4.1) 
When taking into account participant withdrawals during the course of the study, 
97 of an expected 98 stool samples (99%) were obtained for faecal microbiome 
analysis from 20 study participants. 
6.3 Stool DNA extraction and purification  
Ninety seven stool samples stored at -80ºC underwent DNA extraction. The 
median 260/280 and 260/230 ratios of DNA samples were 2.05 (range 1.66 to 
2.22) and 2.00 (range 1.17 to 2.28) respectively. When analysing both 260/230 
and 260/280 ratios, eight samples had markedly low ratio values (<10% of 
recommended ratio values). Therefore the relevant frozen stool samples 
underwent repeat DNA extraction and purification. Two of the eight repeated 
stool samples achieved higher 260/230 ratios but neither were within the desired 
range (greater than 1.8). The eight stool samples that reported 260/230 and 
260/280 ratios below the desired range were still taken forward for faecal 
microbiome analysis. A repeat sample was only taken forward if both the purity 
of the sample and DNA concentration were higher than the original sample 
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extraction. This was exhibited in only one of the eight repeat extractions. The 
median DNA concentration across all 97 samples was 1025ng/µl (range 
140ng/µl to 3162ng/µl).  
6.4 PCR amplification of the 16S rRNA gene 
Gel electrophoresis of the product from PCR amplification of the V4 hyper-
variable region of the 16S rRNA gene illustrated that 96 of 97 samples underwent 
successful PCR amplification as confirmed by a PCR product of expected size 
(approximately 250bp; Figures 13A & 13B). This was further highlighted by the 
presence of PCR product in the positive control E. coli sample (lane 32, row 2 of 
figure 13A; lane 21, row 2 of figure 13B) and the absence of PCR product in both 
the negative PCR sample and C2020 human cell line sample (lane 32, row 1 and 
lane 30, row 2 of figure 13A; lanes 19 and 23, row 2 of figure 13B) which did not 
contain any bacterial DNA. PCR amplification was unsuccessful in both the initial 
and repeated DNA extraction of the visit 1 stool sample from participant 005. 
This was evident in lanes 10 (row 1) and 19 (row 1) of figures 13A and 13B 
respectively where there was no evidence of PCR product. The purity of this DNA 
sample was below the desired range. 
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A 
  
Row 1  
 
Row 1  
 
Row 2  
 
Row 2  
 
1 50bp ladder 17 019V1 1 50bp ladder 17 020V2 
2 001v1 18 009V1 2 011V2 18 008V3 
3 012V1 19 020V1 3 012V2 19 012V3 
4 002V1 20 010V1 4 001V3 20 009V3 
5 013V1 21 001V2 5 013V2 21 013V3 
6 003V1 22 011V1 6 002V3 22 010V3 
7 014V1 23 002V2 7 014V2 23 014V3 
8 004V1 24 005V2 8 003V3 24 011V3 
9 015V1 25 003V2 9 015V2 25 015V3 
10 005V1 26 006V2 10 004V3 26 019V3 
11 016V1 27 004V2 11 016V2 27 016V3 
12 006V1 28 007V2 12 005V3 28 020V3 
13 017V1 29 009V2 13 017V2 29 017V3 
14 007V1 30 008V2 14 006V3 30 C2020 
15 018V1 31 010V2 15 018V2 31 018V3 
16 008V1 32 NEG PCR 16 007V3 32 E.COLI 
1   2   3   4   5   6    7  8    9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 
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B 
  
Row 1  
 
Row 1  
 
Row 2  
 
Row 2  
 
1 50bp ladder 13 018_V4 1 50bp ladder 13 018_V5 
2 001v4 14 007v4 2 001_V5 14 007_V5 
3 012v4 15 019_V4 3 012_V5 15 019_V5 
4 002v4 16 008_V4 4 002_V5 16 008_V5 
5 013_V4 17 020_V4 5 013_V5 17 020_V5 
6 003v4 18 009_V4 6 003_V5 18 009_V5 
7 014_V4 19 005_V1 7 014_V5 19 C2020 
8 004v4 20 010_V4 8 004_V5 20 010_V5 
9 016_V4 21 empty 9 016_V5 21 E.Coli 
10 005_V4 22 011_V4 10 005_V5 22 011_V5 
11 017_V4 23 empty 11 017_V5 23 Neg PCR 
12 006_V4 
  
12 006_V5 
  
Figure 13A&B: Gel electrophoresis of PCR product following PCR amplification of the V4 
hypervariable region of the 16S rRNA gene.  Individual numbered lanes represent individual 
participant stool samples provided at each study visit (v1, v2, v3, v4, v5). Reference ladder 
(50bp) and control samples also individually labelled. 
1  2   3   4   5   6    7   8  9  10  11 12 13 14 15 16 17 18 19 20 21 22 23 
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6.5 Quant-it assay of PCR product 
The concentration of DNA following PCR amplification of the V4 hyper-variable 
region of the 16S rRNA gene was determined for each participant stool sample. 
The median concentration of DNA post PCR amplification was 23.1ng/µl (range 
7.0ng/µl to 34.6ng/µl). The concentration of PCR product from the participant 
stool sample that showed no evidence of successful PCR amplification at gel 
electrophoresis was also quantified using the Quant-it assay (participant 005, 
visit 1). The concentration of the initial sample was below the reference range of 
the know standard. The re-run sample concentration measured 0.4ng/µl which 
was insufficient for sequencing library preparation. The Quant-it assay measure 
of DNA concentration was validated by the control samples. The negative 
control, the C2020 human cell line and sample containing no PCR product 
showed no recordable DNA concentrations. The positive E. Coli control showed 
adequate PCR amplification of the V4 hyper-variable region of the 16S rRNA 
gene (19.3ng/µl). 
6.6 Tapestation assay of library preparation PCR product 
Ninety seven stool samples were taken forward for library preparation resulting 
in the addition of an adaptor sequence to enable DNA sequencing on the Illumina 
platform. The adaptor sequence was 120bp in length with an expected overall 
library preparation product of approximately 360bp to 390bp in length. To confirm 
that successful library preparation had taken place, samples were analysed on 
the Tapestation analyser. The Tapestation system identifies the DNA fragment 
by size and also determines the presence of any isolated adaptor sequences or 
contaminant DNA from the purification process. Isolated adaptor sequences 
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following library preparation may interfere with sequencing as they preferentially 
bind to the flow cell of the sequencer. 
Ninety seven samples analysed contained a predominant DNA fragment of 
between 360bp to 390bp in length, corresponding to the modified library 
preparation product with adaptor sequence. The median percentage integrated 
area, which is a measure of the presence of the desired PCR product with an 
adaptor sequence was 72%. Therefore samples contained a greater amount of 
adapted PCR product than other background or contaminating sequences and 
were suitable for sequencing. One sample, (participant 005, visit 1) did not exhibit 
a DNA fragment of the expected size. This corresponded to the same sample for 
which there was no PCR product post PCR amplification at gel electrophoresis 
or Quant-it analysis. Ten samples exhibited an adaptor peak of approximately 
120bp in size, however the magnitude of isolated adaptor sequences present 
was below the threshold to inhibit DNA sequencing. 
6.7 Quant-it assay of library preparation product 
The concentration of library preparation DNA for each of the 97 stool samples 
was measured. Median concentration was 69.1ng/µl (range 21.2ng/µl to 
99.1ng/µl). The library preparation sample from participant 005 visit 1 contained 
no library preparation product, which corresponded to the absence of a 
corresponding sized DNA fragment in the Tapestation analysis. Six library 
preparation samples were below the required concentration for sequencing on 
the Illumina next generation sequencer (range 21.2ng/µl to 42.2ng/µl) and 
therefore the process of library preparation was repeated. The six repeat 
samples that underwent library preparation were of adequate concentration as 
measured by the Quant-it assay (range 58.3ng/µl to 89.7ng/µl). 
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6.8 Illumina next generation DNA sequencing 
Ninety six stool samples were taken forward for DNA sequencing. A single 
sample (participant 005, visit 1) was excluded from further faecal microbiome 
analysis as there was no evidence of library preparation product in either 
Tapestation or Quant-it assays. The number of reads per sample is a measure 
of sequence coverage. An increased number of reads provides improved 
accuracy of genomic sequencing as sequencing errors in any individual 
sequence may be indistinguishable from a sequence variant (Sims et al., 2014). 
Across the 96 samples analysed the median number of reads was 46603 (range 
26387 reads to 114130 reads).   
6.9 Bray-Curtis principal co-ordinate analysis (PCoA) 
The 96 stool samples were analysed to measure both the degree of inter-
individual and intra-individual variation between participant stool samples, so-
called β-diversity.  The samples were analysed on the basis of OTUs, whereby 
nearly identical sequences, typically greater than 95% similarity are classified as 
identical genomes (Schloss, 2010; Matsen, 2014). The Bray-Curtis dissimilarity 
calculation quantifies β-diversity and is graphically represented in figure 14 using 
a PCoA. Each point is colour coded by participant and represents a stool sample 
from each of the five study visits irrespective of intervention order. Each data 
point is plotted to create a visual representation of variability and therefore 
microbial compositional differences between samples (Goodrich et al., 2014). 
Assessment of the PCoA illustrates consumption of either O3FA containing 
drinks or capsules had no significant effect on faecal microbiome profiles, 
although inter-individual variation across samples precluded assessment of the 
effect of O3FA supplementation on the microbiome within individual participants. 
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Figure 14: PCoA of β-diversity across 96 stool samples (20 participants) as measured by 
Bray-Curtis Dissimilarity calculation. Individual participants (001 to 020) are uniquely colour 
coded across each of the five planned study visits (V1, V2, V3, V4, V5) irrespective of 
intervention order. Participants 008, 013 and 016 are highlighted (blue circle).  
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Three individuals displayed markedly different faecal microbiome profiles 
(participants 008, 013 and 016). Participants 008 and 013 differed from the 
remaining participants with a reduced proportion of the class Clostridia and a 
larger proportion of the class Gammaproteobacteria with high abundance of the 
family Succinivibrionaceae (figure 15a). Analysis of the microbiome at family 
level excluding Succinivibrionaceae revealed that these microbiome profiles 
were actually similar to the remaining study participants (figure 15b). 
Examination of the baseline characteristics of participants 008 and 013 did not 
reveal differences from the other participants in the study, specifically the use of 
medications, vitamin supplements or underlying medical conditions.  Participant 
016 displayed a very high abundance of the family Succinivibrionaceae, 
specifically the genus Succinivibrio but otherwise the faecal microbiome profile 
was similar to the remaining volunteers in the study as detailed in figure 16. Of 
specific note was this participant was the only individual within the study 
prescribed a proton pump inhibitor (omeprazole) prior to entering the study. As 
participants 008 and 013 exhibited markedly different faecal microbiome profiles 
with respect to the classes Clostridia and Gammaproteobacteria they were 
excluded from subsequent pooled analyses.  
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Figure 15A&B. Microbiome analysis across all 20 participants at individual study visits (V1 to 
V5) at family taxonomic level as measured by number of reads. Figure A includes all families 
identified. Figure B excludes the family Succinivibrionaceae. Participants 008, 013 and 016 
are highlighted by a blue line above relevant study visits. 
B 
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volunteer 016: high 
abundance of 
Succinivibrio moves 
these samples away 
from others 
Figure 16. Family- and genus-level analysis of all stool samples as measured by number of 
reads (excluding volunteers 008 and 013). PCoA included to demonstrate the presence of a 
high proportion of Succinivibrio (family, Succinivibrionaceae) in participant 016 results in 
differences exhibited in β-diversity analysis (highlighted in red).   
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The following analyses measure changes to faecal microbiome profiles based 
on the order to which study participants received the carton and drink 
supplements. Therefore figures 17 and 18 label participants randomised to 
capsules followed by drinks as Int1_Int2. Participants randomised to take drinks 
followed by capsules are labelled as Int2_Int1.  The PCoA in figure 17 illustrates 
that irrespective of intervention order both the baseline and washout faecal 
microbiome profiles of all participants within the study (excluding participants 008 
and 013) were similar. It also appears that following O3FA supplementation there 
was a distinct change to faecal microbiome profiles in participants randomised 
to both intervention orders, although the change was less marked in participants 
randomised to consume capsules during the second intervention period. On the 
basis that following both washout periods, regardless of intervention order the 
pooled faecal microbiome profiles of all participants were similar to baseline, 
subsequent analyses were performed with capsule and carton interventions 
merged. Review of faecal microbiome profiles dependent on intervention order 
did not exhibit any significant differences as measured by the percentage 
number of reads at family level (figure 18). Microbiome analysis irrespective of 
intervention order was further justified by the previously described finding that 
EPA and DHA RBC membrane levels returned to near baseline following the 
washout period across both intervention orders. Subsequent analyses presented 
are performed irrespective of intervention order and are labelled as pre (1.1) and 
post (1.2) capsule or pre (2.1) and post (2.2) drinks supplementation. 
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start & washout 
visits 
Figure 17. Pooled PCoA analysis of β-diversity based on intervention type (capsules versus 
drinks) at individual study visits (V1 to V5).  Consumption of capsules are labelled as Int1. 
Consumption of drinks are labelled as Int2. Arrows highlight the flow of participants through 
the study from visit 1 to visit 5.  
Capsules Drinks Drinks Capsules 
Legend (Taxa):
Ruminococcaceae Lachnospiraceae Bifidobacteriaceae Erysipelotrichaceae Succinivibrionaceae Clostridiaceae Sutterellaceae Akkermansiaceae
Christensenellaceae Acidaminococcaceae Desulfovibrionaceae Rikenellaceae Bacteroidaceae Pseudomonadaceae Enterobacteriaceae Peptostreptococcaceae
Pasteurellaceae Peptococcaceae Veillonellaceae Victivallaceae Porphyromonadaceae Anaeroplasmataceae Selenomonadaceae Coriobacteriaceae
Lactobacillaceae Prevotellaceae Odoribacteraceae Peptoniphilaceae Streptococcaceae Actinomycetaceae Methanobacteriaceae Moraxellaceae
Alcaligenaceae Eggerthellaceae Oxalobacteraceae Aerococcaceae Campylobacteraceae Comamonadaceae Gracilibacteraceae Eubacteriaceae Bacillaceae
Clostridiales Family XIII. Incertae Sedis Micrococcaceae Flavobacteriaceae Syntrophomonadaceae Leptotrichiaceae Morganellaceae Corynebacteriaceae
Brachyspiraceae Carnobacteriaceae Enterococcaceae Leuconostocaceae Brucellaceae Yersiniaceae Atopobiaceae Burkholderiaceae Caulobacteraceae
Erwiniaceae Methylobacteriaceae Neisseriaceae Nocardioidaceae Synergistaceae Bradyrhizobiaceae Caldicoprobacteraceae Deinococcaceae
Microbacteriaceae Parachlamydiaceae Propionibacteriaceae Rhodobacteraceae Thermaceae Vibrionaceae Xanthomonadaceae
Figure 18.  Analysis of effect of intervention order on microbiome profile analysis as measured 
by percentage number of reads at family taxonomic level at each study visit. Capsule and 
drink intervention periods labelled.   
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6.10 β-diversity as measured by Unifrac pooled analysis 
To further assess changes to faecal microbiome profiles in a pooled analysis 
across the five study visits, β-diversity was measured. β-diversity measures the 
degree to which taxa are shared between the overall study population at each 
study visit.  Unifrac analysis differs from previously described Bray-Curtis 
dissimilarity measures by incorporating phylogenetic distances which assess not 
only the abundance, but also the phylogenetic relatedness of organisms within a 
study population. Figure 19 illustrates both weighted and unweighted Unifrac 
analyses. The weighted analysis is a quantitative measure of β-diversity, 
whereas the unweighted analysis is qualitative and only determines the presence 
or absence of organisms (Lozupone et al., 2007).  It is apparent that neither 
weighted nor unweighted Unifrac measures identify any significant changes in β-
diversity following either capsule or drink O3FA supplementation. This is at odds 
with the Bray-Curtis PCoA analysis previously described (figure 17) where there 
appeared to be marked changes post O3FA supplementation irrespective of 
intervention order. This apparent difference between β-diversity analyses may in 
part be due to the method of Unifrac analysis which accounts for phylogenetic 
similarities between separate OTUs. Individual OTUs across the five separate 
study visits may be phylogenetically closely related and therefore any differences 
illustrated in the Bray-Curtis PCoA analysis are no longer apparent.  
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6.11 α-diversity  
α-diversity is a measure of microbial diversity within a specific environment as 
measured by the Shannon diversity index. For the purpose of this study the 
environment is the participant faecal sample at each study visit. The index is 
calculated as the proportion of each species relative to the total number of 
species in the participant environment under analysis. The index is a measure of 
both the richness and distribution of taxa within a single population. Figure 20 is 
a pooled analysis of participant faecal samples at each visit in the study 
irrespective of intervention order. The microbial diversity within participant stool 
samples as measured by the Shannon diversity index was unchanged following 
Int1.1 Int1.2 Int2.1 Int2.2 V5 
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Figure 19. Weighted and unweighted unifrac analysis of β-diversity based on intervention type 
(capsule versus drinks) irrespective of intervention order. Int 1.1 and 1.2 consumed are pre 
and post-supplementation results in the capsule intervention. Int2.1 and 2.2 are pre and post 
supplementation results in the drinks intervention. Weighted (open circles), unweighted (solid 
squares). Results shown are mean values and standard deviation.   
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O3FA supplementation in both capsule and drink forms. There was no change 
to faecal microbial diversity following either of the eight week intervention periods 
or 12-week washout periods.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.12 The Firmicutes:Bacteriodetes (F:B) ratio 
Two of the major phyla colonising the human colon are Firmicutes and 
Bacteroidetes. The ratio of Firmicutes to Bacteroidetes is often cited in studies 
relating to microbial dysbiosis and CRC risk (Sun & Kato, 2016; Raskov et al., 
2017). Paired data were available for 20 and 17 participants in the capsule and 
drink groups respectively as shown in figure 21. Thirteen of 20 participants and 
10 of 17 participants in the capsule and drink interventions groups respectively 
reported an elevation in F:B ratio following the intervention period. However there 
was no statistically significant change in the F:B ratio following either drink or 
capsule O3FA interventions.  
Int1.1 Int1.2 Int2.1 Int2.2 V5 
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Figure 20. Shannon α-diversity index of effect of intervention type on microbiome profiles. Int 
1.1 and 1.2 consumed are pre and post supplementation results in the capsule intervention. 
Int2.1 and 2.2 are pre and post supplementation results in the drinks intervention. Results 
shown are mean values and standard deviation.   
118 
 
 
 
 
 
 
 
 
 
 
 
 
6.13 Analysis of faecal microbiome profiles at family and genus levels 
Faecal microbiome profiles were examined at both genus and family levels to 
determine changes not apparent in the global measures of α-diversity and β-
diversity. 
Results were merged according to O3FA intervention type (capsule or drink) 
irrespective of intervention order (Figure 22). The bacteria were quantified at 
both family and genus levels according to the measured number of reads for 
individual OTUs. At family level, the abundance of both Clostridiaceae and 
Akkermansiaceae of the phyla Firmicutes and Verrucomicrobia respectively, 
increased after both capsule and carton intervention periods with subsequent 
reversibility following the corresponding washout periods.  
There was an increase in the abundance of Sutterellaceae of the phylum 
Proteobacteria. This family of bacteria also exhibited a return to near baseline 
levels following the 12-week washout periods in both drink and capsule 
interventions.  
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Figure 21. Paired Firmicutes/Bacterioidetes (F:B) ratio values before and after 
capsules (Int1) and drinks (Int2) for both orders of intervention. V5 are the final visit (second 
washout) values. 
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Legend (Taxa):
Bifidobacterium Oscillospira Coprococcus Faecalibacterium Lachnospira Ruminococcus
Succinivibrio Roseburia Sutterella Akkermansia Blautia Phascolarctobacterium
Desulfovibrio Bacteroides Pseudomonas Haemophilus Clostridium Peptococcus Dorea
Anaerostipes Turicibacter Dehalobacterium Parabacteroides Dialister Mitsuokella
Lachnobacterium Lactobacillus Catenibacterium Bilophila Acidaminococcus Bulleidia
Prevotella Streptococcus Actinomyces Christensenella Megasphaera Butyricimonas
Peptoniphilus Odoribacter Holdemania Veillonella Methanobrevibacter Parvimonas
Gemella Acinetobacter Coprobacillus Aggregatibacter Collinsella Epulopiscium
Slackia Scardovia Paraprevotella Campylobacter Actinobacillus Peptostreptococcus
Erysipelothrix Lactococcus Victivallis Bacillus Anaerococcus Gracilibacter Anaerofustis
Anaerovorax Oxalobacter Adlercreutzia Citrobacter Rothia Myroides Alistipes
Morganella Syntrophomonas Oribacterium Porphyromonas Desulfosporosinus Finegoldia
Leptotrichia Varibaculum Facklamia Corynebacterium Selenomonas Brachyspira
Leuconostoc Desulfotomaculum Granulicatella Ochrobactrum Vagococcus Aerococcus
Butyrivibrio Caloramator Erwinia Mogibacterium Schwartzia Serratia Abiotrophia
Atopobium Brevundimonas Lautropia Leucobacter Methanosphaera Methylobacterium
Oxobacter Paracoccus Pyramidobacter Achromobacter Alkaliphilus Caldicoprobacter
Deinococcus Eikenella Enterococcus Gallicola Klebsiella Moryella Neisseria
Photobacterium Propionibacterium Stenotrophomonas Thermus Trichococcus
Figure 22. Family (A) and Genus (B) taxonomic level microbiomes profiles based on 
intervention type pre-and post-supplementation as measured by number of reads. Int 1.1 and 
1.2 consumed are pre and post supplementation results in the capsule intervention. Int2.1 
and 2.2 are pre and post supplementation results in the drinks intervention.  
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To identify changes to faecal microbiome profiles not apparent at family level, 
the genus level was examined in an unpaired analysis, with specific attention to 
the top 5 abundant genera across study participants (figure 23).  
There was an increased abundance of Bifidobacterium of the family 
Bifidobacteriaceae (Phylum, Actinobacteria) following both capsule and drink 
interventions. The increase was most notable following the drinks intervention 
period. The abundance of Bifidobacterium appeared to remain elevated following 
the second 12-week washout period compared to pre-intervention 
measurements for either intervention type.   
The remaining four most abundant genera identified within the stool samples of 
study participants were from the phylum Firmicutes. Following both capsule and 
drink intervention periods there was an increase in abundance of both 
Oscillospira of the family Ruminococcaceae and Lachnospira of the family 
Lachnospiraceae. The magnitude of increase in abundance of Lachnospira was 
greatest following the O3FA drinks intervention period, whereas the increase in 
abundance of the genus Oscillospira was greater following the O3FA capsule 
intervention. At the end of the final 12-week washout period (visit 5) the 
abundance of both aforementioned genera returned to pre-intervention levels.  
The abundance of Coprococcus of the family Lachnospiraceae and 
Faecalibacterium of the family Clostridiaceae were reduced after both capsule 
and drink interventions. The reduction to both genera was most pronounced 
following the O3FA capsule intervention period. However it was noted that the 
mean number of reads for both Coprococcus and Faecalibacterium were higher 
prior to the capsule intervention period when compared to the O3FA drinks 
period. 
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Alterations to faecal microbiome profiles in relation to the genus lactobacillus of 
the family Lactobacillaceae (Phylum, Firmicutes) following O3FA 
supplementation were also examined. Figure 24 illustrates an increase in 
lactobacillus following both O3FA capsule and drink interventions. The rise was 
most prominent following the O3FA drinks intervention period. The increase in 
Lactobacillus associated with either intervention type was not statistically 
significant (capsules, p=0.11; drinks, p=0.9). Following the final 12 week washout 
period (visit 5), the abundance of Lactobacillus fell but remained elevated 
compared to baseline levels.  
 
  
Figure 24. Analysis of the effect of O3FA supplementation on lactobacillus (capsule versus 
drinks) as measured by number of reads. Int 1.1 and 1.2 consumed are pre and post 
supplementation results in the capsule intervention. Int2.1 and 2.2 are pre and post 
supplementation results in the drinks intervention. 
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6.14 Paired analysis of changes to faecal microbiome profiles 
Paired analysis of the 20 most abundant genera was performed to assess 
changes to faecal microbiome profiles following each intervention type (figure 
25). The mean change in the observed number of OTUs was calculated by 
subtracting the number of OTUs measured post-intervention from the pre-
intervention value. Seventeen study participants were included within the 
analysis that completed both capsule and drinks O3FA supplementation periods. 
The paired analysis revealed similar findings to the unpaired analysis previously 
described. It confirmed Bifidobacterium, Oscillospira and Lachnospira increased 
following O3FA supplementation. Across all three of the aforementioned genera 
the increase in the mean number of OTU reads was highest following the O3FA 
drink intervention period. Both Bifidobacterium and Oscillospira also exhibited 
notable positive changes in the observed number of OTUs post O3FA capsule 
supplementation, whereas the increase in abundance of Lachnospira following 
capsule O3FA supplementation was negligible.  
There was a reduction in the number of OTUs observed between pre and post-
intervention periods in both capsule and drink interventions for Coprococcus and 
Faecalibacterium. However only the negative change identified in Coprococcus 
during the capsule supplementation period reached statistical significance 
(p=0.01, one sample t-test). When adjusting for multiple testing the 
aformentioned change to Coprococcus was not statistically significant ((False 
discovery rate, Benjamini, Krieger and Yekutieli method)  
A number of genera, within the microbiome including Akkermansia, Roseburia 
and Rumminococcus illustrated opposing changes dependent on O3FA 
intervention type, although this only reached statistical significance when 
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examining Roseburia (p=0.03, one sample t-test) where there was an increase 
post O3FA drink intervention.  However with adjustment for multiple testing this 
was not significant (False discovery rate, Benjamini, Krieger and Yekutieli 
method). 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.15 Bacteria of interest  
Faecal microbiome profiles from this cohort of healthy volunteers were examined 
for specific bacteria associated with CRC carcinogenesis. 
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Figure 25. Changes in the abundance of specific genera following 8 weeks O3FA 
supplementation as measured in the difference in number of reads of OTUs. Red bars are 
drinks. Black bars are capsules.  
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Fusobacterium of the family Fusobacteriaceae is associated with CRC 
carcinogenesis (Ahn et al., 2013; Wu et al., 2013; Liang et al., 2017; Yu et al., 
2017). Fusobacterium nucleatum has previously been identified in studies as a 
species which is overrepresented in CRC patients compared to controls. 
Analysis of the sequenced data from faecal microbiome analysis did not identify 
any OTUs representative of the genus Fusobacterium within this cohort of 
healthy volunteers.  
Bacteroides fragilis of the genus Bacteroides (family, Bacteroidaceae) is 
associated with CRC carcinogenesis (Qin et al., 2010; Sobhani et al., 2011; Wu 
et al., 2009; Wu et al., 2013; Karrasch et al., 2007). At genus level Bacteroides 
was present in the stool samples of healthy volunteers. At a species level, 
Bacteroides fragilis and specifically an enterogenic toxin producing strain which 
has been implicated in CRC carcinogenesis was not identified (Toprak et al., 
2006). 
Escherichia coli of the genus Escherichia (family, Enterobacteriaceae) is cited in 
studies as being overrepresented in the faecal samples of CRC patients 
(Swidsinski et al., 1998; Martin et al., 2004; Grivennikov et al., 2012; Bonnett et 
al., 2014). The present study did not identify the genus Escherichia in the faecal 
samples analysed from healthy volunteers.  At higher taxonomic levels the family 
Enterobacteriaceae was identified but there was no significant difference across 
intervention and washout periods for either intervention type.  
6.16 Discussion 
The present study highlights subtle changes to faecal microbiome profiles 
following O3FA supplementation in both drink and capsule forms. The 
significance of these changes is unclear given the significant inter-individual 
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variation demonstrated in the faecal microbiome profiles of healthy volunteers. 
The variation across individual participant faecal microbiome profiles both within 
and between individuals is likely to mask any changes induced by O3FA 
supplementation over a relatively short intervention period. Long-term, rather 
than short-term dietary alterations are more likely to induce changes to individual 
faecal microbiome profiles (Flint et al., 2017; Wu et al., 2011). When examining 
the effects of O3FA supplementation across the entire study population, O3FA 
supplementation had little or no effect on microbiome diversity measures 
irrespective of intervention order. This would appear to correspond with rodent 
studies that also show O3FA supplementation has no measurable effect on 
microbiome diversity (Caesar et al., 2015; Robertson et al., 2017). 
Measures of β-diversity varied according to the method of analysis performed. 
Pooled analysis of participant samples taking into account intervention type 
revealed changes to the microbiome following O3FA supplementation that 
returned to baseline profiles after the 12-week washout period. However, the 
Unifrac measure of β-diversity which takes into account the phylogenetic 
distances between OTUs did not show any change to microbiome profiles during 
the course of the study (Lozupone et al., 2007).  The likely explanation for this 
difference is that individual OTUs across the five separate study visits were 
phylogenetically closely related and therefore any differences illustrated in the 
Bray-Curtis PCoA analysis were no longer apparent.  
The lack of significant change to faecal microbiome profiles was further 
confirmed by the analysis of α-diversity, a measure of overall bacterial diversity 
within a specified environment (Morgan & Huttenhower, 2012). There was no 
change to microbiome profiles following O3FA supplementation, irrespective of 
127 
 
the order in which participants received the capsule and drink supplementation. 
Although the present intervention study does not suggest any changes to 
diversity associated with O3FA supplementation, a recent study by Menni et al. 
of over 800 individuals enrolled in the TwinsUK registry highlighted a correlation 
between DHA serum levels and microbial α-diversity as measured by the 
Shannon index (Menni et al., 2017). However, this apparent linkage is likely to 
reflect longer term exposure to O3FAs compared to the present study.   
The aforementioned measures of diversity give an insight into changes to faecal 
microbiome profiles but overlook subtle alterations at various taxonomic levels 
which may be influenced by O3FA supplementation. When microbiome profiles 
were analysed on a genus level, more nuanced changes to microbiome profiles 
of participants within the study were identified. There were increases to varying 
degrees at genus level for Bifidobacterium, Lachnospira, Roseburia and 
Lactobacillus. Interestingly, the magnitude of change to the abundance of the 
aforementioned bacteria differed between capsule and drinks interventions. An 
increased abundance of Roseburia and Lachnospira was only observed during 
the drink intervention. This again suggests that differences between the contents 
of the drinks and capsules may be responsible for alterations to faecal 
microbiome profiles, including the presence of additional proteins, carbohydrates 
and fibre (see appendix 1).  
The genera Bifidobacterium, Lachnospira, Roseburia and Lactobacillus are of 
particular interest in the context of CRC carcinogenesis as they are butyrate-
producing bacteria that generate SCFAs from the fermentation of fibre. These 
SCFAs are proposed to have a number of beneficial effects including modulating 
the pH of the colon, regulating apoptosis of CRC cells, modulating inflammatory 
128 
 
pathways within the colon, reducing oxidative stress and improving gut barrier 
function by promoting mucin formation (Hamer et al., 2008; Havenaar, 2011; 
Macfarlane & Macfarlane, 2012; Louis & Flint, 2009; Wu et al., 2018; Zeng et al., 
2019).  Butyrate also plays a role in the epigenetic regulation of gene expression 
via inhibition of histone deacetylase function (Donohoe et al., 2012; McIntyre et 
al., 1993; Davie, 2003; Chang et al., 2014; Han et al., 2018). Large scale case-
control studies have identified differences in the abundance of butyrate-
producing bacteria across CRC patients and healthy individuals (Chen et al., 
2013). Although not universal, there was a degree of reversibility following the 
washout period to changes exhibited in the abundance of butyrate-producing 
bacteria. This may suggest the presence of high doses of EPA and DHA were 
responsible for any increase. There is limited evidence from human studies 
examining the effect of O3FAs on colonic microbiome profiles. Menni et al. report 
that serum and dietary levels of DHA correlate with an increased presence of 
bacteria from the Lachnospiraceae family which include Lachnospira and 
Roseburia (Menni et al., 2017). Further evidence that O3FA-rich diets result in 
an increased presence of butyrate-producing bacteria is provided by an O3FA 
supplementation study implementing high dietary fish intake (Noriega et al., 
2016). They report reversible increases to Roseburia and Coprococcus both of 
the Lachnospiraceae family. However the study by Noriega et al. was limited by 
examining the faecal microbiome profile of a single male individual. An increased 
abundance of bacteria from the Lachnospiraceae family is also reported in a 
study of 30 individuals at risk of metabolic syndrome following supplementation 
with DHA-enriched canola oil over a 30 day period (Pu et al., 2016). However, it 
is necessary to consider that individuals prone to developing metabolic 
syndrome may have multiple underlying metabolic factors that influence changes 
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to microbiome profiles. Given that butyrate is generated by the fermentation of 
fibre it would be of interest to assess whether the intake of fibre in conjunction 
with O3FA supplementation has any synergistic effect on CRC risk, as already 
reported in rats (Crim et al., 2008).  
Although there is limited evidence pertaining to human studies exploring the 
influence of O3FAs on microbiome profiles, there are animal studies that report 
similar changes to the abundance of various genera exhibited in the present 
study. In the context of CRC, Piazzi et al. reported that EPA supplementation not 
only impaired tumour development in the AOM-DSS mouse model of colitis-
associated CRC, but also showed an increase in the abundance of Lactobacillus 
(Piazzi et al., 2014).  Lactic acid-producing bacteria including Lactobacillus are 
proposed to modulate a number of CRC pathways including enhancement of 
mitogen-activated protein kinase (MAPK) enhanced apoptosis and expression of 
tumour suppressor genes (Iyer et al., 2008; Wu et al., 2018).  There is evidence 
to suggest these bacteria generate an anti-tumour immune response via 
generation of cytokines including TNFα and also by inhibition of ROS induced 
DNA damage (Zhong et al., 2014). 
The balance between the two predominant phyla Firmicutes and Bacteroidetes 
is proposed to be significant in colorectal carcinogenesis (Sun & Kato, 2016; 
Raskov et al., 2017). A reduction to the F:B ratio is associated with CRC in animal 
studies (Myles et al., 2014). However, O3FA induced changes to the F:B ratio 
were not apparent in the present study. There was evidence of an increased 
abundance of individual bacteria from the phylum Firmicutes, including various 
SCFA producing bacteria, but there was no corresponding alteration to the F:B 
ratio. The association of the F:B ratio with mechanisms of CRC carcinogenesis 
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is unclear. It may be that the F:B ratio per se is not of significance in CRC 
carcinogenesis, but instead it is individual changes to bacteria from the 
Firmicutes phylum. A recent study comparing healthy individuals and CRC 
patients reported that contrary to current thinking, there was in fact a higher F:B 
ratio in CRC patients compared to healthy individuals (Bamolaa et al., 2017). 
This study also reported that the F:B ratio was significantly higher in vegetarians 
compared to non-vegetarians, suggesting that there are multiple other dietary 
factors that may outweigh changes induced by O3FA supplementation (Bamolaa 
et al., 2017). 
There are a number of bacterial species associated with CRC carcinogenesis 
including Escherichia coli, Bacteroides fragilis and most notably Fusobacterium 
nucleatum, which were not identified at any point in the current study (Kostic et 
al., 2012; Ahn et al., 2013; Wu et al., 2013; Liang et al., 2017). Many studies 
identifying an association between Fusobacterium nucleatum and colorectal 
carcinogenesis were noted to identify pathogenic strains within colonic tumour 
tissue samples rather than faecal samples of individuals diagnosed with CRC 
when compared to controls (Castellarin et al., 2012; Mima et al., 2015) 
Escherichia coli was not identified in the present study. A potential explanation 
is that some strains of the bacterium are pathogenic and therefore unlikely to be 
present in this cohort of ‘healthy’ study participants. Equally it may be a technical 
limitation of the microbiome analysis methodology that was unable to resolve 
these species in stool samples.  
It is unclear whether changes to faecal microbiome profiles of healthy volunteers 
reflect changes to microbiome profiles within colonic mucosa or tumour tissue, 
and whether this governs any protective effect in relation to CRC risk. Recent 
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evidence indicates that faecal microbiome profiles differ to those found at 
mucosal level both in healthy individuals and CRC patients (Flemer et al., 2017). 
Furthermore, the aforementioned study reported that mucosal microbiome 
profiles varied according to colonic tumour location, suggesting that the effects 
of alterations to the microbiome are complex and may vary according to the 
specific environment at different points within the colon.    
An inherent limitation of all ‘healthy’ volunteer studies is the inability to describe 
a single profile that constitutes a healthy microbome. Approximately 60% of the 
microbiome is influenced by host factors and only 40% of humans share any 
form of consistent profile (Raskov et al., 2017). The individuals examined in this 
study were by definition ‘healthy’ and therefore it was not possible to determine 
whether any alterations to the microbiota induced by O3FAs are able to 
ameliorate other factors including obesity and consumption of red meat, both of 
which may increase the risk of CRC development. It is also unclear whether the 
potential beneficial effects of O3FAs on faecal microbiome profiles are of a 
magnitude needed to overcome dietary factors that may alter the faecal 
microbiome profile to one that increases CRC risk.   
There are also multiple uncontrolled factors in this study that may have 
influenced changes to faecal microbiome profiles. The O3FA drinks contained 
multiple ingredients which over an eight week supplementation period may have 
influenced changes to microbiome profiles or conversely masked any subtle 
changes induced by O3FA supplementation. The present study reported 
variations in bacterial changes following O3FA supplementation dependent on 
intervention type, for example opposing changes exhibited by the genera 
Akkermansia, Roseburia and Rumminococcus. This suggests that despite the 
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dose equivalence of O3FAs in both capsule and drinks interventions, there were 
additional unmeasured properties unique to each intervention that outweighed 
EPA and DHA induced changes to faecal microbiome profiles. Over the course 
of the study there were multiple unmeasured dietary factors that may have 
affected faecal microbiome profiles.  
It was not possible to determine whether the absorption of O3FAs from the small 
intestine and therefore the amount of O3FAs transiting into the colon had any 
influence on changes to faecal microbiome profiles. It is unclear at present 
whether alterations to faecal microbiome profiles were influenced by direct 
luminal exposure to O3FAs or via systemic incorporation into colonic mucosal 
tissue. There is limited evidence from a study measuring O3FA levels in patients 
with an ileostomy fashioned from terminal ileum, that approximately 99% of orally 
supplemented O3FAs are absorbed within the small bowel (Sanguansri et al., 
2013). In the context of the present study, it is feasible that the subtle changes 
to faecal microbiome profiles potentially induced by O3FA supplementation, 
were in fact secondary to colonic mucosal incorporation following systemic EPA 
and DHA exposure. Alternatively it may be that only subtle changes to faecal 
microbiome profiles were evident because of limited direct exposure to O3FAs 
in the colonic lumen.  
There are a number of technical factors that require consideration when drawing 
conclusions form the present study. There remains significant methodological 
variation across studies performing microbiome analysis, particularly with 
respect to the 16S rRNA gene hyper-variable region selected for primer design. 
There is data to suggest primer selection influences both the number of OTUs 
generated and various measures of microbial diversity (Rintala et al., 2017). Due 
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to the nature of the present study there was inevitable variation in the duration of 
time between collection, processing and storage of stool samples which may 
have affected the extraction process and overall microbiome profile. Published 
recommendations from the International Human Microbiome Standards describe 
a similar protocol for stool sample collection to that used in the present study for 
a period of up to seven days prior to processing (Dore et al., 2015). However a 
key variant that may affect the DNA extraction process was the inability to 
perform immediate freezing of volunteer samples post-collection. In the present 
study stool samples took up to 48 hours to arrive in the laboratory prior to 
processing for freezing. It is unclear whether the duration of time between initial 
storage of stool samples at -80ºC and subsequent DNA extraction had any 
detrimental effect on the results of faecal microbiome analysis. A previous study 
of stool samples from a limited number of individuals detailed variations in 
microbial diversity dependent on the length of time between sample collection, 
freezing and subsequent DNA extraction (Cardona et al., 2012). The main 
determinant of variation across microbiome analysis of stool samples in the 
aforementioned study was the process of repeated freezing and thawing of 
samples which resulted in fragmentation of DNA and thus affected analysis at 
both species and genus levels (Cardona et al., 2012). 
6.17 Conclusion 
In conclusion, O3FA supplementation appeared to alter the abundance of 
butyrate-producing bacteria within faecal microbiome profiles, which in the 
context of CRC may confer a protective effect.  The results of the healthy 
volunteer study should be interpreted with caution given some of the technical 
limitations and the inability to control for all the potential confounding factors. It 
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is unclear whether changes to faecal microbiome profiles induced by O3FA 
supplementation have a direct influence on long-term CRC risk and whether 
there is any interaction with other known risk factors.  At present there is a lack 
of clinical evidence in humans to ascertain a microbiome profile associated with 
CRC and any causal relationship with the various mechanisms of colorectal 
carcinogenesis. In order to determine whether O3FA supplementation has a 
potential application as a dietary chemoprevention, further research is required 
to elucidate both the effects of O3FAs on colonic microbiome profiles and the 
mechanisms via which both the microbiota and O3FAs influence CRC 
carcinogenesis.  
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Chapter 7: Analysis of RBC membrane PUFA levels from the EMT trial 
7.1 Introduction 
The molecular gastroenterology group at LIMM previously published the results 
of the EMT study (Cockbain et al., 2014). EMT was a Phase II randomised, 
double-blind, placebo-controlled trial examining EPA treatment in patients 
awaiting surgical resection of CRCLM. As part of this study venous blood 
samples were collected to measure baseline, post treatment and washout RBC 
membrane PUFA levels including EPA, DHA and AA. This was not performed at 
the initial analysis of the study due to financial constraints. Therefore I measured 
RBC membrane PUFA levels from the EMT study in order to determine PUFA 
incorporation profiles in patients with CRCLM. Measurement of individual RBC 
membrane PUFA profiles allowed assessment of compliance, variability and 
correlation with tumour tissue PUFA content. There was also the opportunity to 
explore any association between RBC EPA membrane levels and clinical 
outcomes in patients following resection of CRCLM.    
I tested the hypothesis that patients undergoing surgical resection of CRCLM 
exhibited elevated RBC membrane EPA levels following EPA treatment 
compared to patients randomised to placebo.  
7.2 Analyses 
Primary analysis 
- Change in percentage RBC membrane EPA content compared with 
baseline following EPA treatment. 
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Secondary analyses 
- Change in RBC EPA membrane levels after washout compared with 
post-treatment 
- Change in RBC membrane levels of DHA, DPA and AA after EPA 
treatment compared with baseline. 
- Change in RBC membrane levels of DHA, DPA and AA after washout 
- Effect of sex, duration of treatment and compliance on EPA RBC 
membrane levels 
- Correlation between EPA RBC membrane levels and CRCLM tumour 
tissue EPA levels 
- Correlation between EPA RBC membrane levels and tumour 
vascularity as measured by CD31 immunohistochemistry  
- Survival analysis based on EPA RBC membrane levels 
7.3 Overview of study 
The EMT study design is detailed by Cockbain et al. (Cockbain et al. 2014). In 
summary, 88 patients awaiting surgical resection of CRCLM were enrolled into 
the EMT study. Patients were randomised to either 2g EPA (FFA) orally per day 
(n=43) or placebo (n=45). The duration of pre-operative EPA supplementation 
was variable across all participants randomised into the study with a median 
duration of 26 days (15 to 73 days) and 30 days (12 to 65 days) in the intervention 
and placebo groups respectively. This is of particular relevance in the context of 
measuring RBC PUFA membrane levels. Venous blood samples were collected 
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at randomisation (pre-treatment n=87) and on the day prior to liver surgery (post-
treatment n=80). There was a ‘washout’ period (n=71) of approximately 6 weeks 
after cessation of intervention following surgery (EPA, median number of days 
47, range 16–110 days; placebo, median number of days 44, range 21–68 days). 
Baseline characterisitics of patients in placebo and intervention groups are 
detailed in table 4. 
The main finding of the EMT study was a statistically significantly higher 
percentage EPA content in CRCLM tissue in the EPA treatment group compared 
to patients receiving the placebo (1.82% versus 1.30%, p<0.001). Although not 
statistically significant, there was reduced tumour vascularity as measured by 
CD31 immunohistochemistry, in patients receiving EPA supplementation 
compared with placebo. Kaplan-Meier survival analysis also indicated a possible 
overall survival benefit in patients receiving EPA supplementation, although the 
study was not powered to answer this question formally.  
 
  
 Placebo 
(n=45) 
EPA (n=43) 
Age (years) 71 (35-87) 68 (44-82) 
Sex (male:female, % male) 35:10 (78%) 26:17 (61%) 
Previous fish oil supplement use (%) 9 (20%) 5 (12%) 
Primary CRC Dukes stage (%) A 2 (4%) 
B 13 (29%) 
C 10 (22%) 
D 20 (44%) 
A 2 (5%) 
B 11 (26%) 
C 17 (40%) 
D 13 (30%) 
Lymph node positive (%) 25 (56%) 26 (61%) 
Interval between primary CRC surgery 
and presentation with CRCLM (months)* 
19 (3-80)  
(n=30) 
24 (6-91) 
(n=32) 
Table 4. Baseline characteristics of patients enrolled into the EMT study.*15 patients in the 
placebo group and 11 patients in the EPA group underwent first resection of synchronous 
CRCLM   
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7.4 PUFA analysis 
Although this was a purely EPA intervention study, it was necessary to analyse 
the effect of EPA treatment on DPA, DHA and AA RBC membrane levels. As 
previously highlighted in Figure 2 DPA and DHA are downstream products of 
EPA metabolism. EPA, DHA and AA are proposed to affect both inflammatory 
pathways and mechanisms of colorectal carcinogenesis (See section 1.5).  
7.4.1 EPA (Figure 26a) 
Baseline mean EPA RBC membrane levels were similar in both EPA intervention 
and placebo groups (EPA, 1.06%; Placebo, 1.11%). Following EPA treatment 
there was an increase from baseline in measured mean RBC EPA membrane 
levels, which was not apparent in the placebo group (absolute change from 
baseline: EPA, 1.26% points, one sample t-test p <0.0001; placebo, -0.03% 
points, one sample t-test p=0.57). The increase in post-treatment RBC EPA 
membrane levels in the intervention group amounted to a 2.40 fold increase from 
baseline (95% CI, 2.07 to 2.73), whereas EPA RBC membrane levels were 
unchanged in patients randomised to placebo (fold change from baseline, 1.02; 
95% CI, 0.94 to 1.10) Following the washout period there was a decrease in RBC 
EPA membrane levels, although there appeared to be incomplete washout from 
RBCs, with a mean change of absolute EPA RBC membrane levels from 
baseline of 0.20% points (95% CI, 0.04% points to 0.35% points; one sample t-
test, p=0.02). As shown in figure 27 the magnitude of EPA RBC membrane 
incorporation post-treatment in the intervention group varied between individual 
patients. However 92% (33/36) of patients that provided the full complement of 
venous blood samples exhibited an EPA RBC membrane rise post-treatment 
followed by a reduction after washout.   
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7.4.2 DPA (figure 26b) 
Mean DPA RBC membrane levels were similar across both EPA intervention and 
placebo interventions at baseline (EPA, 2.43%; capsules, 2.33%). Post-
treatment DPA RBC membrane levels as measured by mean absolute change 
were higher in the EPA intervention group than in patients that received placebo 
(EPA, 0.60% points, one sample t-test p=0.002; placebo, 0.07% points, one 
sample t-test p=0.39). After the washout period mean DPA RBC membrane 
levels in patients receiving EPA treatment were 0.26% points higher than EPA 
RBC membrane levels measured at baseline (one sample t-test, p=0.03), which 
was not apparent in the patients receiving placebo (mean absolute change, 
0.00% points) 
7.4.3 DHA (figure 26c)  
Mean baseline DHA RBC membrane levels were 4.65% and 4.24% in EPA 
intervention and placebo groups respectively. Post-treatment there was a 0.31% 
points decrease from baseline in DHA RBC membrane levels which was not 
statistically significant (one sample t-test, p=0.20). The lower than baseline DHA 
membrane levels persisted following the washout period (mean absolute 
change; -0.40% points; 95% CI, -0.78% points to -0.02% points; one sample t-
test, p=0.04) and was not apparent in the placebo group. 
7.4.4 AA (figure 26d)  
The AA RBC membrane levels in EPA intervention and placebo groups were 
similar at baseline (12.56% and 11.41% respectively). Following EPA treatment 
there was a statistically significant decrease in absolute AA RBC membrane 
levels of -1.31% points (95% CI, -2.46% points to -0.16% points; one sample t-
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test, p = 0.03) which was not seen in the placebo group. This decrease appeared 
to persist following the washout period but was not statistically significant (mean 
absolute change, -0.90% points; one sample t-test, p=0.07). 
  
Figure 26. Baseline % RBC PUFA level and absolute difference in % RBC PUFA levels 
between baseline and post-treatment or after surgery (washout). The left y-axis is the baseline 
% RBC PUFA value and the right y-axis is the absolute difference between the post-treatment 
value or ‘washout’ post-operative value and baseline % level. Columns (baseline % values) 
and symbols (absolute difference in % value from baseline) denote the mean for EPA and 
placebo (Plac.) groups. Error bars denote the SE of the mean. * p < 0.05, ** p < 0.001; one 
sample t-test. 
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7.4.5 Individual PUFA analysis 
Figure 27 illustrates individual PUFA profiles of trial participants in both EPA 
intervention and placebo arms of the study. There was marked inter-individual 
variation across study participants particularly at baseline in both the intervention 
and placebo arms. Twenty three participants were assessed prior to entering the 
study as either having regular intake of O3FA rich fish or being regular users of 
O3FA containing nutritional supplements. These individuals demonstrated 
statistically significant higher EPA RBC membrane levels at baseline (1.39 ± 
0.15%) compared to naïve O3FA participants (0.97 ± 0.04%; n=64; p=0.003) 
irrespective of intervention group.  Individuals identified as being regular users 
of O3FA supplements were required to cease supplementation prior to entering 
the study.  
Closer examination of the profiles of individuals within the placebo group 
identified four participants with notably higher EPA RBC membrane levels 
(greater than two percent) at baseline. These individuals had been identified as 
prior users of O3FA supplements with three of these individuals demonstrating 
a decrease in RBC EPA membrane levels following commencement of the study 
and therefore presumed cessation of additional O3FA supplements (Figure 27: 
EPA placebo).  
As previously stated 92% (33/36) of patients randomised to the EPA treatment 
group that provided a full complement of venous blood samples exhibited an 
EPA RBC membrane rise post-treatment followed by a reduction after washout. 
A single individual demonstrated notably higher EPA, DPA, DHA and AA RBC 
membrane levels following EPA treatment.   
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Figure. 27. Individual % PUFA profiles in active and placebo groups. Each coloured line and 
symbol denotes an individual participant %RBC membrane level at baseline, post-treatment 
and washout.   
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7.4.6 EPA:AA (figure 28) 
As discussed in chapter 1, the ratio of O3FAs to AA is reported in studies 
exploring the relationship and mechanisms by which O3FAs are thought to 
derive anti-inflammatory benefits. In the context of an EPA treatment study the 
EPA:AA ratio was calculated. Baseline EPA:AA RBC membrane levels were 
0.09 and 0.10 in the EPA intervention and placebo groups respectively. In line 
with the changes exhibited in individual EPA and AA RBC membrane levels, 
there was a statistically significant increase of 0.12 to the EPA:AA ratio in the 
EPA intervention group post-treatment (95% CI, 0.10 to 0.14; one sample t-test, 
p<0.0001) which was not apparent in the placebo group. Following the washout 
period there was a fall in the EPA:AA ratio in the EPA intervention group, 
although it remained elevated compared to baseline (95% CI, 0.01 to 0.03; one 
sample t-test, p=0.0006). 
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Figure. 28. Baseline RBC membrane EPA:AA ratio and absolute difference in RBC 
membrane EPA:AA ratio between baseline and post-treatment or after surgery (washout). 
The left y-axis is the baseline EPA:AA ratio and the right y-axis is the absolute difference 
between the post-treatment value or ‘washout’ post-operative value and baseline EPA:AA 
ratio. Columns and symbols denote the mean for EPA and placebo (Plac.) groups. Error bars 
denote the SE of the mean. 
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7.5 Univariate analyses 
A number of variables were examined to explore any relationship with RBC EPA 
membrane levels. Analysis was performed using the Pearson correlation 
coefficient for continuous data. The unpaired t-test was employed when 
analysing categorical variables and the Mann-Whitney test for non-normally 
distributed data.  
7.5.1 Duration (figure 29) 
There was no relationship between the duration of EPA supplementation and 
post-treatment EPA RBC membrane levels (n=38, range; 12 to 65 days, r =0.25, 
95% CI; -0.07 to 0.53, p=0.12). Analysis was also undertaken based on the 
absolute change in EPA RBC membrane levels between baseline and post-
treatment. Again, there was no statistically significant correlation (r=0.29, 95% 
CI; -0.03 to 0.56, p=0.07). 
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Figure 29. Relationship between the % RBC EPA level at the end of the trial intervention and 
treatment duration. Open symbols denote individual data from the placebo group and filled 
symbols denote EPA group data. Line of best fit plotted for EPA treatment group. 
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 7.5.2 Compliance (figure 30) 
Compliance was calculated based on a capsule count undertaken following the 
intervention period. It was calculated as the following, (expected–
returned)/expected and expressed as a percentage. A number of patients 
reported compliance of over 100%, whereby a participant had returned fewer 
capsules than expected. Post-supplementation capsule count data was available 
for 34/43 patients (79%) in the EPA intervention group. Median compliance in 
the active intervention group was 95%, ranging from 41% to 117%. There was 
no correlation between percentage compliance in patients receiving EPA 
treatment and post-treatment RBC membrane EPA levels (Spearman’s 
correlation; r=0.15, 95% CI; -0.21 to 0.47, p=0.40). Examination of absolute 
change between baseline and post-treatment RBC EPA membrane levels also 
revealed no correlation with compliance (r=0.22, 95% CI; -0.13 to 0.52, p=0.21).  
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Figure 30. Relationship between the % RBC EPA level at the end of the trial intervention and 
%compliance in the active EPA intervention group.  
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7.5.3 Sex  
The effect of sex on EPA RBC membrane levels in the EPA intervention group 
was examined. Median RBC membrane EPA levels were similar in both sexes 
at baseline, with measured levels of 0.99% and 0.95% in female and male 
participants respectively. Post-treatment RBC EPA membrane levels were 
measured in 23 of 25 males and 16 of 17 females randomised to the EPA 
intervention group.  Median post-treatment EPA membrane levels were higher 
in female patients compared to their male counterparts, at 2.69% (range 1.31% 
to 4.84%) and 1.83% (range 1.22% to 3.32%) respectively. Analysis revealed 
the difference between male and female EPA RBC membrane levels post-
treatment was statistically significant (p=0.02).  
7.6 Multivariate analysis 
In order to verify that sex was a statistically significant predictor of EPA RBC 
membrane incorporation, linear regression analysis was undertaken taking into 
account gender, compliance and duration of treatment. This confirmed that 
gender was the only statistically significant predictor of RBC EPA membrane 
levels in the EPA intervention group (beta −0.35, p=0.039). 
7.7 Relationship between EPA measurements in RBC membranes and 
CRCLM tumour tissue EPA and AA levels 
The relationship between EPA RBC membrane levels and corresponding 
CRLCM tissue levels from resected liver metastases was explored (figure 31). 
RBC EPA membrane levels are a surrogate marker of EPA levels in a variety of 
tissues, but there is a lack of evidence pertaining to EPA incorporation into 
tumour tissue (Metcalf et al., 2007; Harris et al., 2004). In the context of CRC 
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treatment it is important to determine whether EPA RBC membrane levels are 
related to tumour tissue levels as the proposed anti-CRC mechanisms of O3FAs 
are likely to take place in tumour tissue (see section 1.5). The RBC samples were 
collected on the day prior to surgery. There were 37 patients in each of the EPA 
intervention and placebo groups with measurements of EPA levels for both RBC 
membrane and corresponding CRCLM tumour tissue. Irrespective of intervention 
group there was a correlation between post-treatment RBC membrane EPA 
levels and CRCLM tumour levels. The correlation appeared to be stronger in the 
placebo group of patients (r=0.72, p<0.0001) compared to the EPA intervention 
group (r=0.36, p=0.03). Analysis of the correlation between RBC membrane EPA 
content and tumour tissue EPA content was also undertaken irrespective of 
intervention group where there was a statistically significant correlation (figure 
32; r=0.65, p<0.0001). There was no correlation between CRLCM tumour levels 
of either DPA or DHA and EPA RBC membrane levels in the EPA intervention 
group. There was a weak inverse relationship between post-treatment RBC 
membrane EPA levels and CRCLM tumour tissue AA levels in both placebo (r=-
0.18, p=0.29) and EPA (r=-0.27, p=0.10) intervention groups, although neither 
reached statistical significance. Merging of intervention intervention groups 
revealed a statistically significant inverse correlation between post-treatment 
RBC EPA membrane content and CRLCM tumour tissue AA content (Figure 33; 
r=-0.25, p=0.03)  
  
148 
 
0 2 4 6
0
1
2
3
4
post-treatment % RBC EPA content
tu
m
o
u
r 
%
 E
P
A
 c
o
n
te
n
t EPA
Placebo
 
 
 
 
 
0 2 4 6
0
1
2
3
4
post treatment % RBC EPA content
tu
m
o
u
r 
%
 E
P
A
 c
o
n
te
n
t
 
  
Figure 31. Relationship between the % RBC EPA level and % EPA CRCLM tumour tissue 
content at the end of the trial intervention. Open symbols denote individual data from the 
placebo group and filled symbols denote EPA group data. Line of best fit plotted for EPA 
treatment group. 
Figure 32. Relationship between the % RBC EPA level and % EPA CRCLM tumour tissue 
content irrespective of intervention.  
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7.8 Relationship between EPA RBC membrane levels and CRCLM tumour 
tissue vascularity 
A finding of the EMT study was a reduction in tumour vascularity as measured 
by CD31-positive microvessel density in patients treated with EPA. Therefore 
analysis of the relationship between RBC EPA membrane levels and CRCLM 
tumour CD31-positive microvessel density was performed (figure 34). There 
were 33 and 36 patients in the EPA intervention group and placebo group 
respectively with both RBC membrane EPA levels and CD31-positive 
microvessel density measurements. There was no correlation in the EPA 
intervention group. However in the placebo group it appeared that a higher RBC 
EPA membrane  level was associated with a reduction in tumour vascularity as 
measured by CD31-positive microvessel density measurements (r=-0.37, 
p=0.03). The association was again demonstrated when analysis of tumour 
Figure 33. Relationship between the % RBC EPA level and % AA CRCLM tumour tissue 
content irrespective of intervention.  
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vascularity was performed irrespective of intervention group (r=-0.14), although 
this was not statistically significant (p=0.26).  
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7.9 RBC EPA membrane levels and overall survival 
On the basis that there was a correlation between RBC membrane and CRCLM 
tissue EPA levels in both EPA intervention and placebo groups, Kaplan-Meier 
survival analysis was performed to assess whether there was any association 
with overall survival outcomes (figure 35). An intervention independent survival 
analysis was performed. RBC EPA membrane levels were dichotomised based 
on the lowest post-treatment RBC EPA membrane level measured in the EPA 
intervention group following treatment (1.22%). Fourty nine patients exhibited 
measured RBC EPA membrane levels of 1.22% or greater post-treatment, 
versus 29 patients with measured RBC membrane EPA levels of less than 
1.22%. Ten patients randomised to the placebo treatment group exhibited post-
treatment RBC EPA membrane levels of 1.22% or greater and therefore for the 
Figure 34. Relationship between log % vascularity in CRCLM tumour tissue and % RBC EPA 
membrane levels. Open symbols denote individual data from the placebo group and filled 
symbols denote EPA group data. Line of best fit plotted for EPA treatment group. 
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purpose of survival analysis were pooled with patients that had been randomised 
to the EPA treatment group. The survival analysis illustrated that a RBC EPA 
membrane level of greater than or equal to 1.22% was associated with overall 
survival benefit. The associated hazard ratio was 0.4 (Mantel-Haenszel) with a 
95% confidence interval of 0.16 to 0.96, which was statistically significant (log 
rank, p =0.04). 
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7.10 Discussion 
The present study clearly demonstrates incorporation of EPA into the RBC 
membrane of CRC patients with CRCLM following treatment with EPA prior to 
surgical resection of CRCLM. The RBC PUFA membrane profiles in CRC 
patients are similar to other studies in healthy volunteers and women with breast 
hyperplasia (Cao et al., 2006; Ohnishi & Saito, 2013; Fabian et al., 2015). In the 
Figure 35. Overall survival analysis of CRCLM patients stratified on the basis of post-
treatment % RBC EPA level, irrespective of treatment allocation with a cut off % RBC EPA 
membrane level of 1.22% corresponding with the lowest post-treatment % EPA RBC 
membrane value in the intervention group. Solid line denotes events in individuals with post-
treatment RBC % EPA level ≥1.22%. Dashed line denotes events in individuals with post-
treatment RBC % EPA level < 1.22%. Log rank P=0.04. 
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context of CRC, Coviello et al. reported baseline EPA RBC levels of 0.46% 
compared to approximately 1% in the present study (Coviello et al., 2014). 
Mikirova et al. have previously reported that RBC EPA and DHA membrane 
levels are lower in CRC patients, which may in part be due to differential activity 
of the delta-6 desaturase enzyme (Mikirova et al., 2004). However comparison 
of baseline O3FA RBC membrane levels in the present study to healthy 
volunteers does not support this finding (Cao et al., 2006).  
The consensus across studies examining the bioavailability of O3FAs is that 
maximal RBC membrane levels are reached within four to eight weeks of starting 
supplementation (Katan et al., 1997; Cao et al., 2006; Stonehouse et al., 2011).  
It is unclear whether maximal RBC levels were achieved within the median 30 
day intervention period of this study. There are few studies for direct comparison 
of RBC PUFA levels following EPA treatment in CRC patients. A double-blind 
RCT in lung cancer patients treated with a preparation containing a mix of EPA 
and DHA, but providing an equivalent daily dose of EPA to the present study 
showed similar levels of EPA RBC membrane incorporation at around 2% 
following a 22 day treatment period (Finocchiari et al., 2012). Scaioli et al. 
examined an identical EPA preparation to that used in the present study in both 
healthy volunteers and patients with inflammatory bowel disease (Scaioli et al., 
2015). They report a greater increase in O3FA RBC membrane levels following 
an eight week treatment period with an absolute post-treatment increase from 
baseline of approximately of 4.3% compared to 1.3% in the present study. In part 
this may be explained by the longer treatment period of eight weeks compared 
to a median treatment period of 26 days in this study. In the aforementioned 
study, EPA RBC membrane levels continued to rise at measurement intervals of 
four and eight weeks, suggesting that the 30 day treatment period may have 
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been insufficient to reach maximal RBC membrane EPA incorporation. This 
possible explanation is also supported by a study in lung cancer patients in which 
both EPA and DHA RBC membrane levels continued to rise between RBC 
measurements intervals of 22 and 66 days (Finocchiari et al., 2012). Both 
inflammatory bowel disease patients and healthy volunteers from the study by 
Scaioli et al. exhibited significantly lower baseline RBC EPA, DPA and DHA 
levels compared to the present study, which may also explain the apparent 
differential in EPA RBC membrane incorporation.  
There was no correlation between either the compliance or duration of treatment 
and post-treatment EPA RBC membrane levels. This may in part be due to a 
relatively small sample size in the EPA treatment group which was not powered 
to detect changes on the basis of RBC PUFA analyses. There is also unreliability 
associated with a capsule count reliant on study participants returning unused 
trial medication. This may mask any underlying relationship between compliance 
and RBC membrane PUFA levels (Lam & Fresco, 2015).   
The finding that there was an increase in RBC membrane DPA levels following 
EPA treatment is expected secondary to enzymatic elongation of EPA by the 
ELOVL2 elongase enzyme (Gregory et al., 2011). Increases in DPA have been 
reported elsewhere in studies of healthy individuals following O3FA 
supplementation (Scaioli et al., 2015; Gregory et al., 2011). The present study 
suggests that elongase conversion of EPA to DPA also occurs in patients with 
CRCLM. However it is unclear whether there is differential elongase activity in 
tumour tissue or whether the magnitude of elongase activity in cancer patients 
differs to that of healthy individuals. There may also be specific PUFA 
metabolism profiles in patients with metastatic CRC, as highlighted in a recent 
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study where metastatic colorectal tissue exhibited a different PUFA profile to 
primary tumour tissue in patients with localised disease, although RBC PUFA 
membrane profiles were similar (Notarnicola et al., 2018).   
Despite an increase in both EPA and DPA RBC membrane levels, there was no 
evidence of increase in DHA RBC membrane levels. Conversely there was a 
statistically significant decrease in DHA RBC membrane levels that persisted 
following cessation of EPA treatment. One might expect a stepwise conversion 
of EPA to DPA and DHA by a series of enzymatic reactions involving elongase 
and desaturase enzymes (figure 2). There are a number of possible explanations 
for this finding including displacement of DHA from RBC membranes by the 
presence of excess EPA. It is also possible that various stages of the enzymatic 
conversion of EPA to DHA were saturated by the presence of high levels of EPA 
thus limiting conversion to DHA. Gregory et al. reported saturation of the 
elongase (Elovl2) step in the conversion of DPA to 24:5n-3 DPA as a potential 
rate-limiting step in the presence of excess EPA, as demonstrated in rodent 
models (Gregory et al., 2011).      
The relationship between O3FAs and O6FAs is of significant interest with respect 
to the role of PUFAs in inflammatory pathways and CRC carcinogenesis. O3FAs 
including EPA compete with AA for COX binding, thereby effecting the dynamics 
of eicosanoid production (Smith, 2005). The present study demonstrates a 
statistically significant decrease in AA RBC membrane levels after EPA 
treatment which persisted following the washout period. Baseline RBC 
membrane levels of AA prior to EPA treatment were similar to those reported 
elsewhere (Scaioli et al., 2015). The ratio of O3FA to O6FA is a measure of the 
dynamic relationship between O3FAs and O6FAs. As one might expect, when 
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patients receiving EPA treatment demonstrated an increase in RBC EPA 
membrane levels and reciprocal decrease in AA levels there was also a 
statistically significant increase in the EPA:AA ratio that persisted following the 
washout period. This has been widely reported in the scientific literature and 
suggests that there is displacement of AA from the RBC membrane by EPA (Cao 
et al., 2006; Gibney et al., 1993).Whether this is of any clinical benefit in CRCLM 
patients is unclear, although animal studies have suggested that there may be 
an anti-cancer effect primarily via interaction with COX enzymes and reduction 
in generation of the pro-inflammatory PGE2 (Sarotra et al., 2012). The presence 
of excess EPA may also induce a reduction in AA by acting as a competitive 
substrate for desaturase and elongase enzymes which are required for 
conversion of LA to AA (Rose & Connolly, 1999).  
The individual PUFA profiles generated by this study reveal widespread inter-
individual variation in EPA RBC membrane levels following EPA treatment. This 
has also been reported by Kohler et al. when examining the O3FA index following 
EPA and DHA supplementation (Kohler et al., 2010). The inter-individual 
variation exhibited was not dependent on compliance, although there are clear 
limitations with the validity of a ‘capsule count’ performed at the end of a study 
period. The lack of correlation between duration of EPA supplementation and 
EPA RBC membrane levels also fails to explain why there was significant 
variation across participants in the intervention group.  
There is variation in the metabolism and bioconversion of PUFAs across humans 
with the conversion of ALA to EPA inefficient due to limited delta-6 desaturase 
activity (Horrobin, 1993). There is inter-individual differential expression of the 
fatty acid desaturase 1 (FADS1) and fatty acid desaturase 2 (FADS2) genes that 
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encode for the delta-5 and delta-6 desaturase enzymes required for enzymatic 
conversion of ALA to EPA, with a significant proportion of individuals unable to 
perform enzymatic conversion (Rzehak et al., 2009; Xie & Innis, 2008; Plourde 
& Cunnane, 2007). A potential explanation for the inter-individual variation 
exhibited in the present study is the variation in conversion of dietary ALA to EPA 
and DHA due to differential enzyme activity (Rzehak et al., 2009; Xie & Innis, 
2008). However it is unlikely that the relatively small contribution of EPA to RBC 
membrane EPA levels from dietary ALA would make a significant difference to 
overall membrane levels generated by EPA incorporation from capsule 
treatment, unless an individual was a highly efficient converter of ALA.  It was 
not possible to determine whether dietary intake of ALA during the intervention 
period influenced O3FA RBC membrane levels as it was not measured. A 
proportion of PUFAs undergo mitochondrial and peroxisomal degradation via β-
oxidation to generate energy (Kanamori et al., 2018, Camões et al., 2009). It is 
feasible that variation exists across individuals as to both the rate and quantity 
to which β-oxidation take place, which may subsequently impact on RBC 
membrane EPA levels.       
The individual PUFA profiles provide an insight into possible ‘contamination’ by 
the use of additional PUFA supplements outside the study protocol. In the 
placebo group, individuals exhibiting the highest baseline EPA levels were 
identified as either prior O3FA supplement users or having had a diet containing 
high amounts of oily fish. These individuals showed decreased RBC membrane 
levels at subsequent visits in the study, suggesting that they had complied with 
the study protocol and ceased any prior O3FA supplementation. With respect to 
both the treatment and placebo groups there was evidence that individuals had 
taken O3FA supplementation outside the prescribed study protocol. This was 
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evident in the placebo group where following the intervention period a number of 
individuals exhibited elevated RBC EPA and DHA membrane levels and on 
occasion elevated AA levels. A single individual in the EPA treatment group 
exhibited significant increases in EPA, DPA, DHA and AA RBC membrane levels 
over the treatment period of the study. This rise in both O3FAs and O6FAs 
suggests the use of a supplement that was not disclosed to researchers over the 
course of the treatment period. An alternative explanation is that this individual 
was able to convert EPA to DHA highly effectively. 
This is the first published data from a RCT that illustrates a correlation between 
EPA RBC membrane levels and CRCLM tissue, providing evidence that RBC 
EPA levels may be used as a surrogate marker of tumour tissue incorporation. It 
is already widely accepted that RBC membrane O3FA levels are an accurate 
reflection of multiple target tissues (Metcalf et al., 2007; Harris et al., 2004; Tu et 
al., 2013; Brenna et al., 2018). However from the present study it is not possible 
to ascertain whether colorectal tumour tissue demonstrates differential 
incorporation of O3FAs compared to healthy colonic tissue which may be 
relevant in the context of the proposed anti-inflammatory and anti-neoplastic 
mechanisms of O3FAs. 
Based on the assumption that there appeared to be O3FA contamination within 
both the placebo and treatment arms of the study survival analysis irrespective 
of treatment allocation was undertaken. An absolute RBC EPA membrane level 
of 1.22% was selected on the basis of the minimum post-treatment rise in the 
EPA treatment group, thus including individuals from the placebo group that 
exhibited higher or equivalent RBC membrane levels to those in the EPA 
treatment group. Individuals from the placebo group that were effectively moved 
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into the EPA treatment group for the purpose of survival analysis, invariably 
corresponded with individuals previously identified as consumers of high 
amounts of oily fish or prior users of O3FA supplements. Although seemingly 
arbitrary, the dichotomisation of participants within the study at a cut off of 1.22% 
was similar to a study that explored the risk of developing colorectal adenomas 
where EPA RBC membrane levels above 0.89% were associated with a 
decreased risk of adenoma development (Cottet et al., 2013). The present study 
provides the first evidence that RBC EPA membrane levels are associated with 
improved overall survival in patients with CRCLM. Whether this finding is 
indicative of a direct mechanistic effect on colorectal carcinogenesis cannot be 
determined. There was no indication of any relationship between O3FA RBC 
membrane levels and CRCLM tumour tissue vascularity, with anti-angiogenesis 
within tumour tissue one of the mechanisms by which O3FAs are thought to exert 
anti-cancer effects (Calviello et al., 2004). It may be that higher EPA levels have 
more global beneficial health effects given that there is recent evidence to 
suggest that higher RBC membrane O3FA levels are associated with reduced 
risk for all-cause mortality (Harris et al., 2017).  
Following multi-variate analysis it was apparent that there were statistically 
significantly higher post-treatment EPA RBC membrane levels in females 
compared to males. Much of the published literature on sex and PUFA levels is 
focused on the measurement of plasma PUFA levels as highlighted in two 
comprehensive reviews (Childs et al., 2008, Lohner et al., 2013). A systematic 
review of twelve studies examining the effect of sex on PUFA levels identified 
higher levels of DHA in the RBC membrane of females compared to males, but 
no difference in relation to EPA (Lohner et al., 2013). The higher post-treatment 
EPA RBC membrane in females compared to males suggests that hydrolysis of 
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high doses of triglyceride-bound EPA by pancreatic lipases and subsequent 
gastrointestinal absorption of EPA differs between sexes. Alternatively EPA may 
be metabolised at a more rapid rate in males thus reducing the amount present 
in the RBC membrane. The difference between sexes in DHA RBC membrane 
levels has been proposed to be secondary to differential β-oxidation and 
variations across the activity of desatuarase and elongase enzymes as 
influenced by circulating hormones (Childs et al., 2008). A study of transsexuals 
identified that circulating plasma levels of DHA were higher in males that had 
transitioned to female within four months of taking oral ethyinyl oestradiol and 
cyproterone acetate hormones, whereas females who had transitioned to males 
exhibited lower circulating DHA levels when taking testosterone after four 
months (Giltay et al., 2004).  
Given the concerns of placebo or treatment arm contamination in any human 
trials by readily available ‘over the counter’ PUFA supplements the present 
findings suggest it would be appropriate to perform additional analyses 
irrespective of treatment allocation when exploring the effects of RBC PUFA 
membrane levels, an approach already undertaken in a study on the effects of 
O3FAs on non-alcoholic fatty liver disease (NAFLD) (Scorletti et al., 2014). In 
addition the individual PUFA profiles reported in this study suggest that RBC 
membrane PUFA levels may be a potential method of monitoring compliance to 
O3FA treatments in clinical studies and also allow identification of contamination 
by O3FA supplement consumed outside a study protocol. A limitation to this 
method of monitoring compliance is that as exhibited in the present study there 
is substantial variability in the RBC EPA membrane incorporation following EPA 
treatment which may make it particularly difficult to differentiate whether an 
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individual is not compliant or whether the magnitude at which they incorporate 
EPA into the RBC membrane is low.  
7.11 Conclusion 
In summary there was incorporation of EPA into the RBC membrane following 
pre-operative EPA treatment in CRCLM patients, corresponding with a reciprocal 
decrease in RBC membrane AA levels. There was also evidence of a correlation 
between RBC EPA membrane levels and CRCLM tumour tissue EPA levels. This 
study also suggests that RBC EPA membrane levels of 1.22% and above are 
associated with a potential survival benefit. Therefore O3FA supplementation as 
an adjunct in the treatment of CRC is of potential future clinical significance, 
particularly in the context of treatment of micrometastases. However further 
research is required to elucidate the mechanisms of action by which any survival 
benefit is conferred. 
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Chapter 8: Discussion 
8.1 Suitability of O3FA drinks cartons for chemoprevention or adjuvant 
treatment of CRC 
The present study provides evidence that O3FA supplement drinks exhibit a 
similar O3FA RBC membrane incorporation profile to traditional triglyceride-
bound O3FA capsules. Given the previously described anti-inflammatory and 
anti-neoplastic properties they have a potential clinical application as both a CRC 
chemoprevention and as an adjunct in CRC treatment (see section 1.5). The 
widespread inter-individual variation of O3FA bioavailability across both 
intervention types requires further investigation to determine whether there is any 
influence on the efficacy of mechanisms via which O3FAs have both anti-
inflammatory and anti-cancer effects.   
With respect to O3FA bioavailability, the non-inferiority of drinks compared to 
capsules is of key significance when considering O3FA supplementation as a 
treatment adjunct in CRC patients. A significant proportion of patients recovering 
from surgery or other treatment modalities have an impaired appetite and may 
be unable to consume conventional dietary fats required for O3FA capsule 
supplementation. In addition fortified O3FA nutrition drinks may provide 
additional calories in patients who are unable to achieve adequate calorific 
intake, as is already commonplace with the use of various calorific supplements. 
There is also a potential application for O3FA supplementation in combination 
with traditional chemotherapy regimens, with evidence to suggest synergistic 
effects and the amelioration of cancer cachexia (Lee et al., 2017). Further 
research in a population of CRC patients is required to ascertain whether there 
would be similar acceptability and tolerability in this cohort of patients.  
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Both preparations of O3FA supplementation demonstrated similar acceptability 
and tolerability profiles, although only 58% and 68% of participants would 
consider continuing drinks cartons and capsules respectively for an indefinite 
period. Long-term acceptability and tolerability are key properties for any 
chemoprevention and therefore traditional O3FA containing capsules may be 
more suited to this purpose than drinks. As evidenced in the present study there 
were concerns regarding the calorific content of the O3FA supplement drinks 
which led to a participant withdrawing from the study. Although in the US there 
is a relatively high proportion of the population (approximately 8%)  taking O3FA 
supplements, it is important to recognise that the general population do not yet 
have irrefutable evidence to support the use of O3FA supplementation as a 
chemoprevention for CRC (Clarke et al., 2015; Black et al., 2015). Indeed, if the 
mechanisms and body of evidence to support the use of O3FAs as a 
chemoprevention in CRC were more robust, then the adoption of long-term 
supplementation may increase.  
Although there are a number animal models and human polyp prevention 
studies, there is at present a lack of clinical data to justify recommendation to 
implement O3FA supplementation as a form of chemoprevention or adjuvant 
treatment in CRC (See section 1.5). A long-term study is required to explore 
implementing O3FA supplementation as a method of CRC chemoprevention, 
rather than retrospective estimation of exposure to O3FAs via dietary 
assessment. Any such study is likely to be of complex design and it remains to 
be seen how investigators would control for a plethora of known risk factors 
associated with CRC. 
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8.2 The effect of O3FA supplementation on faecal microbiome profiles and 
association with colorectal carcinogenesis 
O3FA supplementation was associated with an increased abundance of the 
genera Bifidobacteria, Roseburia, Lachnospira and Lactobacillus, with some 
evidence of reversibility during the washout periods. The present study 
contributes to mounting evidence in both animal models and humans that EPA 
and DHA induce subtle changes to the abundance and composition of the faecal 
microbiota (Costantini et al., 2017). The enrichment of SCFA-producing bacteria 
including Lactobacillus in the faecal microbiome profiles of healthy participants 
following O3FA supplementation is of significant interest with respect to 
colorectal carcinogenesis. SCFAs including butyrate and acetate are generated 
by bacterial fermentation of fibre in the colon (Dahl et al., 2017). Butyrate is 
proposed to have anti-CRC effects via both regulation of inflammatory pathways 
and maintenance of the intestinal epithelium (Peng et al., 2009; Kim et al., 2013; 
Chang et al., 2014; Chen et al., 2017). Although butyrate is an energy source for 
normal colonocytes, in colon cancer cells it has a pro-apoptotic effect via 
inhibition of histone deacetylase (Bergman, 1990; Encarnacao et al., 2015; 
Bultman, 2016; Han et al., 2018). It is unclear whether any anti-CRC effects 
associated with O3FAs and alterations in the abundance of SCFA-producing 
bacteria are also dependant on fibre intake.   
There are unanswered questions regarding the effects of O3FAs on the colonic 
microbiota as measured by changes to faecal microbiome profiles. The present 
study did not investigate whether compositional changes to faecal microbiome 
profiles induced by O3FA supplementation are drivers of any beneficial effects 
on the human colon and amelioration of CRC risk. There is also a lack of data 
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with respect to the interaction between O3FAs and bacteria, particularly whether 
O3FAs modulate bacterial metabolic function. It remains to be seen whether 
O3FAs are directly metabolised by bacteria and if the products of bacterial O3FA 
metabolism affect the colonic environment. The lack of consensus as to the 
specific microbiome profile associated with colorectal carcinogenesis is also a 
key limitation when assessing the effect of O3FAs on CRC risk. The mechanisms 
via which changes to microbiome profiles influence colorectal carcinogenesis 
and the complex interplay with genetic, environmental and dietary risk factors 
are not completely understood. It is unclear whether changes to the microbiome 
profiles of CRC patients are a causative factor in colorectal carcinogenesis or 
merely an association.  
Differences between how EPA and DHA individually alter faecal microbiome 
profiles are not explored in the present study and there is limited data in the wider 
published literature. There is a single human study utilising a DHA containing 
intervention, but no EPA study for comparison (Pu et al., 2016). A mouse study 
exploring the effect of DHA on faecal microbiome profiles showed an increase in 
the presence of SCFA-producing bacteria (Davis et al., 2017).  At present it is 
not possible to determine whether EPA and DHA have differing contributions to 
alterations exhibited in faecal microbiome profiles.   
The present study examined faecal microbiome profiles. The bacterial 
composition and microbiome profile of the colon varies according to anatomical 
location and colonic environmental conditions (Donaldson et al., 2016). In both 
CRC patients and healthy individuals luminal faecal microbiome profiles vary 
from those found within the colonic mucosa (Chen et al., 2012; Flemer et al., 
2017). Given that the molecular mechanisms of colorectal carcinogenesis take 
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place within the colonic mucosa it is unclear whether changes to the faecal 
microbiome profile observed in this study bear any relationship to ameliorating 
CRC risk.  
The results of the present study should be interpreted with caution given some 
of the technical limitations of the study and the inability to control for all the 
potential confounding factors which are inherent to a healthy volunteer study. 
There were additional ingredients in the drink cartons that may have influenced 
alterations to faecal microbiome profiles. It is unclear whether changes to faecal 
microbiome profiles induced by O3FA supplementation have a direct effect on 
long-term CRC risk, especially given that the present study was performed in a 
‘healthy’ population. There is also lack of understanding as to any interaction with 
other known risk factors, particularly whether the potential beneficial changes 
induced by O3FA supplementation are sufficient to ameliorate other risk factors. 
The current evidence base exploring the effect of O3FAs on the colonic 
microbiota and specifically CRC risk is limited. In part, advancing the 
understanding of how changes to the microbiota affects CRC risk is hampered 
by a lack of standardisation across the field of microbiome analysis.  It is clear 
that further research is required to determine whether O3FA supplementation 
induced changes to microbiome profiles exhibited in healthy individuals translate 
to a potential application as a dietary CRC chemoprevention via modulation of 
the colonic microbiota. 
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8.3 RBC cell PUFA analysis in CRCLM patients receiving pre-operative 
O3FA supplementation  
In summary, analysis of CRCLM patient PUFA profiles following pre-operative 
EPA treatment highlighted incorporation of EPA into RBC membranes.  This 
corresponded with a reciprocal decrease in RBC membrane AA levels. This data 
provides evidence of EPA bioavailability profiles in CRC patients. Of potential 
application in future clinical trials is the interpretation of RBC membrane PUFA 
profiles to assess compliance with trial design, as on a number of occasions 
PUFA profiles highlighted potential contamination by ‘own use’ O3FA 
supplements.  
There was a correlation between RBC EPA membrane levels and CRCLM 
tumour tissue EPA levels, which suggests there is no difference in the ability of 
CRCLM tissue to incorporate O3FAs compared to other tissues (Metcalf et al., 
2007; Harris et al., 2004). However, a significant limitation of this work is the 
inability to compare RBC membrane PUFA profiles with thiose in normal liver 
tissue or colonic mucosal tissue. The finding that there was an association 
between RBC membrane EPA levels and overall survival in patients undergoing 
resection of CRCLM is of clinical significance, specifically the use of O3FA 
supplementation as a potential adjunct in the treatment of CRC. Song et al. 
identified that a higher intake of marine O3FAs (>0.3g/day) is associated with a 
lower risk of CRC specific mortality in a study of 1659 individuals diagnosed with 
CRC over a median follow-up period of 10.4 years (Song et al., 2017). Whether 
there is a causal link between RBC EPA membrane incorporation and survival 
remains to be seen. There are a number of potential avenues via which EPA 
supplementation may confer a survival advantage including both anti-
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inflammatory and anti-neoplastic mechanisms. In addition there is evidence to 
suggest O3FAs may have more general health benefits including the treatment 
and prevention of cachexia associated with cancer (Harris et al., 2017; Lee et 
al., 2017). As an adjunct in CRC treatment there is also a potential clinical 
application in patients undergoing curative resection of CRC to treat 
micrometastases. However, before O3FA supplementation can be 
recommended as a treatment adjunct in CRC further research is required to 
confirm whether O3FAs provide a definite survival advantage and to elucidate 
the mechanisms via which this is conferred. Currently there is a phase III multi-
centre randomised, double-blind, placebo-controlled trial of EPA 
supplementation in patients undergoing surgical resection of CRCLM with 
curative intent (EMT2 study; ClinicalTrials.gov NCT: 03428477). 
8.4 Future work 
At present a study is being undertaken to determine the amount of O3FAs in ileal 
fluid (REC reference: 15/YH/0547; ISRCTN: 14530452, see appendix 4 & 5). 
This study is being performed to determine the proportion of O3FAs, given in 
doses similar to those employed in clinical studies, absorbed in the small 
intestine. The study is of interest as it will develop our understanding of O3FA 
bioavailability, specifically whether colonic exposure to O3FAs is secondary to 
direct luminal exposure or systemic distribution and subsequent incorporation 
into the colonic mucosa. Participants with a loop ileostomy are required to take 
O3FA containing gelatin capsules twice a day for four weeks, providing a 
combined daily total of 1000mg EPA and 1000mg DHA. Stoma fluid samples are 
to be collected prior to starting supplementation, within two hours of taking the 
first O3FA capsules and at the end of the study. RBC membrane PUFA levels 
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will be measured prior to starting supplementation and at the end of the four 
week intervention period. Subjects with a loop ileostomy have been selected as 
these individuals have maximal length of disease free small intestine, which near 
replicates the small intestine of healthy individuals prior to ejection of terminal 
ileal fluid into the colon. It is hoped this work will inform the design, and 
specifically the dosing of O3FAs to be employed in future studies using in-vitro 
modelling of the colonic microbiome. The in-vitro gut model has been reported 
in Clostridium difficile research and will allow assessment of the effect of O3FA 
supplementation on the colonic microbiota, with the ability to control for multiple 
confounding factors that to date have significantly limited explorative studies in 
both human and animal models (Baines et al., 2005; Freeman et al., 2007; 
Baines et al., 2009).  
The present study highlights subtle changes to the composition of faecal 
microbiota induced by O3FA supplementation. Further research is required to 
determine whether changes to microbiome profiles also take place within the 
colonic mucosa. The most appropriate application for O3FA supplementation as 
a potential method of beneficially modulating the colonic microbiota is yet to be 
determined. Many studies examining the effect of O3FAs on colonic mucosal or 
faecal microbiome profiles employ O3FAs as a prebiotic (Pu et al., 2016; 
Rajkumar et al., 2014). A prebiotic is defined by the World Health Organisation 
(WHO) and Food and Agriculture Organisation (FAO) as a non-viable food 
component that confers a health benefit via modulation of the microbiota 
(Pineiro, 2008). The present study in healthy volunteers provides further 
evidence supporting the application of EPA and DHA as a prebiotic, particularly 
relating to an increased abundance of beneficial butyrate-producing bacteria. 
There is a lack of research into the effects of O3FAs on bacterial metabolic 
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function, where it is unclear if O3FAs are metabolised by bacteria and if any 
products of bacterial O3FA metabolism have an effect on the colonic mucosa. 
There is emerging evidence to employ O3FAs in conjunction with probiotic 
bacteria to provide synergistic benefits on the colonic microbiota. A placebo 
controlled RCT in 140 CRC patients undergoing chemotherapy, tested a 
combination of probiotic bacteria (Lactobacillus and Bifidobacterium) with a 2g 
daily dose of O3FAs (Golkhalkhali et al., 2018). The study reported improved 
quality of life and a reduction in measured inflammatory markers. Further 
research into how O3FAs affect the colonic microbiota and any impact on long-
term CRC risk is required. To account for the plethora of confounding factors 
associated with O3FA supplementation and microbiome analysis a RCT would 
be desirable, although a cohort study would be a more viable study design. 
There is now extensive data pertaining to the bioavailability of O3FAs following 
O3FA supplementation. The present study suggests O3FA containing drink 
supplements exhibit equivalent bioavailability profiles to traditional capsule 
supplementation. There is still debate as to whether O3FA supplementation is 
required to deliver the proposed health benefits associated with O3FAs, or if this 
could be achieved via dietary intake (Song et al., 2017). In order to justify the 
clinical application of O3FA supplementation as either a method of 
chemoprevention or adjuvant treatment in CRC, further evidence is required to 
elicit their anti-CRC mechanisms. There is significant scope for research into the 
fate of O3FAs following RBC membrane incorporation. There are a number of 
potential pathways that O3FAs enter including lipid signalling pathways, β-
oxidation and PUFA conversion (Kanamori et al., 2018; Camões et al., 2009). Of 
current interest is the field of lipidomics with research focused on the metabolic 
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fate and function of various lipids including EPA and DHA (Zárate et al., 2017; 
Schmöcker et al., 2018).  
In summary, future work to justify the implementation of O3FA supplementation 
for chemoprevention or adjuvant treatment of CRC requires focus on long-term 
effects and the mechanisms via which these take place. There is a particular 
paucity of data examining the effects of O3FA on the colonic microbiota, for 
which the present study has given a key insight.  
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Appendix 1. 
 
Content of Smartfish® Remune (per 200 ml) 
Energy 233 kcal 
Fat (53% total energy) 13 g 
Saturates 2.8 g 
Monounsaturates 5.3 g 
Polyunsaturates 3.1 g 
Omega-3 PUFAs 2.0-2.5 g 
EPA 850-1100 mg 
DHA 1100-1300 mg 
Carbohydrates (33% total energy) 19 g 
Fibre (2% total energy) 1 g 
Protein (12% total energy) 10 g 
Calcium 56 mg 
Vitamin D3 10 µg 
Vitamin E 4.1 µg 
Osmolarity 698 mOsmol/l 
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Appendix 2. 
 
From: Clinical Trial Helpline <ctdhelpline@mhra.gsi.gov.uk> 
Sent: 13 February 2015 15:06 
To: Henry Watson [ugm3hsw] 
Subject: RE: Omega-3 nutritional supplement study 
  
Notification that a Clinical Trial Authorisation (CTA) is not required 
Dear Mr Watson 
 
Thank you for your email dated 25th January 2015, and please accept our 
sincere apologies for the delay in responding to you. 
Following a review of your protocol, I can confirm that your proposal is not a 
Clinical Trial of an Investigational Medicinal Product (IMP) as defined by the EU 
Directive 2001/20/EC and no submission to the Clinical Trials Unit at the MHRA 
is required.  
Kind regards 
 
Clinical Trial Helpline 
MHRA 
  
Your views matter. Please tell us what you think of the service you have 
received from us by following the link below: 
https://www.surveymonkey.com/s/ClinicalTrialHelplineFeedback 
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Appendix 3. 
 
   NRES Committee Yorkshire & The Humber - South Yorkshire  
    Unit 001  
         Jarrow Business Centre  
     Rolling Mill Road  
       Jarrow  
        Tyne and Wear  
 NE32 3DT  
     Telephone: 0191 4283563  
29 April 2015  
Professor M A Hull  
University of Leeds  
Level 9  
Leeds Institute of Biomedical and Clinical Sciences  
St James' University Hospital  
Leeds LS9 7TF  
Dear Professor Hull  
 
 
Study title:  
 
 
 
A randomised cross-over trial to 
compare the bioavailability, 
acceptability and tolerability of omega-
3 fatty acids in a drink carton 
formulation with an equivalent dose of 
omega-3 fatty acids in soft gelatin 
capsule form.  
REC reference:  15/YH/0142  
IRAS project ID:  166337  
 
 
Thank you for your letter of 23 April 2015, responding to the Committee’s request for 
further information on the above research [and submitting revised documentation].  
 
The further information has been considered on behalf of the Committee by the Chair.  
 
We plan to publish your research summary wording for the above study on the HRA 
website, together with your contact details. Publication will be no earlier than three 
months from the date of this favourable opinion letter. The expectation is that this 
information will be published for all studies that receive an ethical opinion but should you 
wish to provide a substitute contact point, wish to make a request to defer, or require 
further information, please contact the REC Manager, Mrs Helen Wilson, 
nrescommittee.yorkandhumber-southyorks@nhs.net .Under very limited circumstances 
(e.g. for student research which has received an unfavourable opinion), it may be 
possible to grant an exemption to the publication of the study.  
 
Confirmation of ethical opinion  
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting 
documentation [as revised], subject to the conditions specified below. 
With the Committee’s best wishes for the success of this project.  
Yours sincerely  
pp  
Dr Ian Woollands (Chair) 
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Appendix 4. 
A pilot study to measure omega-3 fatty acid levels in terminal ileal content following four 
weeks of omega-3 fatty acid supplementation in patients with a temporary ileostomy.  
The omega-3 fatty acids (O3FAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 
are essential fatty acids predominantly found in oily fish. O3FAs are commonly used as 
nutritional supplements. O3FAs are considered safe up to, and exceeding, daily doses of 4 g, 
although doses exceeding 2 g daily usually require split dosing1. Side effects that have been 
observed in large cardiology trials with O3FA capsule formulations are usually minor and 
predominantly relate to the gastrointestinal tract with nausea, eructation, abdominal 
discomfort and diarrhoea in up to 10% of cases2. 
Marine O3FAs are naturally present predominantly as the triglyceride (TG) conjugate1. 
‘Nutraceutical’ O3FA TGs, as well as free fatty acid and ethyl ester forms, are also available for 
use in capsule form1. O3FAs in the triglyceride form undergo hydrolysis by pancreatic lipase, 
after which the free fatty acids are re-esterified to a TG conjugate within enterocytes in the 
small intestine. O3FAs are then incorporated into chylomicrons and subsequently released into 
circulating lymph for systemic distribution1. Absorption is believed to take place predominantly 
in the small intestine, but a proportion of O3FAs may be directly bioavailable in the large 
intestine. There is a single study which examined O3FA levels in ileostomy fluid in order to 
determine absorption of different forms of O3FA formulation3. The authors reported that 
approximately 99 % of O3FAs were absorbed in the small intestine within 24 hours of 
administering a single O3FA capsule. However, this study was limited by the relatively small 
dose of O3FA supplementation used (266 mg) and the failure to measure both stoma fluid and 
plasma O3FA concentration. It has not been studied whether there is colonic luminal exposure 
to O3FAs and whether it  is explained by  direct transition of  O3FAs through the gastrointestinal 
tract into the colon, or whether it is secondary to shedding of  enterocytes that have 
incorporated O3FAs following systemic distribution of O3FA after small bowel absorption.  This 
question is of increasing relevance when considering the role of O3FAs in colorectal cancer 
chemoprevention and potential effects of O3FAs on the intestinal microbiota.  
There is increasing recognition and interest in the intestinal microbiota and its role in health 
and disease4. Change in diet alters the intestinal microbiome significantly5. However there has 
been no study of the effect of oral O3FA supplementation on the intestinal microbiome. 
Moreover, the intestinal microbiota may incorporate and metabolise O3FAs altering host O3FA 
bioavailability and the overall host O3FA ‘lipidome’. 
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Study synopsis 
A pilot study to measure fatty acid levels in terminal ileal luminal fluid content at the 
beginning of and after 4 weeks O3FA supplementation with two O3FA capsules twice daily 
(total  daily dose 1000 mg EPA and 1000 mg DHA) in patients who have a temporary ileostomy 
following anterior colonic resection for colorectal cancer.  
Individuals with a temporary loop ileostomy have been identified as an appropriate group of 
patients to study as terminal ileal content is accessible non-invasively from a stoma and is 
directly relevant to O3FA exposure in the proximal colon.  These individuals also have an 
intact small bowel in continuity and therefore is likely to reflect small bowel physiology 
(particularly transit time) in healthy individuals.  
The primary endpoint of the study is the level of EPA and DHA in terminal ileal luminal content 
after four weeks of oral O3FA supplementation compared with O3FA levels detected at the 
start of supplementation. Secondary endpoints include change in erythrocyte membrane EPA 
and DHA levels after four weeks O3FA supplementation and levels of other FAs. 
The data will be used to inform the design of a future study to determine the contribution of 
either direct local O3FA delivery to the colon and/or colonic exposure to O3FAs secondary to 
systemic incorporation, to O3FA concentrations in the proximal colon.  
 
Hypothesis 
After 4 weeks of O3FA supplementation there is an increase in terminal ileal EPA and DHA 
levels compared with basal levels.  
Primary endpoint 
Change in terminal ileal fluid EPA and DHA concentration at four weeks compared with baseline. 
Secondary endpoints 
- Change in percentage erythrocyte membrane content of EPA and DHA  at four weeks 
compared with baseline 
- Change in terminal ileal fluid EPA and DHA concentration within 24 hours of taking the 
first O3FA dose.  
- Tolerability and adverse events related to O3FA supplementation  
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Exploratory endpoints 
Changes in the intestinal microbiome after O3FA intake for 4 weeks 
Inclusion criteria 
- Aged 50 years or over 
- Either gender  
- Temporary ileostomy fashioned at least 2 months prior to commencing study 
- Able to self medicate 
- A minimum period of 2 months availability for the study prior to planned ileostomy 
reversal  
Exclusion criteria  
- Seafood allergy 
- Ongoing and/or previous use (within 4 weeks of commencing the study) of other 
O3FA or cod-liver oil supplements 
- Previous small bowel resection 
- Metastatic colorectal cancer 
- Less than 4 weeks since any chemotherapy or radiotherapy 
- Inflammatory bowel disease or other intestinal disease (e.g. coeliac disease) 
Intervention 
A four week intervention period in which participants are required to take two O3FA 
containing soft gel capsules twice daily with meals (total 1000 mg EPA and  1000 mg DHA 
daily).    
As confirmed for a previous study (ISRCTN 18662143), the Medicines and Healthcare Products 
Regulatory Authority (MHRA) considers O3FA capsules to be a nutritional supplement and 
therefore the study does not require Clinical Trials Authorisation.   
Recruitment 
Suitable patients with a temporary loop ileostomy following anterior resection for colorectal 
cancer will be identified from electronic colorectal surgery department records at St James’ 
University Hospital. Currently, reversal of the ileostomy is undertaken at between 6 to 12 
months following primary resection. Potential participants will be sent a covering letter and 
participant information leaflet by post or e-mail. This will include a phone number and e-mail 
address to contact if an individual wishes to be considered for recruitment into the study. 
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Individuals that express an interest in participating in the study will be contacted by phone at 
least 24 hours later to assess eligibility for inclusion in the study and, if appropriate, will be 
invited to an appointment at SJUH.  At the hospital visit, a researcher will confirm eligibility for 
inclusion into the study, answer any questions and complete the consent process, if 
appropriate.  
When any potentially suitable patients are already scheduled for a out-patient/stoma-related 
hospital visit, a covering letter and participation information leaflet will be sent at least one 
week prior to the clinic visit. A researcher will be present at the clinic to check eligibility for 
inclusion into the study and answer any questions. If an individual agrees to take part in the 
study a consent form will be completed.  
O3FA capsules will be issued to patients after completing the consent process. A planned start 
date for commencing the capsules will be agreed based on the timing of the most convenient 
next hospital visit. 
Timing of intervention and study visits 
To ensure participants are able to complete the 4 week intervention period, patients will be 
asked to commence taking O3FA capsules 4 weeks prior to a planned hospital study visit.  
Participants will be expected to self-administer capsules with meals for 28 days up until and 
including the day of the   scheduled study visit. Participants will be asked to provide a pre-
supplementation baseline stoma sample at the first hospital visit. Current evidence indicates 
that maximal O3FA content in stoma fluid occurs at between 2 to 8 hours after low dose 
administration3. Therefore participants will be required to provide a stoma fluid sample 
between 2 and 8 hours after the first capsule dose to identify any immediate change in 
terminal ileal O3FA concentration.  After 4 weeks, participants will be required to provide a 
post intervention stoma sample after their final O3FA capsule dose at the same time after 
dosing, at which the first sample was obtained (plus or minus 1 hour). An extra two weeks of 
O3FA supplements will be supplied in the eventuality that a participant cannot attend the 
scheduled study visit. Dietary intake in the past 24 hours will be recorded in order to 
determine the fat and calcium intake in the 24 hour period prior to obtaining each stoma fluid 
sample6. If an individual experiences side-effects, which are believed to be related to O3FA 
use during the supplementation period, he/she will be advised to reduce the number of 
capsules consumed per day e.g. two capsules per day with a subsequent attempt to increase 
the dose again, symptoms permitting. Any adverse events occurring over the four week 
supplementation period will be recorded by a researcher. Participants will also be provided 
with the contact details of the research fellow overseeing the study.   
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Study visit one 
At the initial study visit, a researcher will be present to answer any questions and administer a 
baseline questionnaire to ensure eligibility for inclusion into the study. If eligible the 
participant will be asked to complete a consent form.  
Those agreeing to take part in the study will be asked to provide a venous blood sample for 
measurement of erythrocyte membrane EPA/DHA levels. Participants will be asked to provide 
a stoma fluid sample from their ileostomy bag for measurement of baseline O3FA levels. 
Dietary intake in the 24 hours prior to obtaining the first stoma fluid will be assessed.  In order 
to assess individual stoma output, participants will be asked to report the number of stoma 
bag changes, both on the visit day and the day prior to the hospital visit. A convenient date 
will be arranged to undertake visit 2 and commence taking the O3FA capsules (28 days 
earlier). 
Study visit two 
Participants will be required to provide a stoma fluid sample within 2 to 10 hours of the first 
capsule dose to identify any immediate change in terminal ileal O3FA concentration. If this 
cannot be done at St James’s University Hospital, a researcher will arrange to visit the 
participant at their home to collect a stoma fluid sample after the first O3FA capsule dose.  
The time of the first capsule dose and the time at which the stoma sample is collected will be 
recorded. The researcher will also check dietary intake in the few hours since the first capsule 
dose was taken.  
Study visit three  
At the final hospital visit, a venous blood sample will be taken for measurement of erythrocyte 
membrane EPA/DHA levels. A pill count will be performed and an adverse events 
questionnaire administered. The patient will be asked to provide a stoma fluid sample for 
measurement of O3FA levels. The stoma fluid sample should be collected within 2 to 8 hours 
of taking the last capsule dose, at a time point matched (+/- 1 hour)  to the time the visit 2 
stoma fluid sample was taken after capsule dosing.  The time of the final capsule dose and the 
time at which the stoma fluid sample is collected will be recorded. In order to assess individual 
stoma output, participants will be asked to report the number of stoma bag changes, both on 
the day and the day prior to the hospital visit. The dietary intake in the 24 hours prior to the 
last capsule dose will be recorded. If an individual stops taking capsules during the four week 
supplementation period they will be still asked to attend to provide a stoma fluid and venous 
blood sample. 
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Laboratory analyses 
Venous blood will be collected into two EDTA sample tubes and transferred to the Leeds 
Institute of Biomedical & Clinical Sciences (LIBACS) in the Wellcome Trust Brenner Building, 
where they will undergo immediate centrifugation (800 g for 5’) for preparation of plasma and 
erythrocytes. Plasma samples from each participant will be split between four individual vials 
for subsequent storage at -80oC across two separate freezers at the LIBACS. For the 
measurement of erythrocyte membrane EPA and DHA levels, the blood samples will be 
transported to the Institute of Cancer Therapeutics at the University of Bradford to undergo 
liquid-chromatography tandem mass-spectrometry analysis.  
Stoma contents will be collected into 20ml sterile plastic containers and transferred to the 
Leeds Institute of Biomedical & Clinical Sciences (LIBACS) in the Wellcome Trust Brenner 
Building on the St James’s site. Samples will be stored at -80oC across two separate freezers at 
the LIBACS. For the measurement of stoma content EPA and DHA levels, the samples will be 
transported to the Institute of Cancer Therapeutics at the University of Bradford to undergo 
liquid-chromatography tandem mass-spectrometry analysis.  
Stool samples will be stored at -80oC for a period of less than 2 weeks prior to total DNA 
extraction by bead-beating followed by the Qiagen© Stool DNA extraction method. Stool DNA 
will be stored at -80 oC in the LIBACS Human Tissue Authority-approved freezer. If an increase 
in EPA and/or DHA level in ileal fluid is observed, we have the opportunity to investigate 
whether this is associated with changes in intestinal microbiome. PCR amplification of 
hypervariable regions of bacterial 16S rRNA genes will be performed using barcoded universal 
primers. In order to identify the variety of bacterial species present, the PCR amplified 
samples will be sequenced on the Illumina MiSeq platform, followed by classification at a 
genus level using the Ribosomal Database Project (RDP) Naive Bayesian Classifier in Mothur. 
Analysis of the relative proportions of individual bacterial taxa will be performed using 
quantitative PCR of the total 16S rRNA gene content. 
Sample size calculation and statistical analysis  
There are no data available in relation to terminal ileal or faecal EPA and DHA levels in subjects 
consuming O3FA supplements and so we are therefore unable to perform a formal sample size 
calculation. This is a pilot study in order to inform an appropriate sample size calculation for a 
future study. In view of previous studies examining O3FA erythrocyte membrane incorporation 
there is likely to be both significant inter-individual (between 4.4 and 11.8 %) and intra-
individual variability (4.1 % +/- 1.9 %) in terminal ileal content of O3FAs7. Therefore, we estimate 
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eight participants will be sufficient to produce an appropriate 95 % confidence interval for 
EPA/DHA concentration in terminal ileal fluid. 
According to St James’ University Hospital Colorectal stoma department records approximately 
102 patients underwent formation of a temporary ileostomy between June 2014 and June 2015.   
Therefore it is feasible to recruit eight participants into the study over a 10 week period 
assuming a 50 % recruitment rate.  
For the purpose of comparing absolute pre- and post-supplementation levels of stoma content 
and erythrocyte O3FA levels, a paired Student’s t-test will be employed. Adverse events in each 
group will be compared by Fisher’s exact test. 
Confidentiality 
The participant information sheet (PIS) and participant consent form will specify clearly that 
any records identifying the participants (e.g. the recruitment questionnaires) and all the 
information collected from participants during the course of the research will be kept strictly 
confidential. Participants will be given a unique ID number on entry to the study and all study 
paperwork (e.g. questionnaires) will coded by ID number rather than participant name or 
other participant identifier. All electronic data will be kept on a password-protected computer 
in LIBACS. Hard copy data will be kept securely in a locked cabinet in a locked office in LIBACS. 
References 
1. Wang C, Harris WS, Chung M et al. 2006. n-3 Fatty acids from fish or fish-oil supplements, 
but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary and 
secondary-prevention studies: a systematic review. American Journal of Clinical Nutrition. 84, 
pp. 5-17. 
 
2. Schuhardt JP and Hahn J. 2013. Bioavailability of long-chain omega-3 fatty acids. 
Prostaglandins, Leukotrienes and Essential Fatty Acids. 89, pp. 1-8. 
 
3. Sanguansri L, Shen Z, Weerakkody et al. 2013. Omega-3 fatty acids in ileal effluent after 
consuming different foods containing microencapsulated fish oil powder – an ileostomy study. 
Food & Function. 4, pp. 74-82. 
 
4. Tlaskalová-Hogenová H, Štěpánková R, Kozáková H et al. 2011. The role of gut microbiota 
(commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and 
autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of 
human diseases. Cellular & Molecular Immunology. 8, pp. 110–120. 
 
5. David L, Maurice CF, Carmody RN et al. 2014. Diet rapidly and reproducibly alters the human 
gut microbiome. Nature. 505, pp559-563. 
 
6. Bingham SA, Gill C, Welch A et al. 1997. Validation of dietary assessment methods in the UK 
arm of EPIC using weighed records, and 24-hour urinary nitrogen and potassium and serum 
212 
 
vitamin C and carotenoids as biomarkers. International Journal of Epidemiology .26(Suppl 
1):S137-S151 
 
7. Harris WS and Thomas RM. 2010. Biological variability of blood omega-3 biomarkers. 
Clinical Biochemistry. 43, pp. 338-340.  
  
213 
 
Appendix 5.  
 
NRES Committee Yorkshire & The Humber - South Yorkshire  
    Unit 001  
         Jarrow Business Centre  
     Rolling Mill Road  
       Jarrow  
        Tyne and Wear  
 NE32 3DT  
     Telephone: 0191 4283563  
 
 
05 January 2016  
Professor MA Hull  
Level 9, Leeds Institute of Biomedical and Clinical Sciences  
St James' University Hospital  
Leeds  
Beckett Street  
Leeds  
LS97TF  
Dear Professor Hull  
 
Study title:  
 
 
A pilot study to measure omega-3 fatty 
acid levels in terminal ileal content 
following four weeks of omega-3 fatty 
acid supplementation in patients with a 
temporary ileostomy.  
REC reference:  15/YH/0547  
IRAS project ID:  182428  
 
Thank you for your letter of 23rd December 2015, responding to the Committee’s 
request for further information on the above research and submitting revised 
documentation.  
 
The further information has been considered on behalf of the Committee by the Vice-
Chair. We plan to publish your research summary wording for the above study on the 
HRA website, together with your contact details. Publication will be no earlier than 
three months from the date of this opinion letter. Should you wish to provide a 
substitute contact point, require further information, or wish to make a request to 
postpone publication, please contact the REC Manager, Miss Christie Ord, 
nrescommittee.yorkandhumber-leedswest@nhs.net.  
 
Confirmation of ethical opinion  
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised, subject to the conditions specified below. 
pp  
Dr Vera Neumann  
Vice Chair   
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AbstrAct
Objective Omega-3 polyunsaturated fatty acids 
(PUFAs) have anticolorectal cancer (CRC) activity. The 
intestinal microbiota has been implicated in colorectal 
carcinogenesis. Dietary omega-3 PUFAs alter the mouse 
intestinal microbiome compatible with antineoplastic 
activity. Therefore, we investigated the effect of omega-3 
PUFA supplements on the faecal microbiome in middle-
aged, healthy volunteers (n=22).
Design A randomised, open-label, cross-over trial of 
8 weeks’ treatment with 4 g mixed eicosapentaenoic 
acid/docosahexaenoic acid in two formulations (soft-
gel capsules and Smartfish drinks), separated by a 12-
week ’washout’ period. Faecal samples were collected 
at five time-points for microbiome analysis by 16S 
ribosomal RNA PCR and Illumina MiSeq sequencing. 
Red blood cell (RBC) fatty acid analysis was performed 
by liquid chromatography tandem mass spectrometry.
results Both omega-3 PUFA formulations induced 
similar changes in RBC fatty acid content, except 
that drinks were associated with a larger, and more 
prolonged, decrease in omega-6 PUFA arachidonic 
acid than the capsule intervention (p=0.02). There 
were no significant changes in α or β diversity, 
or phyla composition, associated with omega-3 
PUFA supplementation. However, a reversible 
increased abundance of several genera, including 
Bifidobacterium, Roseburia and Lactobacillus 
was observed with one or both omega-3 PUFA 
interventions. Microbiome changes did not 
correlate with RBC omega-3 PUFA incorporation or 
development of omega-3 PUFA-induced diarrhoea. 
There were no treatment order effects.
conclusion Omega-3 PUFA supplementation induces 
a reversible increase in several short-chain fatty acid-
producing bacteria, independently of the method of 
administration. There is no simple relationship between 
the intestinal microbiome and systemic omega-3 PUFA 
exposure.
trial registration number ISRCTN18662143.
IntrODuctIOn
The two main omega-3 polyunsaturated fatty acids 
(PUFAs), eicosapentaenoic acid (EPA; C20:5 ω3) 
and docosahexaenoic acid (DHA; C22:6 ω3) are 
widely used as nutritional supplements, as fish 
oil or in more concentrated ‘nutraceutical’ form.1 
Multiple health benefits have been claimed for these 
long-chain omega-3 PUFAs, including secondary 
prevention of ischaemic heart disease,2 treatment of 
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significance of this study
What is already known on this subject?
 ► The naturally occurring omega-3 
polyunsaturated fatty acids (PUFAs), 
eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) have 
anticolorectal cancer (CRC) activity. 
 ► High-purity EPA and DHA can be provided in 
soft-gel capsule form or as a ‘nutrition’ drink 
providing greater than 2 g omega-3 PUFAs daily. 
 ► The intestinal microbiota are implicated in 
colorectal carcinogenesis, as well as modulation 
of chemotherapy and immunotherapy of CRC.
What are the new findings?
 ► Oral high-dose omega-3 PUFAs do not produce 
marked changes in the intestinal microbiome 
in healthy volunteers, even in individuals with 
treatment-emergent diarrhoea. 
 ► Intake of 4 g daily mixed EPA/DHA for 8 weeks 
was associated with a reversible increase 
in Bifidobacterium, Oscillospira, Roseburia 
and Lachnospira species, but decreased 
Coprococcus and Faecalibacterium.
 ► Similar effects of omega-3 PUFAs on the faecal 
microbiome were observed for both capsule 
and drink formulations.
 ► Capsule and drink formulations provide 
equivalent tissue omega-3 PUFA incorporation, as 
measured by red blood cell levels, but only drinks 
were associated with prolonged suppression of 
proinflammatory arachidonic acid levels.
How might it impact on clinical practice in the 
foreseeable future?
 ► An increase in short-chain fatty acid-producing 
bacteria may be relevant to the beneficial 
anti-CRC effects of EPA in both prevention and 
adjuvant treatment settings.
 ► Clinical evaluation of the anticancer properties 
of omega-3 PUFAs needs to consider 
the intestinal microbiota and its role in 
carcinogenesis and immune regulation.
 Gut Online First, published on September 26, 2017 as 10.1136/gutjnl-2017-314968
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rheumatoid arthritis3 and anticancer activity,4 some of which are 
supported by evidence from randomised trials.5 6
The mechanism(s) underlying the colorectal cancer (CRC) 
chemopreventative activity of EPA reported by West et al is 
unclear.5 It has been proposed that the intestinal microbiota 
may play a role in colorectal carcinogenesis based on the asso-
ciation of CRC with a specific intestinal microbiome profile, or 
so-called dysbiosis, characterised by low phylogenetic diversity, 
altered Firmicutes/Bacteriodetes ratio, under-representation of 
short-chain fatty acid (SCFA)-producing genera such as Rose-
buria and Eubacterium as well as presence of putative pathobi-
onts such as Fusobacterium nucleatum.7 8 One possibility is that 
modulation of the intestinal microbiota may contribute to the 
cancer-preventative properties of omega-3 PUFAs.
Data from mouse models suggest that dietary omega-3 PUFA 
intake or high tissue levels of omega-3 PUFAs are associated with 
differences in intestinal microbiota, including increased quanti-
ties of certain genera, including Bifidobacterium and Lactoba-
cillus.9 10 There has been only one case report of the effect of 
an omega-3 PUFA-rich diet on human intestinal microbiota.11 
In this case, there was a notable increase in several SCFA (butyr-
ate)-producing genera including Blautia, Bacterioides, Roseburia 
and Coprococcus.11
Therefore, a plausible hypothesis is that omega-3 PUFA intake 
alters the composition of human intestinal microbiota, thereby 
attenuating the intestinal dysbiosis associated with colorectal 
carcinogenesis.
Nutritional supplementation with omega-3 PUFAs can occur 
in several ways, either as unrefined fish oil, in ‘nutraceutical’ 
form, usually as the triglyceride or ethyl ester conjugate in 
soft-gel capsules, taken with food or more recently as an emul-
sion in drink form.1
To address the above hypothesis and, at the same time, 
compare two different formulations of omega-3 PUFAs, we 
performed a randomised, open-label, cross-over study of the 
effect of omega-3 PUFAs on the intestinal microbiome of healthy 
volunteers aged over 50 years (a population relevant to CRC 
screening and chemoprevention), thus comparing equivalent 
doses of equimolar amounts of EPA and DHA in capsule or drink 
form with an integrated ‘washout’ period, with which to deter-
mine reversibility.
MetHODs
study design and interventions
The randomised, cross-over trial was carried out in the 
Human Appetite Research Unit (HARU), University of Leeds. 
Approval was obtained from the South Yorkshire Research 
Ethics Committee (15/YH/0142). Interventions were not classi-
fied as Investigational Medicinal Product by the Medicines and 
Healthcare Products Regulatory Agency. The study was regis-
tered with International Standard Randomised Controlled Trials 
Number (18662143).
Healthy volunteers aged ≥50 years of both sexes were sought 
using a HARU volunteer database and advertising across the 
university. Participants received £20 per study visit. At a screening 
visit, the following exclusion criteria were considered: ongoing 
or planned regular use of other omega-3 PUFA or cod liver oil 
supplements; seafood allergy; concomitant use of non-steroidal 
anti-inflammatory medications, including aspirin; current treat-
ment for any chronic inflammatory condition or malignancy; 
previous colonic or small bowel resection; current smoker 
(minimum 6 months smoking cessation) and pregnancy. If an 
individual was eligible, he/she underwent a ‘lead-in’ taste test 
of the peach-flavoured drink and also swallowed two study 
capsules with water, after providing written informed consent to 
confirm likely compliance and minimise dropout.
Visit 1 occurred within 2 weeks of the screening visit, at 
which participants were randomised to take either two 200 mL 
Smartfish Remune drinks (see online supplementary methods 
for content) per day (providing approximately 2000 mg EPA 
and 2000 mg DHA, as the triglyceride) at any suitable time 
of day or four soft-gel capsules (each containing 250 mg EPA 
and 250 mg DHA as the ethyl ester) twice daily with meals 
(providing 2000 mg EPA and 2000 mg DHA per day), both for 
8 weeks (intervention A; figure 1). After a 12-week ‘washout’ 
period, participants took the second intervention for 8 weeks 
(Intervention B; figure 1). We also included a final study visit 
after a second 12-week ‘washout’ period (V5; figure 1). Rando-
misation was performed by Leeds Teaching Hospitals Pharmacy 
using random permuted block allocation in concealed envelopes. 
Neither participants nor researchers were blinded to the inter-
ventions and hence allocation order.
At each visit, adverse event (AE) monitoring was undertaken 
by a brief interview based on questioning for recognised AEs of 
omega-3 PUFA supplements, including loss of appetite, eructa-
tion (‘fishy’ burping), nausea, vomiting, dyspepsia, abdominal 
pain and diarrhoea, as well as bleeding events. Review of AEs was 
performed by an independent data monitoring committee every 
3 months. Tolerability of both drinks and capsules was assessed 
with a palatability questionnaire and capsule acceptability ques-
tionnaire at the end of each 8-week intervention period (visit 2 
or 4). Participants’ height and weight were measured at the start 
of the study.
Blood and urine were collected at each visit and a faecal sample 
(obtained with a Fe-Col faecal collection device) was returned 
by hand or by Royal Mail Safebox within 2 days of each visit. 
Participants did not start either intervention until the baseline 
(visit 1 or 3) faecal sample had been collected. Faecal samples 
were stored at −20°C in RNA later (Thermofisher Scientific) 
until DNA extraction, which occurred within 2 weeks of collec-
tion in the majority of cases.
Omega-3 PuFA measurement
Red blood cells (RBCs) were obtained from whole blood EDTA 
samples as described.12 Samples were stored at −80°C until lipid 
extraction and measurement of fatty acids by liquid chromatog-
raphy tandem mass spectrometry (LC-MS/MS) as described.13 
Data are presented as the % (w/w) content of the total fatty acid 
pool measured.13
Intestinal microbiome analysis
Microbial DNA extraction, PCR and Illumina sequencing were 
performed as described (see online supplementary methods).14
Demultiplexed FASTQ files were trimmed of adapter 
sequences using cutadapt.15 Paired reads were merged using 
fastq-join16 under default settings and then converted to FASTA 
format. Consensus sequences were removed if they contained any 
ambiguous base calls, two contiguous bases with a Phred quality 
score lower than 33 or a length more than 2 bp different from 
the expected length of 240 bp. Further analysis was performed 
using QIIME.17Operational taxonomy units (OTUs) were picked 
using Usearch18 and aligned to the Greengenes reference data-
base using PyNAST.19 Taxonomy was assigned using the RDP 
2.2 classifier.20 The resulting OTU biom files from the above 
analyses were imported in MEGAN for detailed group-specific 
analyses, annotations and plots.21
group.bmj.com on December 18, 2017 - Published by http://gut.bmj.com/Downloaded from 
3Watson H, et al. Gut 2017;0:1–10. doi:10.1136/gutjnl-2017-314968
Figure 1 Schedule of study visits and participant flow through the study. The duration of the intervention and washout periods in weeks (w) is 
noted in the left column. *One participant ceased the drink intervention early and completed intervention period B (capsules). **Two participants 
ceased drink intervention early (remained in study). n, number of individuals in study as per protocol.
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As well as comparisons of observed taxa, rarefication was 
performed to various levels to compare α diversity. All groups 
were rarefied to the lowest read number, and β diversity 
calculated using weighted and unweighted UniFrac as well 
as the non-phylogenetic Bray-Curtis dissimilarity measure.14 
β diversity was compared using principal coordinate anal-
ysis (PCoA) on all samples. Correlations between the micro-
biome and RBC fatty acid data were computed using package 
‘Hmisc’22 in R.23
end points and sample size calculation
In the absence of any data on the effect of omega-3 PUFAs 
on human intestinal microbiota, we determined the sample 
size based on testing non-inferiority of the drink formulation 
compared with capsules for the RBC level attained after 8 
weeks’ dosing. There are no prior RBC omega-3 PUFA data 
available in subjects consuming Smartfish Remune. However, 
based on data from healthy individuals consuming omega-3 
PUFA capsules that reported intraindividual variability of 
4%,24 we set a non-inferiority margin of 3%. Assuming partic-
ipant dropout of 20%, we estimated that a sample size of 
20 participants would be required to exclude a difference in 
combined levels of RBC, EPA and DHA between the interven-
tion groups of greater or equal to 0.3 absolute per cent points, 
with 90% power at a significance level of 0.05.
Data were analysed on an intention-to-treat basis. The paired 
Student’s t-test was used to evaluate the difference between RBC 
omega-3 PUFA levels for participants who completed both inter-
vention periods. Unpaired data from participants, who did not 
complete both intervention periods, were included in unpaired 
data analyses. Comparison of absolute presupplementation and 
postsupplementation levels of RBC omega-3 PUFA levels within 
intervention groups was by paired Student’s t-test. AEs in each 
group were compared by χ2 analysis.
For intestinal microbiota analysis, OTU read numbers at 
different time-points for the two interventions were compared 
by unpaired and paired analysis. Having excluded a significant 
treatment order effect on both RBC omega-3 PUFA incorpora-
tion and the intestinal microbiome profile, data for the capsule 
intervention (termed Int1) and the drink intervention (termed 
Int2) were combined regardless of the intervention order (either 
A or B).
results
Twenty-two participants were randomised between July 2015 
and April 2016 (figure 1). There were 12 women and 10 men 
with a median age of 57 years (range 51–65 years) and a median 
body mass index of 27.1 kg/m2 (22.0–33.8 kg/m2). Both inter-
ventions were well tolerated with good acceptability scores (see 
online supplementary results). Two individuals withdrew from 
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table 1 AEs during capsule and drink intervention periods
capsules (n=22) Drinks (n=19)
AE during intervention period (no of 
participants)
29 (14) 17 (10)
Diarrhoea 5 5
Abdominal discomfort 6 3
Eructation (burping) 10 4
Dyspepsia 5 1
Nausea/vomiting 3 4
One or more symptoms defined as moderate 3 (2 ceased 
intervention)
3 (3 ceased 
intervention 
early)
Resolution of symptoms after washout (no 
of participants)
14 9
Symptoms experienced during both 
intervention periods (proportion occurring 
during second intervention that were present 
during the first intervention)
4/10 (40%) 4/9 (44%)
AE, adverse event.
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the study during intervention period A (both capsules) because 
of an AE. One individual did not take drinks because of concern 
about calorific intake but remained in the study. Of those indi-
viduals completing intervention periods for drinks (n=16) and 
capsules (n=20), the median duration of the intervention period 
was 57 (54–59) and 57 (55-63) days, respectively.
Symptoms reported during all capsule interventions (n=22) 
and all drink interventions (n=19) are detailed in table 1. In 
general, there was an excess of treatment-emergent AEs during 
the capsule intervention, particularly for dyspeptic symptoms 
(heartburn, acid regurgitation). All AEs were defined as minor 
(any symptom experienced during intervention but did not 
require cessation of intervention or dose reduction) except for 
three AEs in each group that were classified as moderate (any 
symptom experienced that required subsequent dose reduction 
or cessation of intervention) and led to cessation of the inter-
vention. All the AEs during the capsule intervention and the AEs 
in 9/10 individuals during the drink intervention had resolution 
of the AE during washout, suggesting that these were definite 
adverse reactions.
changes in rbc omega-3 PuFA content
Fatty acid analysis was performed on those samples from partic-
ipants who completed one or both intervention periods and 
washout (n=20). Only three individuals did not complete a 
second intervention washout cycle with full blood sampling. 
Overall, 98 RBC samples underwent lipid extraction for omega-3 
PUFA analysis. Data were available for 97 samples as one sample 
did not extract well and was uninterpretable.
Individual PUFA data are represented as the absolute per cent 
level, change between baseline and the post-treatment level and 
difference between baseline and ‘washout’ value in figure 2. Data 
for the order of intervention (drinks then capsules or capsules 
then drinks) are shown only for EPA and DHA (figure 2A and 
B). The ‘washout’ period (12 weeks) was effective with return 
to baseline RBC levels of EPA and DHA for both drinks and 
capsules for either order of intervention. There was a lower 
post-treatment % RBC content of EPA or DHA (figure 2A and B) 
if drinks were consumed after capsules compared with the oppo-
site intervention order, but this difference was not statistically 
significant. There were no intervention order effects on content 
of the other fatty acids measured (data not shown).
As there was no significant difference in RBC PUFA levels 
related to the order of intervention, data for individual PUFAs 
were pooled, independently of the intervention order, for the 
further comparison of drinks and capsules (figure 2C-F). Baseline 
and post-treatment levels of EPA, docosapentaenoic acid (DPA) 
and DHA were well matched with no significant difference 
between the post-treatment level of EPA and DHA attained 
following consumption of drinks or capsules (figure 2C and E). 
The mean individual difference between the combined RBC EPA 
and DHA level attained after the drink intervention and that 
attained after capsule use was −0.12 (95% CI −1.84 to 1.61; 
n=16 paired data), thereby confirming non-inferiority of the 
drink formulation compared with capsules for omega-3 PUFA 
incorporation in RBCs. There was little conversion to C22:5 ω-3 
DPA from EPA (figure 3D). Incomplete washout of DHA from 
RBC membranes after the capsule intervention was observed 
unlike that after the drink intervention (figure 2E). Drink intake 
was associated with a larger decrease in relative C20:4 ω-6 
arachidonic acid (AA) content compared with capsules, which 
remained evident at the end of washout (figure 2F). However, 
there was no statistical post-treatment difference in the per cent 
AA content between drink and capsule use (figure 2F). The 
omega-3:omega-6 ratio is commonly used as a biomarker of 
omega-3 PUFA bioactivity.12 Therefore, we examined the effect 
of drink consumption and capsule intake on the EPA+DHA:AA 
ratio (figure 2G). The larger decrease in AA content contributed 
to the higher EPA+DHA/AA ratio gained after use of drinks 
compared with capsules (figure 2G), a difference which was 
statistically significant (p=0.02).
Online supplementary figures 1 and 2 demonstrate indi-
vidual EPA and DHA profiles based on intervention order. As 
expected, there was wide variability in omega-3 PUFA incorpo-
ration between individuals. In general, EPA profiles were less 
variable, for both capsule and drink interventions (see online 
supplementary figure 1) than for RBC DHA levels, both within 
and between individuals (see online supplementary figure 2). 
Incorporation of either EPA or DHA with one intervention did 
not predict the individual response to the other intervention.
changes in the intestinal microbiome
A faecal sample was collected at all five time-points from all 
20 volunteers. Three samples were excluded from PCR ampli-
fication because of repeated poor quality DNA extraction, 
leaving 97 samples that were analysed (median 46 603 reads; 
minimum 26 387, maximum 114 130). Bray-Curtis PCoA 
of all samples considering all taxonomic levels is shown in 
figure 3A. Interindividual differences in the intestinal micro-
biome exceeded any treatment effect of omega-3 PUFA in 
either capsule or drink form. In particular, volunteers 8 and 13 
were markedly different from the others related to a reduced 
proportion of Clostridia and a larger proportion of the class 
Gammaproteobacteria with high abundance of Succinivibrion-
aceae (see online supplementary figure 3). For unpaired anal-
ysis of microbiome profiles across time-points, data from these 
volunteers were excluded. Volunteer 16 also had a different 
microbiome with very high abundance of Succinivibriona-
ceae, but the rest of the taxonomic groups in this case were 
consistent with the other volunteers (see online supplementary 
figure 4). Therefore, we did not exclude this (volunteer 16) 
individual’s data from further analysis. For the subsequent 
analyses, all capsule (Int1) and drink (Int2) intervention data 
were combined, regardless of the order of the interventions, 
on the basis of complete tissue (RBC) omega-3 PUFA washout 
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Figure 2 Red blood cell PUFA levels during the study. In each case (A–G), the left y axis is the baseline % RBC PUFA value or ratio, and the right y 
axis is the absolute difference between the post-treatment value or ‘washout’ value and the baseline % level. Columns (baseline per cent values) and 
symbols (absolute difference in per cent value from baseline) denote the mean. Error bars denote the SE of the mean. (A–B) Comparison of RBC EPA 
and DHA levels depending on whether the drink intervention was first or second. (C–F) Individual RBC PUFA levels comparing pooled data from the 
drink versus capsule intervention, independently of the intervention order. (G) Comparison of the EPA+DHA/AA ratio at baseline, post-treatment and 
after washout for the drink and capsule intervention. *p<0.05 for the difference between drinks and capsules; paired t-test. DHA, docosahexaenoic 
acid; EPA, eicosapentaenoic acid; PUFA, polyunsaturated fatty acid; RBC, red blood cell. 
Gut microbiota
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Figure 3 Changes in the intestinal microbiome associated with omega-3 PUFA supplementation. (A) Principal coordinate analysis of all samples 
(V1–V5) for all participants. Each participant is denoted by a different colour. Clustering of data from individuals is prominent with relatively small 
differences between different time-points per individual. Circles highlight participants with high Gammaproteobacteria (blue) or Succinivibrioacceae 
alone (red). (B) Cladogram. Int1.1 and Int1.2 denote visits/samples before and after the capsule intervention regardless of the intervention order (A 
then B, and B then A). Int2.1 and Int2.2 are corresponding time-points for the drinks intervention regardless of intervention order. (C) Shannon α 
diversity index (23 305 sequences per sample) and weighted (open circles) and unweighted (solid squares) unifrac β diversity scores for all participant 
samples from each visit (Int1.1–1.2 and Int2.1–2.2 and V5). Symbols denote the mean and bars represent the SD. (D) Family and genus-level profiles 
before and after capsule and drink interventions and at final ‘washout’. PUFA, polyunsaturated fatty acid.
Gut microbiota
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Figure 4 Abundance of top five genera and Lactobacillus at each visit. Columns represent the mean value for each time-point for each intervention 
(Int1 and Int2) irrespective of the order of the interventions (see figure 3 legend).
Gut microbiota
and similarity of the microbiome profile at the two baseline 
assessments at visit 1 and visit 3 for either order of interven-
tions (see online supplementary figure 5). The cladogram high-
lights that the omega-3 PUFA intervention, either as capsules 
or as drinks, was not associated with any significant overall 
taxonomic shift (figure 3B). There was no significant change 
in α (Shannon diversity index) or β (unweighted and weighted 
unifrac distance) diversity at the end of each intervention 
period (Int1.2 and Int2.2) compared with baseline (Int1.1 and 
Int2.1) or the final washout time-point (V5) (figure 3C).
The Firmicutes:Bacteriodetes (F:B) ratio is frequently 
reported in cohort studies investigating the relationship 
between intestinal dysbiosis and CRC.7 However, neither 
capsule nor drink intake was associated with statistically 
significant changes in the F:B ratio (see online supplementary 
figure 6).
However, presentation of data at individual family and 
genus level revealed consistent differences associated with both 
capsule omega-3 PUFA and drink omega-3 PUFA interven-
tions that returned towards baseline on cessation (figure 3D). 
For example, some relatively low abundance families including 
Clostridiaceae, Sutterellaceae and Akkermansiaceae were each 
increased at the end of both interventions with reversibility after 
the washout period (figure 3D). A similar phenomenon was 
observed at genus level, for example Oscillospira and Lachno-
spira (figure 3D). Individual histograms are shown for the top 
five abundant genera in figure 4A-E, which highlight changes 
associated with 8 weeks’ intervention with capsules or drinks, 
each time with reversibility after 12 weeks. Supplementation 
with omega-3 PUFAs was associated with increased abundance 
of Bifidobacterium, Oscillospira, Lachnospira and a reduction in 
abundance of Coprococcus and Faecalibacterium (figure 4A-E). 
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Figure 5 Changes in abundance of genera at the end of the 8-week omega-3 PUFA intervention period. Differences in OTU read number are 
calculated as the value at the end of the treatment period minus the value at the start of the intervention. Bars denote the mean value and bars 
denote the SD Black and red bars distinguish capsule and drink intervention data, respectively. Positive values represent an increase associated 
with intervention and negative values represent a decrease in abundance at the end of the intervention period. *p<0.05 (one sample t-test). OTU, 
operational taxonomical unit; PUFA, polyunsaturated fatty acid.
Gut microbiota
We also performed a paired analysis, in which OTU read numbers 
for the top 20 genera were compared before and after capsule 
or drink interventions within individuals. This confirmed that 
Bifidobacterium and Oscillospira (increase), as well as Copro-
coccus (decrease), changed most for both interventions, whereas 
an increase in Roseburia and Lachnospira abundance was promi-
nent only after the drink omega-3 PUFA intervention (figure 5). 
A paired t-test comparing the treatment effect (in OTU reads) 
between the capsule and drink intervention for the 17 individ-
uals who had complete paired (before and after intervention) 
data revealed that the drink intervention was associated with 
increased abundance compared with capsules for Roseburia 
only (p<0.05). Mouse studies have consistently demonstrated 
an increase in Lactobacillus abundance after dietary fish oil 
supplementation.9 10 25 26 Therefore, we analysed changes in this 
lower abundance genus following both omega-3 PUFA interven-
tions. There was an increase in Lactobacillus OTU number after 
both interventions that returned towards baseline values after 
washout (figure 4F). However, these differences were not statis-
tically significant between baseline and postintervention time-
points (p=0.11 capsules; p=0.9 drinks) or comparing drinks 
versus capsules in a pair-wise manner (p=0.59). Fusobacterium 
spp. (including nucleatum) were not detected in faeces from this 
cohort of non-cancer individuals.
There was no effect of gender on baseline microbiome profile 
or treatment effect of either omega-3 PUFA intervention (data 
not shown). We also tested whether development of diarrhoea 
on omega-3 PUFA supplementation was associated with a shift 
in the intestinal microbiome. There was no consistent profile 
observed in stool samples collected at the visit during/after 
which diarrhoea was reported (see online supplementary figure 
7). Moreover, we investigated whether the RBC EPA and DHA 
levels generated by each of the interventions correlated with 
changes in the intestinal microbiome. Correspondence analysis 
and correlation testing did not demonstrate any consistent rela-
tionship between RBC EPA/DHA levels and microbiome profile, 
with the relationship for EPA and DHA being weak in compar-
ison with the other FAs tested (see online supplementary figure 
8).
DIscussIOn
We report small, consistent and reversible changes in the 
human intestinal microbiome associated with omega-3 PUFA 
supplementation for 8 weeks. The lack of significant change in 
microbial diversity associated with omega-3 PUFA intervention 
is consistent with mouse studies, in which there was either no 
change,10 or a small change,9 in α diversity. Our data are also 
consistent with the concept that short-term dietary interventions 
do not overcome the dominant interindividual variation in the 
intestinal microbiome.27
The increased abundance of butyrate-producing, so-called 
‘beneficial’, bacterial genera such as Bifidobacterium, Lachno-
spira, Roseburia and Lactobacillus during one or both types of 
omega-3 PUFA intervention is consistent with the mouse litera-
ture.9 10 25 26 28–30 Whether the relatively small changes in intes-
tinal microbiome that we observed at the end of the 8-week 
intervention period have functional consequences, including an 
increase in luminal SCFA levels, is a question that will require 
a metabolomic approach, including lipidomic profiling. The 
increase in Roseburia and Lachnospira was only observed during 
the drink intervention. Further studies are required to determine 
what aspect of the drink formulation may explain this difference.
Studies of CRC and colorectal adenoma patients have 
reported a reduction in OTUs of SCFA-producing bacteria 
compared with healthy controls.7 31–33 An increase in 
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SCFA-producing bacteria such as Bifidobacterium, leading 
to enhanced mucosal SCFA exposure has been suggested to 
reduce mucosal inflammatory tone.34 Therefore, our find-
ings are compatible with a hypothesis that omega-3 PUFA 
intake is associated with intestinal microbiota changes driving 
increased luminal SCFA exposure. In future studies, it will be 
key to investigate the effect of omega-3 PUFAs on the colonic 
metabolome in concert with dietary fibre assessment. Consis-
tent with an interaction between omega-3 PUFAs and fibre, 
Crim et al have reported that fish oil and dietary pectin have 
synergistic antineoplastic activity in rats.35
We did not observe any relationship between intestinal 
microbiome changes and RBC omega-3 PUFA levels (a measure 
of systemic omega-3 PUFA exposure). Therefore, we do not 
provide any evidence that systemic ‘bioavailability’ of omega-3 
PUFAs was modulated by the intestinal microbiota in our study. 
However, mouse studies have demonstrated that supplementa-
tion with Bifidobacterium breve was associated with increased 
tissue EPA and DHA content, suggesting an influence of intes-
tinal microbiota on tissue fatty acid levels.36 It remains unclear 
whether RBC omega-3 PUFA levels after oral omega-3 PUFA 
supplementation predict omega-3 PUFA exposure in the gut 
lumen. In a study of patients (n=6) with a permanent ileostomy 
and minimal terminal ileum removed, less than 1% of the total 
oral omega-3 PUFA dose was recovered in ileal effluent suggesting 
efficient proximal small intestinal absorption.37 However, the 
daily dose of EPA and DHA was less than 300 mg for 4 days 
only.37 It remains unclear what the small intestinal and colonic 
bioavailability of omega-3 PUFAs is at oral dosing ≥2000 mg 
daily.5 6
A randomised trial of control versus sardine diet (100 g 
sardines for 5 days per week for 6 months providing approxi-
mately 3 g daily of EPA and DHA combined) in type II diabetes 
patients reported a significant decrease in F:B ratio in the 
sardine diet arm compared with controls.38 We did not observe 
a significant change in the F:B ratio in our study, which may be 
explained by differences in omega-3 PUFA delivery and duration 
of the intervention.
RBC fatty acid changes were similar during either the drink 
or capsule intervention with a significant increase in RBC EPA 
and DHA (and a parallel decrease in AA content) consistent with 
dosing at 4 g per day for 8 weeks.39 It is not clear why the drink 
intervention was associated with a larger decrease in relative AA 
content, which led to a significantly higher EPA+DHA:AA ratio. 
We acknowledge that despite daily dose equivalence of EPA and 
DHA between drink and capsule interventions, the omega-3 
PUFAs were triglyceride and ethyl ester conjugates, respec-
tively. In the longest comparative study of capsules providing 
1.68 g EPA/DHA per day (6 months), the RBC omega-3 index 
was higher after consumption of omega-3 PUFA triglycerides 
compared with ethyl esters.40 Our study suggests that, at high 
doses (4 g) over several weeks, possible small differences in intes-
tinal bioavailability related to PUFA delivery are not relevant 
to omega-3 PUFA tissue incorporation and subsequent changes 
in the intestinal microbiota. Further investigation of the effect 
of the other macronutrients (eg, fibre) and micronutrients (eg, 
vitamin D) in the Smartfish intervention on tissue PUFA incor-
poration and metabolism is required.
Smartfish Remune drinks providing 4 g per day of EPA and 
DHA combined were well tolerated by healthy middle-aged 
individuals. Treatment-emergent AEs were similar between 
drinks and capsules with a suggestion that upper GI symp-
toms were more common during the capsule intervention. 
An AE occurring during one intervention did not consistently 
predict occurrence during the other intervention. The excellent 
acceptability and tolerability, aligned with good omega-3 PUFA 
absorption characteristics, mirrors previous experience with an 
earlier version of the Smartfish drink.41 The aetiology of the 
dose-dependent diarrhoea caused by omega-3 PUFA intake in 
up to 5%–10% of individuals remains unclear. We describe, for 
the first time, that diarrhoea associated with omega-3 PUFA 
intake is not associated with a significant change in intestinal 
microbiota or predicted by a particular baseline intestinal 
microbiome profile.
The strengths of this study include the cross-over design 
that allowed a direct comparison between two omega-3 PUFA 
formulations, thus minimising the effect of interindividual 
variability in omega-3 PUFA incorporation42 and intestinal 
microbiome profile,43 as well as the middle-aged demographic 
of the study cohort relevant to CRC prevention. A method-
ological weakness was the lack of colorectal tissue to study the 
effect of omega-3 PUFA treatment on the mucosa-associated 
microbiome. This would be particularly relevant if luminal 
bioavailability of oral omega-3 PUFAs is confirmed to be low 
and omega-3 PUFA ‘exposure’ is predominantly via membrane 
fatty acids from surface and/or shed enterocytes. We also did 
not obtain data on the background diet and dietary omega-3 
PUFA intake.
In summary, we report that a high dose (4 g daily) of mixed 
omega-3 PUFAs (EPA and DHA) given for 8 weeks is associated 
with small changes in the intestinal microbiota that are consistent 
across two different omega-3 PUFA interventions.9 10 25–28 The 
increase in density of bacteria known to be butyrate producers 
concurs with the existing preclinical literature and is compatible 
with the known anti-inflammatory and antineoplastic properties 
of omega-3 PUFAs.
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A B S T R A C T
We investigated red blood cell (RBC) PUFA profiles, and the predictive value of RBC EPA content for tumour
EPA exposure and clinical outcomes, in the EMT study, a randomised trial of EPA in patients awaiting colorectal
cancer (CRC) liver metastasis surgery (Cockbain et al., 2014) [8]. There was a significant increase in RBC EPA in
the EPA group (n=43; median intervention 30 days; mean absolute 1.26[ ± 0.14]% increase; P < 0.001), but not
in the placebo arm (n=45). EPA incorporation varied widely in EPA users and was not explained by treatment
duration or compliance. There was little evidence of ‘contamination’ in the placebo group. The EPA level
predicted tumour EPA content (r=0.36; P=0.03). Participants with post-treatment EPA≥1.22% (n=49) had
improved OS compared with EPA < 1.22% (n=29; HR 0.42[95%CI 0.16–0.95]). RBC EPA content should be
evaluated as a biomarker of tumour exposure and clinical outcomes in future EPA trials in CRC patients.
1. Introduction
The clinical efficacy of omega-3 polyunsaturated fatty acids
(PUFAs) has been tested in randomised, double-blind, placebo-con-
trolled trials in multiple adult healthcare settings including studies of
cardiovascular disease [1], inflammatory bowel disease [2], non-
alcoholic fatty liver disease [3] and cancer [4,5]. However, despite
the widespread availability of mass spectrometric techniques for
measuring PUFAs, only a minority of clinical omega-3 PUFA studies
with a primary or secondary clinical endpoint have reported target
organ PUFA incorporation and/or individual blood PUFA profiles
[3,5,6], with which to interpret PUFA ‘bioavailability’ (a term usually
used in omega-3 PUFA studies to indicate the tissue or blood level of
omega-3 PUFAs), compliance and ‘contamination’ by excess ‘own use’
of the intervention or dietary omega-3 PUFA intake, the latter being a
particular threat to correct interpretation of trial data and the statistical
power of a trial for any substance that is easily available ‘over the
counter’ or as a dietary constituent [7].
We have previously reported the results of a Phase II randomised,
double-blind, placebo-controlled trial of 99% pure eicosapentaenoic
acid (EPA) in the free fatty acid (FFA) form in patients undergoing liver
resection surgery for colorectal cancer liver metastasis (CRCLM), called
the EMT study [8]. In this ‘window of opportunity’ trial, gastro-
resistant EPA-FFA or identical placebo capsules were taken for a
variable amount of time between the decision to undergo surgery and
liver resection, at which time the trial intervention was stopped. We
demonstrated that EPA-FFA 2 g daily before liver surgery was safe and
well-tolerated. Analysis of resected CRCLM tissue confirmed that orally
administered EPA was incorporated into target tumour tissue and was
associated with a reduction in tumour vascularity as measured by
CD31-positive microvessel density [8]. An intriguing preliminary
observation was that EPA may provide prolonged overall survival
(OS) and disease-free survival (DFS) benefit after treatment cessation
following liver surgery [8].
A methodological limitation of the trial was that we were only able
to obtain CRCLM tissue at surgery after EPA treatment, thus excluding
any longitudinal analysis of PUFA incorporation and ‘washout’ in
target CRCLM tissue. However, we obtained blood from participants
at randomisation (baseline), the day prior to liver surgery (post-
treatment), and several weeks after surgery (‘washout’). Red blood cell
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(RBC) membrane omega-3 PUFA content is widely accepted as the best
surrogate biomarker of omega-3 PUFA content in other tissues such as
the heart and liver [9,10].
Therefore, we analysed the RBC membrane omega-3 PUFA content
at baseline, post-treatment and at follow-up after surgery in the EMT
study, allowing us to interpret individual PUFA content profiles in both
active (EPA) and placebo groups, correlate RBC PUFA content with
CRCLM levels, and explore the use of RBC EPA content as a predictor
of survival in patients who have undergone liver surgery for CRCLM.
2. Methods
2.1. The EMT study
This Phase II randomised, double-blind, placebo-controlled trial
(ClinicalTrials.gov NCT01070355) has been described in detail pre-
viously [8]. Participants were randomised to EPA-FFA 2 g taken as two
gastro-resistant capsules twice daily with food for a median (range)
duration of 30 (12–65) days (n=43) or placebo (capric and caprylic
acid triglycerides) capsules for a median 26 (15–73) days (n=45).
Blood samples were obtained at randomisation (baseline; n=87), the
day prior to liver surgery (post-treatment; n=79), and approximately
six weeks (EPA median [range] 47 [16–110] days; placebo 44 [21–68])
after surgery (washout; n=70). Participants were stratified by prior fish
oil supplement use and/or high dietary ( > 2 oily fish portions per
week) omega-3 PUFA intake. We have previously reported that dietary
omega-3 PUFA intake did not change significantly in either treatment
group during the trial as measured by a modified validated food
frequency questionnaire [8]. Percentage compliance with capsules
was calculated from the difference in actual and expected capsules
use based on a capsule count at the trial visit immediately prior to
surgery. Participants were all given capsules in slight excess of
requirements and were admitted for surgery at different times after
randomisation. A lower than expected capsule count before surgery is
expressed as ‘compliance’ > 100%.
2.2. PUFA measurement
Blood was collected in two EDTA-coated VACUETTE® tubes on ice
and the RBC slurry was obtained after centrifugation at 700g for
10 min at 4 °C within three hours of venipuncture. Isolated RBCs were
stored at −80 °C until fatty acid extraction.
Fatty acids were extracted from erythrocytes using the following
method adapted from the protocol first published by Rose et al. [11].
Isolated erythrocytes were washed three times with 5 volumes of 0.89%
Sodium chloride (NaCl), before transferring 50 μL into a 1.7 mL
Eppendorf® tube. Erythrocytes were mixed with 50 μL distilled water
and allowed to stand for 15 min. 550 μL isopropanol was added slowly
with mixing, and following incubation for 1 h at room temperature,
350 μL chloroform was added. After a further 1 h incubation, samples
were centrifuged at 10 000g for 5 min. The supernatant was then
evaporated in a rotary evaporator and reconstituted in 500 μL acet-
onitrile. Hydrolysis was performed with the addition of 50 μL 5 M HCl
followed by incubation at 80 °C for 1 h. 50 μL of 5 M NaOH was then
added, and the sample mixed, before addition of 350 μL chloroform.
The sample was left to stand for 5 min to allow the solvent layers to
separate, before taking the top 800 μL and evaporating in a rotary
evaporator. Extracted fatty acids were then reconstituted in 50 μL
methanol prior to derivatization.
We measured FAs by liquid chromatography-tandem mass spectro-
metry (LC-MS/MS) [12]. The following FAs were measured with the
relative level of each PUFA expressed as the % of the total FA content:
alpha-linolenic acid (C18:3ω3), EPA (C20:5ω3), docosapentaenoic acid
(DPA; C22:5ω3), docosahexaenoic acid (DHA; C22:6ω3), linoleic acid
(C18:2ω6), arachidonic acid (AA;C20:4ω6), palmitic acid (C16:0),
stearic acid (C18:0), oleic acid (C18:1ω9). Tumour tissue PUFA content
was measured previously and has been reported in the EMT study
publication [8].
2.3. Statistical analysis
PUFA data are quoted as the mean ( ± standard error of the mean
[SEM]) relative (%) amount of each PUFA compared with the total fatty
acid content measured by LC-MS/MS. Individual absolute and fold
changes in PUFA content over time were compared using the one-
sample T test. Pairwise differences in relative PUFA content over time
were analysed by the paired-sample T test. Data that were not normally
distributed were analysed by the Mann Whitney U test. Pearson's
correlation test was used to explore the relationship between contin-
uous variables including RBC and tumour % PUFA content.
Comparison of OS in trial participants with a % RBC EPA level or
1.22 (the lowest post-treatment % EPA level in the EPA group) was
performed using Kaplan-Meier survival analysis and log rank test.
3. Results
3.1. Time course of RBC EPA incorporation and ‘washout’ in CRCLM
patients
Baseline % RBC PUFA levels in patients with CRCLM are displayed
in Fig. 1. There was a rise in RBC EPA content in patients randomised
to EPA-FFA treatment with a mean absolute 1.26 ( ± 0.14 [SEM])%
increase during treatment (P < 0.001, one-sample T test; Figs. 1A and
2A), which was not observed in the placebo group (−0.03 ± 0.04%;
Figs. 1A and 2B). This equated to a mean 2.40 ( ± 0.16)-fold increase in
RBC EPA content during EPA treatment (placebo 1.02 ± 0.04 fold
change). There was also a smaller increase in RBC DPA content (mean
0.60 ± 0.18[SEM] absolute increase; P < 0.05; Figs. 1B and 2C). A
small, but statistically significant, reduction in relative DHA content in
RBC membranes (mean absolute 0.31 ± 0.24% reduction) was also seen
following EPA treatment (Fig. 1C). There was a concurrent, statistically
significant decrease in omega-6 PUFA AA content (mean absolute 1.31
± 0.57% reduction) in those individuals receiving EPA (P < 0.05;
Figs. 1D and 2G). The EPA/AA ratio is widely quoted as a predictive
biomarker of omega-3 PUFA activity, particularly in cardiology studies
[13]. There was a mean absolute increase in EPA/AA ratio of 0.12
(SEM 0.01) at the end of the intervention period in those allocated to
EPA with RBC EPA/AA ratio values at the end of the intervention
period ranging between 0.09 and 0.37 (mean 0.21).
There was no overall change in % RBC content of any PUFA in the
placebo group (Figs. 1 and 2B, D, F and H). For each PUFA, there was
significant, but incomplete, reversal of the changes in PUFA content
related to EPA treatment during the post-intervention ‘washout’ period
(Figs. 1 and 2A, C, E and G). A persistent, small elevation in RBC EPA
and DPA content was observed at six weeks after cessation of EPA
treatment (Fig. 1A and B), along with reduced AA content (Fig. 1D).
Individual RBC PUFA content profiles varied significantly between
individuals in both EPA and placebo groups (Fig. 2A–H). Previous fish
oil supplement users (who were required to stop this for the duration of
the trial) and those with high dietary omega-3 PUFA intake (n=23) had
a significantly higher baseline % RBC EPA content (1.39 ± 0.15%) than
participants ‘naïve’ to both (0.97 ± 0.04%; n=64; P=0.003). The four
participants in the placebo arm with the highest baseline % EPA
content (all > 2%) were all fish oil supplement users or those classified
as having a high dietary omega-3 PUFA intake (Fig. 2B). All these
individuals that supplied blood samples after baseline displayed a
reduction in RBC EPA content during the intervention period consis-
tent with adherence to the protocol, which demanded cessation of
existing omega-3 PUFA supplement use (Fig. 2B). Thirty-three out of
36 (92%) participants, who received EPA and for whom data from all
three time-points were available, demonstrated an increase in RBC
EPA content during the intervention period, which then reduced after
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treatment cessation (Fig. 2A). This suggests excellent compliance with
trial treatment. However, the magnitude of the EPA ‘response’ varied
widely with only 20 individuals displaying a %EPA RBC content of
greater than 2% (Fig. 2A).
There was no statistically significant correlation between the % RBC
EPA content at the end of the intervention period and the duration of
EPA treatment (r=0.25; P=0.12; Fig. 3A). The post-treatment absolute
EPA level attained in females (mean 2.68 ± 0.23%; n=16) was greater
than in male participants (mean absolute 2.07 ± 0.0.14%; n=23) in the
EPA group (P=0.02). There was no difference in baseline or post-
intervention RBC PUFA levels in concurrent aspirin users (n=9)
compared with non-users in the EPA group (data not shown).
‘Compliance’ with capsules measured by ‘pill counting’ in both active
and placebo groups was good and has been reported previously [8].
Mean compliance in the EPA group was 89.5 ± 2.9% (range 40.9–
116.7). There was no significant correlation between % compliance and
post-treatment % RBC EPA level (r=0.09; P=0.59) in EPA users.
Multivariate linear regression inputting gender, treatment duration
and compliance confirmed that gender alone (beta −0.35, P=0.039)
remained the only significant predictor of post-treatment RBC EPA
level in the EPA treatment group.
Of note, the individual with the largest increase in RBC EPA content
(gold symbols and line) also demonstrated a marked increase in DPA
and DHA, but also AA (Fig. 2A, C, E and G). The most likely
explanation is ‘contamination’ by concurrent use of a mixed omega-3
and omega-6 PUFA supplement, many of which are available commer-
cially. Only one individual allocated to placebo demonstrated an
increase in RBC EPA content over time (yellow crosses and line), also
suggesting possible ‘contamination’ by ‘own’ omega-3 PUFA use.
3.2. Relative RBC EPA content predicts the CRCLM tissue EPA level
Measurement of the % RBC EPA content the day before surgery
allowed a pairwise comparison of RBC EPA content and the corre-
sponding tumour EPA level at CRCLM resection (Fig. 3B). There was a
significant correlation between the % RBC EPA level just prior to
surgery and the CRCLM EPA content in those participants who
received EPA (r=0.35, P=0.03) and placebo (r=0.72; P < 0.001:
Fig. 3B). Interestingly, those individuals in the placebo group with
relatively high % RBC EPA content, as a consequence of prior omega-3
PUFA use or high dietary intake, had a correspondingly high tumour
EPA content (Fig. 3B).
3.3. RBC EPA incorporation and long-term clinical outcomes
Long-term clinical outcomes were an exploratory end-point in the
Phase II EMT study [8]. A preliminary finding was that those patients
who were randomised to EPA treatment had OS benefit compared with
placebo, although the difference was not statistically significant in this
small randomised trial [8]. On the basis that the lowest post-treatment
% RBC EPA level attained in the EPA group was 1.22%, which is higher
than all the respective placebo group values except for 10 individuals (6
of whom had high baseline levels due to significant prior dietary or
supplement omega-3 PUFA exposure), we compared OS in individuals
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Fig. 1. Baseline % RBC PUFA level and absolute difference in % RBC PUFA level between baseline and post-treatment or after surgery (washout). In each case (A–D), the left y axis is
the baseline % RBC PUFA value and the right y axis is the absolute difference between the post-treatment value or ‘washout’ post-operative value and baseline % level. Columns (baseline
% values) and symbols (absolute difference in % value from baseline) denote the mean for EPA and placebo (Plac.) groups. Error bars denote the standard error of the mean.*P < 0.05,
**P < 0.001; one-sample t test.
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Fig. 2. Individual % RBC PUFA profiles for individuals randomised to either EPA (A, C, E, G) or placebo (B, D, F, H). Different coloured lines join data points for all individuals.
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with a post-treatment % RBC EPA content of ≥1.22% with those with a
post-treatment RBC EPA content of < 1.22%, regardless of treatment
allocation in the trial. Participants with a post-treatment % RBC EPA
content of ≥1.22% (n=49) demonstrated improved OS compared with
those with a RBC EPA level < 1.22% (n=29; Fig. 4). The hazard ratio
was 0.42 (95% confidence interval 0.16–0.95) with a log rank P value
of 0.04.
4. Discussion
This is the first time that individual RBC and tumour PUFA content
values have been analysed together in a randomised, placebo-con-
trolled trial of an omega-3 PUFA in cancer patients. We measured %
RBC omega-3 PUFA content as the biomarker of choice, with least
within-subject variability, for assessment of omega-3 PUFA ‘bioavail-
ability’ in a clinical study lasting several weeks [9,10].
We report that RBC EPA incorporation predicts CRCLM EPA
content and therefore has potential as a surrogate biomarker of
short-term target organ EPA exposure, at least in CRCLM. Consistent
with this finding, RBC and cardiac/breast tissue EPA content correlate
strongly after omega-3 PUFA supplementation in humans [14–16],
and RBC omega-3 PUFA levels correlate with omega-3 PUFA content
in multiple mouse and rat tissues after dietary supplementation
[17,18].
Baseline and post-treatment RBC PUFA levels in EMT study
participants were similar to those reported previously in studies of
omega-3 PUFA supplementation in healthy volunteers [13,19], women
with breast hyperplasia [20,21] and in patients with lung cancer [22].
In particular, post-treatment % RBC EPA values were similar to those
observed in an eight-week study of exactly the same EPA-FFA
formulation and dose in healthy volunteers and inflammatory bowel
disease patients [23]. In keeping with previous studies of pure EPA
treatment, there was some evidence of elongation of EPA to DPA
leading to a small, statistically insignificant increase in RBC DPA
incorporation [8,23,24]. However, there was no evidence of DHA
incorporation in RBC membranes, with an actual small reduction in
% DHA content in EPA users, unlike the previous study with EPA-FFA
[23]. This may be explained by the shorter duration of EPA supple-
mentation in the EMT study, which may lead to displacement of
membrane DHA by excess EPA-FFA, prior to de novo synthesis of DHA
from EPA. Alternatively, it is understood that excess EPA may saturate
the second ELOVL2 elongase reaction necessary for DPA to DHA
conversion, which could lead to a reduced relative DHA content [24].
The literature on omega-3 PUFA supplementation in healthy
volunteers and patient groups would suggest that omega-3 PUFA
incorporation is associated with a reciprocal reduction in membrane
content of the omega-6 PUFA counterpart to EPA, AA [19–
21,23,25,26]. We also observed this phenomenon in the EMT study,
despite the relatively short duration of EPA supplementation.
Overall, there was consistent and uniform, but incomplete, EPA
‘washout’ over the relatively short time period between surgery and
post-operative follow-up mandated in the trial. Longer-term follow-up
would have been required in order to confirm the return of the PUFA
profile in RBCs to that observed pre-intervention. ‘Washout’ kinetics
were not dependent on the prior degree of RBC incorporation or
duration of EPA treatment and are similar (in these CRC patients) to
the decay in RBC EPA content observed in at least three healthy
volunteer studies, in which peak RBC EPA content was similar to that
seen in the EMT study [13,19,27], as well as two more recent studies of
pre- and post-menopausal women [20,21].
Individual omega-3 PUFA profiles allowed us to investigate inter-
patient variability in EPA incorporation in CRC patients. There was
significant heterogeneity in the increase in EPA content of RBC
membranes in response to EPA treatment, which has previously been
noted in intervention studies of daily supplementation with combined
EPA and DHA formulations (measured as the omega-3 index) in
atherosclerotic patients [28,29], but not cancer patients. This is in
contrast to the more uniform incorporation of EPA into RBC mem-
branes observed in the healthy volunteer study of EPA-FFA by Scaioli
et al. [23]. A similar degree of inter-individual variability in plasma
phospholipid DHA level was observed in a DHA intervention study in
breast cancer patients [30].
There was a small but statistically significant difference in RBC EPA
incorporation in women compared with men in the EPA group, which
remained even after adjustment for treatment duration and compli-
ance. A meta-analysis of gender differences in omega-3 PUFA levels in
RBC membranes has previously reported a significantly higher DHA,
Fig. 3. Relationship between the % RBC EPA level at the end of the trial intervention
and either treatment duration (A) or tumour EPA content at surgery (B). Open symbols
denote individual data from the placebo group and filled symbols denote EPA group data.
B) The dashed line denotes the RBC % EPA ‘cut-off’ (1.22 for survival analysis). Arrows
denote examples of individual patient data in prior omega-3 PUFA supplement users
allocated to placebo, who had high tumour % EPA content.
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Fig. 4. Overall survival analysis of CRCLM patients stratified on the basis of post-
treatment % RBC EPA level, not treatment allocation. The cut-off of 1.22% was based on
the lowest value indicative of an EPA ‘response’ (evidenced by an increase in EPA level
from baseline to post-treatment measurement and then ‘washout’) in the EPA group.
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but not EPA, content in RBCs in women compared with men [29].
However, a previous supplementation study, which undertook a
gender-specific analysis, reported on gender difference in omega-3
index [31].
Individual omega-3 PUFA profiles also highlighted possible cases of
‘contamination’ by prior or concurrent omega-3 PUFA intake separate
from the Investigational Medicinal Product. This was most easily
observed in several instances in the placebo arm, in which a concurrent
increase in DHA (but not DPA) suggested use of a combined EPA/DHA
omega-3 PUFA formulation in addition to placebo. ‘Contamination’ by
extra omega-3 PUFA use may also explain the high EPA and DHA
‘outlier’ in the EPA arm of the trial although the concurrent high RBC
DPA content may signal that this individual was, in fact, capable of
extremely efficient EPA-DPA-DHA conversion. There is increasing
understanding of the genetic basis of inter-individual variability in
omega-3 PUFA interconversion, underlying which genetic polymorph-
isms in the FADS1-FADS2 cluster and ELOVL2/5 genes modulate
desaturase and elongase activities [32].
Placebo group contamination is an ever-present risk in a rando-
mised trial of any intervention available ‘over the counter’ [33],
particularly when fish oil use is so widespread (7.8% of US adults in
2012 [34]). However, contamination by omega-3 PUFA use in the
placebo arm (suggested by an increase in omega-3 PUFA RBC content
during the intervention period) appeared relatively low, occurring in
perhaps 4 (9%) of 45 individuals allocated to placebo, and possibly in a
single case (2%) in the EPA group. Therefore, contamination by
additional omega-3 PUFA use is unlikely to have affected significantly
the laboratory and clinical endpoints of the EMT study.
There has been only one previous randomised omega-3 PUFA
intervention trial in cancer patients that has reported individual
omega-3 PUFA levels during treatment [6] and none that have included
an analysis of omega-3 PUFA ‘washout’ after cessation of omega-3
PUFA supplementation. Van der Meij et al. described variability in
plasma phospholipid EPA levels after double-blind intervention for 5
weeks with a daily supplement containing 2 g EPA and 0.9 g DHA or
isocaloric control in patients with non-small cell lung cancer [6]. These
authors obtained similar individual EPA profiles to the EMT study with
a number of ‘non-responders’ in the intervention arm and, conversely,
some individuals with high baseline EPA values or an ‘EPA response’ in
the control arm of the study [6]. We suggest that contamination is
likely to occur in all trials of omega-3 PUFA supplements with
individual randomisation and can be, at least partly, adjusted for by
analysis by absolute or relative change in RBC omega-3 PUFA levels.
To the best of our knowledge, survival analysis based on EPA
incorporation in RBCs, as a surrogate biomarker of tumour EPA
exposure, has not been reported previously. Despite the relatively
small sample size of the EMT trial, there was a statistically significant
difference between individuals dichotomised on the basis of the RBC
EPA content at the end of the intervention period (irrespective of the
trial treatment allocation). Effectively, this moved those individuals in
the placebo group with relatively high RBC EPA levels (explained
mainly by high dietary marine omega-3 PUFA intake or prior supple-
ment use) into the active (EPA) group. A methodological weakness of
this approach is the rather arbitrary cut-off value, which, in this case,
was selected as the lowest relative RBC EPA level in an ‘EPA-responder’
(increase in EPA content during intervention and then reduction
during ‘washout’). However, the EPA value used (1.22%) was similar
to equivalent values used in previous cohort and case-control studies of
the association between omega-3 PUFA levels and CRC risk [35], in
particular the study of Cottet et al. which measured RBC EPA content
[36]. Moreover, in the absence of a widely recognised, standardized
method for measurement of RBC fatty acid content, we used a LC-MS/
MS method, thus restricting future comparison with other studies.
We suggest that a so-called ‘contamination-adjusted’ secondary
analysis [7] should be undertaken in future randomised, double-blind
trials of omega-3 PUFAs in which PUFA levels are measured. Such an
approach was recently taken in the WELCOME study of non-alcoholic
fatty liver disease patients, in which placebo- and active-group
contamination occurred to a similar extent to the EMT study [3].
In conclusion, we report significant variability in RBC omega-3
PUFA profiles during a randomised trial of EPA in patients with
CRCLM awaiting liver resection. There was evidence of contamination
by ‘own use’ omega-3 PUFA in only a small proportion of participants.
There was a significant correlation between the RBC EPA content and
CRC liver metastasis EPA level measured within 24 h of each other in
this EPA intervention trial, implying that the RBC omega-3 PUFA
content may reflect tumour omega-3 PUFA exposure, at least in
CRCLMs.
A fascinating preliminary observation is that OS analysis based on
post-intervention RBC EPA content, rather than treatment allocation,
suggested OS benefit in those individuals with a high relative EPA level.
This finding adds further to the rationale for a phase III omega-3 PUFA
intervention trial in CRCLM patients. Consistent with the hypothesis
that EPA therapy may provide survival benefit in this group of patients,
Song et al. have recently reported that higher marine omega-3 PUFA
intake is associated with reduced post-diagnosis CRC mortality in two
US cohort studies [37].
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